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Abstract	
Trauma	is	one	of	the	main	causes	of	death	worldwide,	accounting	for	4.8	million	deaths	per	
year.	This	death	rate	has	led	to	trauma	being	classed	as	the	top	cause	of	death	for	males,	
aged	between	fifteen	and	twenty-nine.	More	recently,	however,	the	pattern	of	major	
trauma	is	reported	to	be	changing,	with	elderly	cohorts	and	falls	from	less	than	2	meters	
emerging	as	the	dominant	presenting	complaint.	In	addition	to	these	deaths,	directly	caused	
in	the	early	phase	following	major	trauma,	a	second	peak	of	deaths	resulting	from	the	
complications	including	sepsis	and	multiple	organ	failure,	occurs	in	the	days	and	weeks	
following	the	initial	traumatic	insult.		
	
These	complications	develop	due	to	an	imbalance	between	the	pro-inflammatory	and	anti-
inflammatory	response	to	traumatic	injury.	This	imbalance	results	in	the	counter	
inflammatory	response	becoming	dominant.	This	results	in	complications	including	sepsis	
and	multi-organ	failure	occurring	due	to	the	resultant	immunosuppression.	Thus,	the	ability	
to	monitor	the	pro-	and	anti-inflammatory	responses	through	the	measurement	of	
interleukin-6	and	interleukin-10,	may	allow	an	early	prediction	of	patient	outcome	and	the	
likelihood	of	developing	complications.	
	
Blood	samples	and	clinical	data	were	taken	on	days	1,	3	and	5,	with	additional	clinical	data	
taken	on	day	8,	following	admission.	Patient	blood	serum	was	analysed	for	their	interleukin-
6	and	interleukin-10	concentrations,	using	cytometric	bead	arrays,	in	sequential	samples,	
over	a	five-day	period	following	traumatic	injury.		
	
The	concentrations	of	interleukin-6	and	interleukin-10	for	these	patients	were	then	
compared	to	their	clinical	data	and	scoring	systems.	This	evaluated	the	use	of	interleukin-6	
or	interleukin-10	as	potential	biomarkers	for	the	early	detection	of	complications	and	poor	
clinical	outcome	following	trauma.	Metabolomic	analysis	was	also	conducted	in	parallel	to	
validate	methodology	and	identify	new	molecules	and	patways	involved	in	the	response	to	
trauma.	
	
14	
Interelukin-10	concentration	was	further	utilised	to	cluster	liquid	chromatography/mass	
spectrometry	metabolomic	analysis	to	identify	significant	metabolites	that	are	higher	in	
patients	with	elevated	interleukin-10.	
	
Preliminary	results	show	that	both	interleukin-6	and	interleukin-10	differentiate	between	
good	and	poor	outcome.	Median	interleukin-6	concentrations	were	found	to	be	at	their	
peak	in	day	1	(54.28	pg/ml	±	214.48),	decreasing	in	day	3	(29.43	pg/ml	±	300.19)	and	further	
decreasing	in	day	5	(10.90	pg/ml	±	673.74).	A	similar	pattern	was	observed	following	
analysis	for	interleukin-10	with	the	peak	on	day	1	(5.87	pg/ml	±	20.21),	decreasing	in	day	3	
(2.59	pg/ml	±	4.96)	and	decreasing	further	in	day	5	(1.99	pg/ml	±	8.82).	Furthermore,	Day	1	
interleukin-10	concentrations	were	used	to	cluster	the	metabolomic	analysis.	With	this	
grouping,	a	significant	change	in	penicillin	based	antibiotic	metabolites	was	observed	in	day	
5	metabolomic	analysis	of	trauma	patient’s	serum	samples,	identifying	day	1	interleukin-10	
a	predictive	marker	for	the	need	for	long	term	antibiotic	usage.		
	
This	study	indicates	that	the	balance	between	interleukin-6	and	interleukin-10	has	potential	
predictive	value	for	the	early	detection	of	complications	following	trauma	and	provide	early	
guidance	towards	optimal	therapeutic	intervention.	
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Chapter	1	-	Introduction		
1.1	-	An	introduction	to	trauma	
Major	trauma	is	classed	as	any	injury	that	has	the	potential	to	cause	prolonged	disability	or	
death.	It	refers	to	physical	injuries	of	sudden	onset	and	severity	that	require	immediate	
medical	interventions,	such	as	surgery,	resuscitation	therapy	and	therapeutic	options	to	
return	bodily	functions	back	to	homeostatic	levels.	Major	trauma	results	in	life	changing	
injury	that	can	affect	either	a	single	organ	system,	such	as	during	severe	brain	injury	or	
involve	multiple	body	systems	in	a	process	called	polytrauma	(McCullough	et	al.,	2014).		
	
Due	to	the	complex	nature	of	trauma	injuries,	patients	are	required	to	stay	in	the	hospital	
for	extended	periods	of	time	and	may	require	specialist	care	in	an	intensive	care	unit	(ICU).	
These	necessities	for	patient	care	have	a	major	financial	impact	on	health	care	services	
throughout	the	world.	Each	trauma	patient	admitted	to	hospital	in	the	UK	costs	on	average	
£50,000,	with	trauma	injuries	resulting	in	death	costing	approximately	£750,000	(National	
Institute	for	Health	and	Care	Excellence,	2015).	This	cost	of	treating	traumatic	injury,	results	
in	an	annual	estimated	cost	of	£1.6	billion,	accounting	for	7%	of	the	total	National	Health	
Service	(NHS)	budget	in	2008	(Christensen	et	al.,	2008).		
	
Continuing	advancements	in	medical	technology,	treatment,	trauma	care	and	the	
implementation	of	trauma	audits,	mean	that	patients	can	now	survive	for	extended	periods	
following	traumatic	injury	(Lecky,	2015).	However,	these	patients	still	live	with	high	levels	of	
disability	following	the	initial	traumatic	injury,	along	with	the	risk	of	developing	
complications	such	as	sepsis	and	multi-organ	failure	(Lord	et	al.,	2014).		This	has	been	
shown	in	a	recent	World	Health	Organisation	study	that	trauma	accounts	for	between	10	
and	11%	of	all	disability	worldwide	(World	Health	Organisation,	2014).	Traumatic	injury	
fulfils	the	disease	classification	for	a	global	pandemic,	due	to	it	being	a	recurrent	and	
significant	cause	of	morbidity	and	mortality	over	time	and	occurring	across	numerous	
continents,	despite	best	efforts	to	prevent	and	control	its	impact	(Lecky	et	al.,	2010	in	Pope	
et	al.,	2010).	
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1.1.1	-	Incidence	and	epidemiology	of	trauma	
Trauma	is	one	of	the	main	causes	of	death	worldwide	and	is	the	leading	cause	of	death	for	
those	under	the	age	of	40,	accounting	for	approximately	10%	of	all	deaths	in	this	age	
bracket.	Of	the	55	million	people	that	died	worldwide	during	2013,	4.8	million	(8.7%)	deaths	
were	attributed	to	trauma	(both	unintentional	and	intentional)	(Parker	&	Magnusson,	
2016).			
	
Based	on	a	recent	World	Health	Organisation	report,	injury/trauma	is	amongst	the	main	
cause	of	deaths,	causing	9%	of	total	mortality	worldwide	and	became	number	one	cause	of	
death	in	15-29	years	old	group	(World	Health	Organisation,	2012).	Within	England,	there	are	
at	least	20,000	cases	of	major	trauma	each	year,	resulting	in	5,400	deaths	and	significant	
numbers	resulting	in	permanent	disability	requiring	long-term	care	(England	National	Audit	
Office).	Figure	1	shows	the	change	in	trauma	incidence	in	the	UK	over	the	past	25	years.	
Despite	being	the	number	one	cause	of	death	in	the	population	under	the	age	of	40	
worldwide,	a	change	in	age	distribution	has	been	observed	recently	in	developed	countries	
such	as	the	UK.	This	shift	has	caused	trauma	to	be	a	major	cause	of	death	in	people	over	60	
years	of	age	(Figure	2)	(Kehoe	et	al.,	2015).		
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Figure	1)	The	change	in	UK	trauma	incidence	between	1990	and	2013.	Adapted	using	data	
from	Kehoe	et	al.,	2015.	
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This	is	a	problem	in	the	developed	world	due	to	the	expansion	in	numbers	in	the	ageing	
population	attributed	to	a	higher	life	expectancy	because	of	advancements	in	medical	care.		
This	has	also	resulted	in	a	change	in	the	gender	distribution	with	the	incidence	of	trauma	
shifting	from	a	predominantly	male	population	to	a	more	mixed	gender	population.	This	
change	(Figure	3)	mainly	occurs	in	developed,	higher	economic	countries,	such	as	the	UK.		
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Figure	2)	The	change	in	trauma	incidence	amongst	age	groups,	using	data	from	between	1990	
and	2013.	Adapted	using	data	from	Kehoe	et	al.,	2015.	
Figure	3)	The	change	in	trauma	incidence	between	men	and	women,	between	1990	and	
2013.	Adapted	using	data	from	Kehoe	et	al.,	2015.	
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This	age-related	change	in	trauma	incidence	has	not	occurred	in	middle	to	low-income	
countries,	with	trauma	predominantly	occurring	and	increasing	in	the	classical,	under	40	
population.	This	increase	is	due	to	these	countries	undergoing	rapid	industrialisation,	a	
dramatic	rise	in	the	number	of	motor	vehicles,	and	recurrent	armed	conflicts	(Alberdi	et	al.,	
2014).		
	
Lower	income	countries	that	are	currently	undergoing	industrialisation	have	a	major	source	
of	occupation	in	the	farming	and	manufacturing	sectors	of	industry.	These	groups	of	
industries	are	high	risk	for	the	incidence	of	traumatic	due	to	the	use	of	large	machinery	and	
the	reliance	of	motor	vehicles	on	underdeveloped	road	infrastructure	(Alberdi	et	al.,	2014).		
The	incidence	of	traumatic	injury	differs	significantly	among	lower	income	countries	and	
higher	income	countries.	This	was	presented	in	a	World	Health	Organisation	study	
discussing	the	impact	of	injury	and	violence	worldwide	(World	Health	Organisation,	2014).	
This	study	identified	that	the	mortality	rate	per	100,000	of	the	population,	is	higher	in	lower	
income	countries,	compared	to	high-income	countries	(Figure	4).	
	
	
	
	
Figure	4)	The	mortality	rate	of	traumatic	injury	in	countries	grouped	on	their	economic	
classification.	Adapted	from	World	Health	Organisation,	2014.	
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This	difference	in	mortality	rate	is	primarily	due	to	the	availability	of	rapid	response	medical	
treatment	and	improved	road	safety	measures	in	higher	income,	more	developed	countries,	
allowing	the	victims	of	traumatic	injury	to	receive	medical	intervention	significantly	quicker,	
thus	decreasing	their	risk	of	death	due	to	traumatic	injury	(Vos	et	al.,	2015).		
	
Globally,	major	trauma	is	most	commonly	caused	by	motor	vehicle	accidents	(Figure	5).	This	
is	due	to	poor	road	safety	in	low-income	countries,	differences	in	driving	regulations	in	
comparison	to	developed	countries,	along	with	poor	road	infrastructure,	despite	the	
increasing	number	of	vehicles	(Søreide,	2009;	Nantulya	&	Reich,	2002).	However,	in	higher	
economic	countries,	a	new	main	cause	of	trauma	incidence	is	developing,	in	the	form	of	falls	
from	a	height	of	lower	than	two	meters.	This	is	due	to	the	ageing	population	associated	with	
higher	developed	countries.	These	groups	of	individuals	are	at	a	greater	risk	of	having	poor	
clinical	outcomes	because	of	the	trauma	despite	the	relatively	short	distance	of	the	fall.	This	
is	due	to	this	cohort	having	significant	levels	of	comorbidities	and	increased	susceptibility	to	
nosocomial	infections	in	addition	to	poor	healing.		
	
Figure	5)	The	main	causative	mechanisms	for	trauma	worldwide	and	the	percentage	of	
total	trauma	deaths	associated	with	each	main	causative	mechanism.	Adapted	using	data	
from	(Haagsma	et	al.,	2016).	
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
Road	injury
Falls
Heat	injury
Drow
ning
M
edical	treatm
ent
M
echanical	forces
Self	harm
Interpersonal	
violence
W
ar/Disaster
Other
%
	o
f	t
ot
al
	d
ea
th
s
20	
Over	the	previous	25	years,	the	cause	of	trauma	in	the	UK	has	dramatically	changed	(Figure	
6).	In	this	25-year	period,	there	has	been	a	dramatic	decrease	(30%)	in	road	traffic	related	
trauma,	with	falls	from	a	height	of	less	than	two	meters	becoming	the	most	common	cause	
of	trauma	in	the	UK	(Kehoe	et	al.,	2015).	Overall,	the	incidence	of	trauma	is	increasing	year	
on	year,	in	both	the	developed	and	developing	regions	of	the	world.	This	identifies	the	need	
to	conduct	research	into	preventative	measures,	diagnostics	and	therapeutic	options,	to	
decrease	the	incidence	of	trauma	and	lower	the	mortality	rate	in	both	developed	and	
developing	countries.	
	
	
Figure	6)	The	main	causative	mechanisms	of	major	trauma	in	the	UK	and	the	change	in	
incidence	between	1990	and	2013.	Adapted	using	data	from	Kehoe	et	al.,	2015.	
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1.2	-	The	pathophysiology	of	trauma	
Traumatic	injury	causes	damage	to	tissues	and	organs.	This	damage	induces	several	
responses	by	the	body,	both	local	and	systemic	to	maintain	immune	integrity	and	stimulate	
repair	mechanisms	(Keel	&	Trentz,	2004).		The	response	to	injury	involves	the	activation	of	
both	the	innate	and	adaptive	immune	system	to	initiate	recovery	mechanisms.		The	innate	
immune	system	acts	as	the	first	line	of	defence	for	the	body	against	potential	pathogenic	
agents.	It	does	this	by	detecting	a	potentially	pathogenic	substance	and	triggering	
responses.	The	innate	immune	response	activates	the	adaptive	immune	response	allowing	
the	recruitment	of	B	and	T	cells	to	the	site	of	injury	and	the	production	of	antibodies	and	
cytokines.	These	responses	are	characterised	by	the	local	and	systemic	production	and	
release	of	different	mediators,	including	cytokines,	complement	factors,	coagulation	
proteins,	acute	phase	proteins,	neuro-endocrine	mediators	and	the	initiation	of	
immunocompetent	cells	at	the	site	of	tissue	damage	(Keel	&	Trentz,	2004).	
	
1.2.1	-	Pathogen	and	damage	associated	molecular	patterns	
An	immune	response	following	trauma	is	induced	by	molecules	released	from	damaged	
cells	(DAMP’s)	or	pathogen	cell	surface	structures	(PAMP’s).	These	molecules	interact	with	
receptors	on	the	surface	of	immune	cells,	inducing	the	immune	responses	associated	with	
traumatic	injury.Pathogen	associated	molecular	patterns	are	structures	on	the	surface	of	
bacteria	that	are	recognised	by	innate	immune	cell	receptors	(Mogensen,	2009).	These	
structures	play	a	key	role	in	the	survival	of	bacteria	or	the	pathogenicity	of	the	bacteria	
(Kumar,	Kawai	&	Akira,	2011).	They	bind	to	pathogen	recognition	receptors	on	the	surface	
of	innate	immune	cells	and	trigger	an	inflammatory	response,	shown	in	Figure	8)	(Kumar,	
Kawai	&	Akira,	2011).	
	
Damage-associated	molecular	patterns	are	molecules	found	within	cells	that	avoid	
recognition	by	the	immune	system	under	normal	physiological	conditions	(Land,	2015).	
However,	when	cells	become	stressed	or	following	tissue	damage,	these	molecules	are	then	
released	or	exposed	on	the	surface	of	cells	(Figure	7)	(Land,	2015).		
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DAMP’s	include	intracellular	proteins,	numerous	nuclear,	cytosolic,	mitochondrial	molecules	
along	with	components	from	the	extracellular	matrix	have	been	identified	as	DAMPs.	The	
first	molecule	to	be	identified	as	a	DAMP	was	the	High	mobility	group	box	1	(HMGB1)	and	
since,	numerous	different	molecules	have	been	identified	including	Mitochondrial	DNA,	
Histones,	Heat	shock	proteins,	Genomic	DNA	and	S100	proteins	(Sharma	&	Naidu,	2016).	
These	molecules	can	also	be	passively	released	into	the	extracellular	environment	from	the	
extracellular	matrix	because	of	undergoing	necrotic	cell	death	or	extracellular	damage.		
These	molecules	trigger	an	inflammatory	response	in	a	similar	fashion	as	PAMP’s,	by	binding	
to	PRR’s	on	the	surface	of	innate	immune	cells	(Figure	7)	(Krysko	et	al.,	2011).	
	
1.2.1.1	-	High	mobility	group	box	1		
High	mobility	group	box	1	is	a	nuclear	protein,	which	is	described	as	a	DNA	binding	protein	
and	has	a	function	in	the	transcription	process	(Park	et	al.,	2006).		Within	the	nucleus,	
HMGB1	binds	non-specifically	to	the	minor	groove	of	the	DNA	helix,	causing	the	structure	to	
bend	(Bianchi	&	Agresti,	2005).	When	a	cell	undergoes	necrosis,	following	damage,	HMGB1	
is	released	into	the	environment,	allowing	it	to	interact	with	molecules	and	receptors	it	is	
not	usually	in	contact	with	due	to	its	location	within	the	nucleus	(Bianchi	&	Manfredi,	2007).		
	
	
Figure	7)	The	interactions	that	DAMP’s	can	undergo,	following	their	release	from	stressed	
cells	and	the	potential	responses	that	can	occur	following	their	binding	to	receptors	on	
immune	cells.	
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High	mobility	group	box	1	has	been	shown	to	interact	with	Toll-like	receptors	2	and	4	
resulting	in	a	cell	signalling	cascade	that	results	in	the	production	of	pro-inflammatory	
cytokines.	However,	other	studies	have	shown	HMGB1	to	act	as	a	chemoattractant	for	
proinflammatory	cytokine	secreting	cells,	rather	than	directly	causing	elevations	in	cytokine	
secretion	(Rouhiainen	et	al.,	2007).	This	ability	to	act	as	a	chemoattractant	is	due	to	the	
binding	to	the	receptor	for	advanced	glycation	end	products	(RAGE)	(Hori	et	al.,	1995).	The	
binding	of	HMGB1	to	RAGE	results	in	the	activation	of	Mitogen-activated	protein	(MAP)	
kinases	and	NF-κβ	signalling	pathways	that	are	known	to	be	involved	in	the	production	of	
pro-inflammatory	cytokines	(Bianchi	&	Manfredi,	2007).	
	
1.2.1.2	-	S100	Proteins	
S100	proteins	are	a	collection	of	intracellular	proteins	categorised	by	their	calcium-binding	
motifs	(Donato	et	al.,	2013).	Their	normal	functions	include	calcium	homoeostasis,	cell	cycle	
regulation,	cytoskeletal	interactions,	protein	phosphorylation,	cell	growth	and	migration,	
and	the	regulation	of	transcription	factors	(Srikrishna	&	Freeze,	2009).	The	S100	proteins	are	
passively	released	from	cells	following	cellular	damage	allowing	them	to	undertake	
extracellular	activities	(Donato	et	al.,	2013).	When	released	into	the	extracellular	
environment	S100	proteins	act	as	DAMP’s,	sounding	the	alarm	to	the	immune	system	that	
something	is	abnormal	in	this	region	of	the	body.		
	
Specific	S100	proteins	have	been	shown	to	be	involved	in	processes	that	cause	a	pro-
inflammatory	response,	these	S100	proteins	are	known	as	S100A8,	S100A9	and	S100A12	
(Srikrishna	&	Freeze,	2009).	They	can	induce	both	pro-thrombotic	and	pro-inflammatory	
responses	such	as	chemokine	stimulation,	production	of	adhesion	molecules	and	pro-
inflammatory	cytokine	stimulation	(Donato	et	al.,	2013).		S100A8	and	S100A9	can	form	a	
complex	known	as	Calprotectin	(S100A8/A9),	which	can	activate	pro-inflammatory	cytokine	
production	by	monocytes	and	macrophages	via	the	NF-κβ	and	p38	MAP	kinase	pathways	
(Sunahori	et	al.,	2006).	This	complex	can	also	activate	RAGE,	mediating	the	production	of	
inflammatory	mediators	(Gebhardt	et	al.,	2008).	S100A9	has	also	been	reported	to	
independently	induce	the	production	of	TNF	α,	IL-1β,	IL-6	and	IL-8;	via	the	NF-κβ	signalling	
pathway	(Donato	et	al.,	2013).		
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S100A12	induces	the	production	of	pro-inflammatory	cytokines	from	mast	cells,	particularly	
IL-6	and	IL-8	(Yang	et	al.,	2001).	S100A12	can	also	prompt	the	manufacture	of	chemokines	
important	for	neutrophil,	lymphocyte	and	monocyte	recruitment	to	the	site	of	
inflammation,	along	with	the	release	of	TNF	α	from	preformed	stores	(Yang	et	al.,	2007).	
	
1.2.1.3	-	Heat	shock	proteins		
Heat	shock	proteins	(HSP)	were	originally	discovered	in	1962	by	Ferruccio	Ritossa	during	an	
experiment	on	Drosophila	in	which	they	were	stressed	with	heat	to	study	gene	expression	
(Ritossa,	1962).	These	proteins	under	normal	physiological	conditions	fulfil	an	important	
intracellular	role	relating	to	protein	folding	and	transport	(Grundtman	et	al.,	2011).	These	
proteins	are	expressed	as	cognate	proteins	and	inducible	forms	released	under	stressful	
conditions	(Tsan	&	Gao,	2004).	Heat	shock	proteins	can	be	released	following	several	
different	stimuli	other	than	heat,	including	environmental,	pathological	and	physiological	
stimuli	(Tsan	&	Gao,	2004).	
	
Heat	shock	proteins	are	evolutionarily	conserved	and	are	abundantly	expressed	in	both	
prokaryotic	and	eukaryotic	organisms	(Hauet-Broere	et	al.,	2006).	There	are	six	main	
families	of	heat	shock	proteins	each	distinguished	by	their	molecular	weight.	These	include:	
HSP100,	HSP90,	HSP80,	HSP60,	HSP40	and	small	heat	shock	proteins	(sHSP’s)	(Hauet-Broere	
et	al.,	2006).		
	
Heat	shock	proteins	are	highly	immunogenic	and	have	been	shown	to	play	a	role	in	the	
regulatory	function	of	T-cells	and	the	induction	of	anti-inflammatory	cytokines	during	
chronic	inflammation	(Hauet-Broere	et	al.,	2006).	In	addition	to	T-cells,	heat	shock	proteins	
have	also	been	shown	to	act	on	macrophages,	dendritic	cells,	B-cells	and	natural	killer	cells	
(Quintana	&	Cohen,	2005).	The	regulation	of	autoimmunity	can	be	indirectly	by	activating	
regulatory	T-cells	that	control	pathogenic	T-cells,	specifically	for	self-antigens	other	than	
heat	shock	proteins.	Heat	shock	proteins	have	interactions	with	Toll-like	receptors	inducing	
an	immune	response	(Quintana	&	Cohen,	2005).	Specifically,	human	HSP60	can	directly	
inhibit	chemotaxis	and	anti-inflammatory	responses	via	TLR-2	and	suppress	cytokine	
signalling	(Quintana	&	Cohen,	2005).	
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Damage-associated	molecular	patterns,	such	as	High	mobility	group	box	1,	S100	proteins	
and	heat	shock	proteins,	share	structural	and	functional	similarities	with	the	exogenous	
conserved	microbial	surface	structures,	which	are	released	from	invading	pathogens	termed	
PAMP’s.	These	molecules	are	recognised	by	a	group	of	receptors	called	pathogen	
recognition	receptors	(PRR’s)	including	Toll-like	receptors	(Hirsinger	et	al.,	2012;	Sharma	&	
Naidu,	2016).	
	
1.2.2	-	Toll-like	receptors	
The	release	of	DAMP’s	activates	Toll-like	receptors	(TLR’s)	triggering	the	activation	of	T	cells	
and	causing	an	immune	response.	Toll-like	receptors	are	a	conserved	family	of	receptors	
that	trigger	a	pro-inflammatory	signalling	cascade	in	response	to	either	PAMP’s	or	the	
DAMP’s	released	during	tissue	damage.	
	
Toll-like	receptors	are	type	1	transmembrane	protein	characterised	by	an	extracellular	
domain	containing	leucine-rich	repeats	(LRR’s)	and	a	cytoplasmic	tail	that	contains	a	
conserved	region	called	Toll/IL-1	receptor	domain	(Nishiya	&	DeFranco,	2004).	These	
receptors	are	predominantly	expressed	in	tissues	involved	in	the	immune	response,	such	as	
the	spleen	and	peripheral	blood	leukocytes,	along	with	those	exposed	to	the	external	
environment	including	the	lungs	and	gastrointestinal	tract	(Nishiya	&	DeFranco,	2004).	
To	date,	ten	human	variants	of	toll-like	receptors	have	been	identified,	called	TLR-1	to	TLR-
10.	Most	of	these	receptors	are	expressed	on	the	plasma	membrane	of	cells,	apart	from	
TLR’s	-3,	-7,	-8	and	-9,	which	are	located	within	an	endosomal	compartment	(Nishiya	&	
DeFranco,	2004).	These	endosomal	TLR’s	scan	for	nucleic	acids	of	bacteria,	viruses	or	
parasites,	which	have	been	phagocytosed/endocytosed	into	the	cell.	The	detection	of	
nucleic	acids	triggers	signalling	pathways	that	result	in	the	production	of	inflammatory	
mediators	(Gibbard,	Morley	&	Gay,	2006).	
Toll-like	receptors	act	as	receptors	for	intracellular	signalling	and	the	expression	of	genes.	
Initially,	a	ligand	such	as	a	PAMP	or	DAMP	binds	to	a	Toll-like	receptor,	either	extracellularly	
or	to	internal	receptors	(Figure	8).	Once	bound,	the	ligand	allows	the	recruitment	of	
signalling	adaptor	molecules,	in	the	form	of	MyD88,	TIRAP,	TRAM	and/or	TRIFF,	following	
the	activation	of	Toll/Interleukin-1	receptor(TIR)	domains	on	the	TLR	(Kawai	&	Akira,	2010;	
Lim	&	Staudt,	2013).	
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Depending	upon	the	signalling	adaptor	molecule	used	in	the	signalling	pathway,	various	
kinases	and	ubiquitin	ligases	are	recruited	and	activated,	including	IRAK4,	IRAK1,	IRAK2,	
TBK1,	IKKe,	TRAF6	and	pellino	1	(Lim	&	Staudt,	2013).			
	
This	signalling	pathway	culminates	in	the	engagement	of	NF-kb,	Type	1	interferon,	P53	MAP	
kinase	and	JNK/MAPK	pathways	(Figure	8)	(Kawai	&	Akira,	2010;	Lim	&	Staudt,	2013;	
Morrison,	2012).	These	pathways	cause	the	expression	of	genes	relating	to	pro-
inflammatory	modulators,	cell	survival,	immune	cell	proliferation	and	immune	regulation.	
These	changes	in	gene	expression	allow	the	inflammatory	process	to	begin	and	induce	the	
changes	associated	with	an	inflammatory	response.	
	
	
Figure	8)	The	variety	of	Toll-like	receptors	and	the	vast	array	of	signalling	pathways	
involved	in	initiating	the	inflammatory	response	following	the	detection	of	DAMP’s	and	
PAMP’s.	(O’Neill,	Golenbock	&	Bowie,	2013)	
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1.2.3	-	The	coagulation	response	during	major	traumatic	injury	
Coagulation	is	the	process	used	to	prevent	the	loss	of	blood	from	cuts	and	damage,	to	
maintain	haemostasis	and	limit	blood	loss	following	major	injury	(Thornton	&	Douglas,	
2010).	This	involves	blocking	the	ruptured	blood	vessel	using	a	combination	of	activated	
platelets	and	fibrin	(Lasne,	Jude	&	Susen,	2006).		
	
Platelets	become	activated	by	binding	to	collagen,	which	is	exposed	to	the	blood	circulation	
following	damage	to	the	endothelium	of	the	blood	vessel	(Andrews	&	Berndt,	2004).	This	
binding	of	platelets	to	the	exposed	collagen,	results	in	the	activation	of	integrins	on	
platelets,	resulting	in	a	strong	adhesion	of	platelets	to	the	site	of	damage	or	rupture	
(Heemskerk,	Bevers	&	Lindhout,	2002).	
	
The	process	to	activate	fibrin	involved	numerous	clotting	factors,	which	activate	one	
another	until	it	ultimately	results	in	the	activation	of	fibrin	(Palta,	Saroa	&	Palta,	2014).	The	
activation	of	fibrin	is	a	result	of	the	coagulation	cascade,	this	can	occur	through	two	
pathways,	the	contact	activation	(intrinsic)	and	the	tissue	factor	pathway	(extrinsic).	The	
tissue	factor	pathway	is	commonly	activated	following	tissue	damage,	due	to	its	ability	to	
rapidly	generate	activated	fibrin	(Figure	11).	
	
The	extrinsic	pathway	is	initiated	by	stable	factor	(factor	VII)	leaving	circulation	and	
interacting	with	tissue	factor	(TF),	generating	an	activated	complex	(TF:VIIa)	(Riewald	&	Ruf,	
2002).	This	complex	activates	Christmas	factor	(factor	IX)	and	Stuwart-Prowler	factor	(factor	
X)	to	form	IXa	and	Xa.	Factor	Xa	activates	prothrombin,	converting	it	to	thrombin	(Owens	&	
Mackman,	2010).	Thrombin	can	then	act	on	fibrinogen	converting	it	to	fibrin	and	activating	
fibrin	stabilising	factor	(factor	XIIIa).	This	allows	the	formation	of	a	stable	clot	through	the	
binding	of	strands	to	the	site	of	vascular	injury,	strengthened	via	the	support	of	factor	XIIIa	
(Schenone,	Furie	&	Furie,	2004).	
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Figure	11)	The	clotting	cascade	involved	in	in	the	generation	of	fibrin.	This	either	involves	
the	intrinsic	pathway	or	the	extrinsic	pathway	to	form	activated	factor	X.	
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An	alternative	pathway	of	activating	the	coagulation	cascade	is	through	the	contact	
activation	pathway.	This	is	initiated	by	the	binding	of	plasma	proteins	Hageman	factor	
(factor	XII)	and	prekallikrein	on	collagen,	mutually	converting	each	other	to	XIIa	and	
kallikrein	(Green,	2006).	Factor	XIIa	converts	plasma	thromboplastin	(factor	XI)	to	XIa.	Factor	
XIa	activates	factor	IX,	which	interacts	with	a	co-factor	VIIIa	to	form	the	tenase	complex	
(Gailani	&	Renne,	2007).	The	tenase	complex	then	activates	factor	X.	The	pathway	then	
merges	into	the	common	pathway,	resulting	in	the	formation	of	fibrin	(Adams	&	Bird,	2009;	
Owens	&	Mackman,	2010).	
	
Kallikrein	has	several	functions	including	the	ability	to	convert	plasminogen	to	plasmin	and	
stimulate	the	formation	of	kinins	from	kininogen	(Wu,	2015).	Plasmin	is	an	enzyme	that	
degrades	blood	plasma	products,	including	fibrin	clots.	This	allows	blood	clots	to	be	
degraded	once	they	are	no	longer	required	to	prevent	bleeding	(Bryant	&	Shariat-Madar,	
2009).	Kinin	molecules	such	as	bradykinin	and	kallidin	are	peptides	responsible	for	the	
regulation	of	blood	pressure	and	activation	of	inflammation	(Bryant	&	Shariat-Madar,	2009).		
	
In	the	period	following	trauma,	clotting	factors	can	become	depleted	if	there	is	a	large	
volume	of	blood	loss	because	of	the	patient’s	injuries	(Brummel-Ziedins,	2013;	Callum	&	
Rizoli,	2012).	This	over	utilisation	can	result	in	the	depletion	of	clotting	factors,	causing	an	
inability	of	blood	to	clot	properly,	causing	further	blood	loss	and	potentially	fatal	
consequences	if	external	clinical	intervention	is	not	given	(Shaz	et	al.,	2011).	However,	if	the	
clotting	response	becomes	overactive,	commonly	observed	following	traumatic	injury,	
intravascular	fibrin	clots	can	form	(Lippi	&	Cervellin,	2010).	These	clots	can	lead	to	
microcirculatory	disturbances,	blocking	blood	flow	and	resulting	in	hypoxia	induced	cellular	
damage	(Levi,	2007;	Kumar	&	Gupta,	2008).		
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1.2.4	-	The	inflammatory	response	to	trauma	
Inflammation	is	the	reaction	the	body	invokes	when	it	detects	potentially	pathological	
material.	This	reaction	is	done,	to	prevent	the	causative	agent	from	spreading,	to	aid	in	the	
elimination	of	the	pathological	material,	and	trigger	healing	responses,	to	repair	damage	
caused	by	the	pathological	agent	or	the	inflammatory	response	itself.	
	
This	inflammatory	response	causes	a	variety	of	symptoms	including,	redness	and	warmth	at	
the	site	of	inflammation,	swelling,	and	the	presence	of	oedema.	These	external	symptoms	
are	side	effects	of	the	inflammatory	response	attempting	to	clear	the	pathological	material.	
The	inflammatory	response	involves	a	variety	of	different	immune	cells,	signalling	pathways,	
cytokines,	chemokines	and	receptors.	These	all	work	together	to	elicit	a	successful	immune	
response	and	clear	the	causative	material.	
	
1.2.4.1	-	Cellular	and	vascular	changes	in	inflammation	
Once	a	potentially	pathogenic	molecule,	in	the	form	of	PAMPS	or	DAMPS,	has	been	
detected	by	sentinel	tissue	cells,	such	as	dendritic	cells,	macrophages	and	mast	cells,	it	
triggers	the	release	of	inflammatory	mediators,	causing	a	local	inflammatory	response	
(Nourshargh	&	Alon,	2014).	This	inflammatory	response	causes	changes	to	the	local	cellular	
environment	and	blood	vessels.	The	purpose	of	these	changes	is	to	allow	effector	immune	
cells	to	migrate	from	the	blood	system	into	tissues,	to	eliminate	the	pathogenic	material.	
	
The	key	events	that	occur	to	allow	the	transfer	of	effector	immune	cells	from	the	blood	into	
tissues	are	vasodilation,	increased	vascular	permeability	and	elevated	expression	of	vascular	
adhesion	molecules	(Nourshargh	&	Alon,	2014).	These	processes	allow	the	rapid	delivery	of	
blood-borne	defences	to	the	site	of	the	inflammatory	response,	the	leakage	of	soluble	
proteins	into	tissue	from	the	blood,	and	the	attraction	and	migration	of	leukocytes	to	the	
inflamed	tissue	(Kolaczkowska	&	Kubes,	2013).	Migration	of	leukocytes	into	inflamed	tissue	
is	a	multi-step	process	involving	several	molecular	and	vascular	changes,	allowing	
leukocytes	to	pass	from	the	blood	into	tissue	and	invoke	their	effector	functions.	These	
changes	are	split	into	four	main	steps,	rolling,	crawling,	adhesion,	and	transmigration	
(Figure	9).	
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The	process	of	rolling	begins	following	the	detection	of	a	potentially	pathogenic	molecule	by	
tissue	based	dendritic	cells	and	macrophages.	Once	a	molecule	is	detected,	dendritic	cells	
and	macrophages	release	mediators	(TNFα	and	IL-1)	to	activate	local	endothelial	cells	within	
blood	vessels	(Phillipson	&	Kubes,	2011).	The	activation	of	endothelial	cells	causes	an	
expression	of	adhesion	molecules,	namely	P-selectin	and	E-Selectin,	on	their	surface	
(Kolaczkowska	&	Kubes,	2013).	These	selectins	can	then	bind	to	glycosylated	structures	on	
leukocytes,	causing	them	to	interact	with	the	endothelial	surface,	so	they	can	interact	with	
further	receptors	on	endothelial	cells	(Ley,	2003).	These	interactions	are	rapidly	broken	and	
reformed,	as	the	leukocyte	travels	along	the	endothelial	wall,	causing	it	to	slow	down	on	the	
endothelial	surface	(Rossiter,	Alon	&	Kupper,	1997).	
	
Once	slowed,	stronger	binding	of	leukocytes	to	the	endothelial	surface	can	occur.	This	is	
triggered	by	the	binding	of	positively	charged	chemokines	to	G-coupled	chemokine	
receptors	on	the	leukocyte	surface	(Sun	&	Richard,	2012).	These	chemokines	are	
immobilised	on	the	surface	of	the	endothelium,	by	interactions	with	negatively	charged	
heparin	sulphates.	
Figure	9)	The	processes	involved	in	the	transmigration	of	leukocytes	from	the	blood,	
through	the	vascular	endothelium,	into	the	tissue	containing	the	causative	agent	of	the	
inflammatory	response.	
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	These	interactions	serve	as	anchors	to	prevent	the	sheer	force	of	blood	flow,	from	washing	
leukocytes	away	from	the	endothelial	surface	(Kolaczkowska	&	Kubes,	2013).	The	binding	of	
chemokines	to	chemokine	receptors,	causes	a	conformational	change	on	the	leukocyte	
surface	integrin’s,	allowing	them	to	firmly	attach	to	endothelial	cells	(Herter	&	Zarbock,	
2013).	The	integrin’s	on	the	surface	of	leukocytes	(LFA-1	and	MAC-1),	following	the	
conformational	change,	can	bind	to	ICAM-1,	ICAM-2	and	VCAM-1	cell	adhesion	molecules	
on	the	surface	of	endothelial	cells	(Kolaczkowska	&	Kubes,	2013).	The	binding	of	LFA-1	to	
ICAM-1	is	a	key	component	of	triggering	the	firm	adhesion	of	leukocytes	to	endothelial	cells,	
allowing	the	leukocytes	to	begin	the	process	of	migrating	through	the	endothelial	border	
and	into	the	inflamed	tissue	(Harris	et	al.,	2000).	
	
Transmigration	of	leukocytes	through	the	endothelium	is	a	complex	process,	involving	the	
interaction	of	leukocytes	in	three	dimensions	with	endothelial	cells,	the	subendothelial	
basement	membrane,	pericytes	and	interstitial	tissue	(Muller,	2013).	The	transmigration	
process	involves	key	interactions	of	platelet/endothelial	cell	adhesion	molecule	1	(PECAM).	
These	interactions	are	expressed	diffusely	on	the	surfaces	of	most	leukocytes	and	are	
concentrated	to	the	borders	of	endothelial	cells,	the	main	site	of	transmigration	through	the	
endothelial	membrane	(Muller,	2013).	
	
Studies	have	shown	that	leukocytes	migrate	through	the	subendothelial	basement	
membrane	at	regions	where	the	expression	of	collagen	IV	and	laminin	10	is	at	a	low	density.	
This	allows	the	least	amount	of	proteolysis	to	be	conducted,	to	allow	the	cell	to	pass	
through	the	basement	membrane	(Wang	et	al.,	2006).	To	conduct	this	process,	CD11a	on	
leukocytes	interacts	with	ICAM-1	on	pericytes,	to	guide	them	towards	the	regions	basement	
membrane	with	a	low	density	(Proebstl	et	al.,	2012).	In	an	ideal	situation,	leukocytes	pass	
through	the	endothelial	membrane	at	a	site	where	there	are	gaps	between	endothelial	cells,	
a	low	density	of	basement	membrane	and	a	gap	between	pericytes,	to	allow	the	leukocytes	
to	efficiently	pass	through	the	endothelial	membrane	(Kolaczkowska	&	Kubes,	2013).	
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Once	through	the	endothelial	membrane,	leukocytes	need	to	migrate	through	the	tissue	to	
the	site	that	induced	inflammation.	This	is	done	using	a	chemotactic	gradient	from	the	site	
of	leukocyte	entry	into	the	tissue	increasing	towards	the	focus	of	inflammation.	Potential	
chemotactic	factors	include	bacterial	peptides,	complement	proteins	(C5a),	extracellular	
matrix	degradation	products,	arachidonic	acid	metabolites	(Leukotriene	B4),	other	lipid	
mediators	(Platelet-activating	factor)	and	several	small	molecular	weight	(<10KDa)	cytokines	
(CXC	chemokines)	(Moreland,	2004).	
	
When	the	leukocyte	reaches	the	focus	of	the	inflammation,	it	acts	to	clear	the	causative	
agent.	This	is	done	through	phagocytosis	of	the	causative	agent,	the	release	of	antimicrobial	
molecules	(neutrophil	peptides	LL-37,	HNP-1,	HNP-3	and	Nitric	oxide)	and	the	production	
and	release	of	extracellular	traps	in	the	form	of	Neutrophil	nets	(Kaplan	&	Radic,	2012;	Dale,	
Boxer	&	Conrad	Liles,	2008;	Aarbiou	et	al.,	2006;	Mariano	et	al.,	2012).		
	
The	transmigration	of	leukocytes	into	inflamed	tissue	is	a	key	component	in	the	elimination	
of	pathogenic	sources	and	the	repair	of	damage	following	injury.	Once	in	the	tissues,	they	
have	other	key	roles	including	the	removal	of	causative	agents,	the	recruitment	of	further	
immune	cells,	the	secretion	of	cytokines	and	chemokines,	activation	of	complement	
pathways	and	the	acute	phase	response.		
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Figure	10)	The	interaction	between	pro-inflammatory	cytokines	and	liver	hepatocytes,	
induces	the	acute	phase	response	and	the	production	of	acute	phase	proteins.	
1.2.4.2	-	The	acute	phase	response	to	major	trauma	
The	acute	phase	response	is	a	physiological	process	that	occurs	during	inflammation,	
triggered	by	infection,	trauma	and	malignancy	(Gruys	et	al.,	2005).	The	response	is	caused	
by	the	release	of	pro-inflammatory	cytokines,	secreted	during	an	inflammatory	response	
(Gruys	et	al.,	2005).		Pro-inflammatory	cytokines	(TNFα,	IL-1	and	IL-6)	act	on	hepatocytes	to	
induce	the	production	of	acute	phase	proteins	(Figure	10)	(Moshage,	1997;	Cray,	Zaias	&	
Altman,	2009).	These	proteins	act	as	inflammatory	mediators,	scavenger	molecules	and	
tissue	repair	molecules,	to	allow	enhancement	of	tissue	protection	and	antimicrobial	
mechanisms	(Sander	et	al.,	2010).		
There	are	several	acute	phase	proteins	that	play	a	role	in	the	immune	response	following	
traumatic	injury	including	C	reactive	protein,	fibrinogen,	α2	macroglobulin,	serum	amyloid	A	
and	complement	factors	(Ceciliani,	Giordano	&	Spagnolo,	2002;	Cray,	Zaias	&	Altman,	2009).	
	
C	reactive	protein	is	an	opsonin,	which	binds	to	damaged	and	dying	cells	(Pepys	&	
Hirschfield,	2003;	Black,	Kushner	&	Samols,	2004).	Once	bound,	these	molecules	activate	
the	complement	system,	resulting	in	the	removal	of	the	damaged	cell	by	phagocytosis	(Du	
Clos,	2000;	Volanakis,	2001).	
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Fibrinogen	is	a	glycoprotein	produced	by	the	liver.	It	plays	a	key	role	in	the	coagulation	
cascade	(Lowe,	Rumley	&	Mackie,	2004).	Fibrinogen	acts	as	a	precursor	molecule	to	fibrin,	
which	is	produced	following	the	conversion	of	fibrinogen	using	thrombin	(Kamath	&	Lip,	
2003).	Both	fibrinogen	and	fibrin	can	form	bridges	between	platelets,	strengthening	blood	
clots.	However,	fibrinogen	is	predominantly	utilised	as	a	precursor	molecule	for	fibrin	
(Weisel,	2005).		
	
α2	macroglobulin	is	a	plasma	protein.	It	acts	as	an	anti-protease,	which	inactivates	a	vast	
array	of	proteinases	(Ebersole	&	Cappelli,	2000;	Werner	et	al.,	2003).	Its	major	function	is	
the	inhibition	of	fibrinolysis,	by	inhibiting	plasmin	and	thrombin	(Gouin-Charnet	et	al.,	
2000).	This	inhibition	of	thrombin	has	a	major	role	in	the	coagulation	cascade,	as	it	results	in	
limited	fibrin	production	and	weaker	clot	formation.	α2	macroglobulin	can	also	act	as	a	
transporter	molecule,	with	it	being	shown	to	transport	numerous	growth	factors	and	
cytokines,	such	as	platelet-derived	growth	factor,	basic	fibroblast	growth	factor,	IL-1β,	TGF-
β,	and	insulin	(Rehman,	Ahsan	&	Khan,	2013).	
	
Serum	amyloid	A	(SAA)	is	secreted	during	the	acute	phase	of	inflammation	as	a	part	of	the	
acute	phase	response	in	the	liver	(Richard	&	Sun,	2015;	Uhlar	&	Whitehead,	1999).	It	has	
several	different	functions	including	the	transport	of	cholesterol	and	the	induction	of	
enzymes	that	degrade	extracellular	matrix.	Its	main	role	in	the	inflammatory	response	is	to	
recruit	immune	cells	to	the	site	of	inflammation,	through	chemotactic	action	(Eklund,	Niemi	
&	Kovanen,	2012).		SAA	also	has	the	capability	to	induce	cytokine	production,	further	
enhancing	the	inflammatory	response	(Eklund,	Niemi	&	Kovanen,	2012).	
	
The	acute	phase	response	also	produces	proteins	of	the	complement	system.	The	release	of	
DAMPS	and	PAMPs	induce	the	activation	of	the	complement	system	(Huber-Lang,	Kovtun	&	
Ignatius,	2013).	The	complement	cascade	involves	a	series	of	cleavages,	via	the	classical	and	
alternative	pathways,	leading	to	the	formation	of	C3	and	C5,	which	are	further	cleaved	to	
form	the	functional	components	of	the	complement	system	(Amara	et	al.,	2008;	Murphy	&	
Weaver,	2016).	The	main	functions	of	these	components	are	opsonisation,	inflammation	
and	direct	destruction	of	cells	(Sinno	&	Prakash,	2013).	
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Opsonisation	of	molecules	targeted	for	phagocytosis	involves	the	binding	of	complement	
proteins	to	targeted	cells	(Tosi,	2005).	Complement	proteins	C3b	and	C4b	covalently	bind	to	
pathogens,	apoptotic	cells	and	antibody-antigen	complexes,	allowing	phagocytic	cells	to	
recognise	cells	and	phagocytose	them	(Sharma	&	Ward,	2011).	
	
Anaphylatoxins	are	also	produced	by	the	complement	cascade	(Peng	et	al.,	2009).	
Complement	proteins	C3a	and	C5a	support	different	inflammatory	mechanisms	including	
the	enhancement	of	the	acute	phase	response	(Markiewski	&	Lambris,	2007),	chemotaxis,	
the	recruitment	and	activation	of	phagocytic	cells	(DiScorpio	&	Schraufstatter,	2007),	and	
the	degranulation	of	mast	cells	and	basophils	(Ali,	2010),	resulting	in	increased	vascular	
permeability	and	oedema	(DiScorpio	&	Schraufstatter,	2007).	C5a	also	plays	a	role	in	the	
coagulation	cascade,	by	increasing	the	expression	of	tissue	factor,	activating	the	tissue	
factor	pathway	of	the	coagulation	cascade	(Rittirsch,	Flierl	&	Ward,	2008).	
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1.3	-	The	role	of	cytokines	in	inflammation	
Cytokines	are	small,	secreted	molecules	released	by	cells,	which	have	a	specific	effect	on	the	
interactions	and	communications	between	cells	(Zhang	&	An,	2007).	Cytokines	can	be	
termed	as	lymphokines	(made	by	lymphocytes),	monokines	(made	by	monocytes),	
interleukins	(made	by	leukocytes	that	act	on	other	leukocytes)	and	chemokines	(molecules	
that	possess	chemotactic	activity).		These	groups	of	cytokines	vary,	not	only	in	their	function	
but	also	their	molecular	weight,	which	can	range	from	6-70kDa	(Stanken	&	Poschenrieder,	
2015).	The	word	cytokine	is	a	general	term	used	to	describe	a	secreted	molecule.	This	can	
be	narrowed	down	based	on	the	type	of	cell	which	secretes	the	molecule.		
	
Cytokines	have	multiple	modes	of	action	on	how	they	reach	their	target	cell.	They	can	work	
in	an	autocrine	fashion,	where	the	cytokine	released	by	a	cell	also	bind	to	a	receptor	on	the	
secretory	cell.	Cytokines	can	also	act	on	cells	in	the	area	surrounding	the	secretory	cell,	
termed	paracrine	action.	Or	cytokines	can	enter	the	bloodstream	and	act	on	cells	at	a	great	
distance	from	the	cell	that	secreted	the	cytokine,	this	is	termed	endocrine	action	(Libby	et	
al.,	1995;	Dembic,	2015).	
	
The	dysregulation	of	cytokine	secretion	causes	the	pathogenesis	of	many	inflammatory	
conditions	(Elshaer	&	Begun,	2016),	and	has	been	shown	to	play	a	key	role	in	the	
pathogenesis	of	trauma	complications.	Therefore,	the	balance	of	pro	and	anti-	inflammatory	
cytokines	is	an	important	part	of	homoeostasis,	when	it	becomes	abnormal,	can	lead	to	dire	
consequences	for	the	patients.	
	
1.3.1	-	Interleukin-1	
Interleukin-1	(IL-1)	is	a	central	mediator	of	innate	immunity	and	inflammation	(Garlanda,	
Dinarello	&	Mantovani,	2013).	The	interleukin-1	family	of	cytokines	contains	eleven	
different	molecules,	with	the	key	members	being	Interleukin-1	alpha	(IL-1α)	and	Interleukin-
1	beta	(IL-1β).	IL-1α	and	IL-1β	are	potent	inflammatory	cytokines	that	activate	the	
inflammatory	process	(Di	Paolo	&	Shayakhmetov,	2016).		
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IL-1α	and	IL-1β,	are	encoded	by	separate	genes,	bind	to	the	same	receptor	(IL-1R1)	and	have	
similar	biological	properties.	IL-1α	is	found	as	a	precursor	in	the	epithelial	cell	lining	of	the	
gastrointestinal	tract,	lung,	liver,	kidney,	endothelial	cells	and	astrocytes	(Chen	et	al.,	2007).	
Following	cellular	damage,	such	as	after	traumatic	injury,	the	precursor	is	released,	acting	as	
an	alarmin	for	the	immune	system	and	inducing	an	inflammatory	cascade	(Rider	et	al.,	
2011).	IL-1α	localises	to	the	nucleus	and	functions	as	a	component	of	transcription.	The	
activation	of	transcription	stimulates	the	release	of	TNFα	from	endothelial	cells	(Saperstein	
et	al.,	2009),	induces	the	proliferation	of	CD4+	T	cells	(Ben-Sasson	et	al.,	2013)	and	increases	
the	abundance	of	blood	neutrophils	(Rider	et	al.,	2011).	
	
IL-1β	is	produced	by	hematopoietic	cells	such	as	blood	monocytes,	tissue	macrophages,	skin	
dendritic	cells	and	brain	microglia	in	response	TLR,	activated	complement	components,	
other	cytokines	(such	as	TNF-α)	and	IL-1	itself	(Dinarello,	2011).	In	vivo,	IL-1β	can	evoke	
fever,	hypotension,	release	of	adrenocorticotrophic	hormone	and	production	of	cytokines	
which	in	turn	induce	various	inflammatory	and	immune	responses	(Li	et	al.,	2008).	IL-1β	has	
been	shown	to	be	elevated	in	the	period	following	traumatic	injury	(Li	et	al.,	2008).	It	has	
also	been	shown	to	be	a	major	cytokine	in	the	development	of	auto	inflammatory	
conditions,	such	as	rheumatoid	arthritis	and	Type	2	diabetes	(Dinarello,	2009;	Lopalco	et	al.,	
2015).	Correlations	have	also	been	observed,	that	link	the	serum	concentration	of	IL-1β	to	
patient	survival	following	the	development	of	septic	shock	(Casey,	Balk	&	Bone,	1993).				
	
1.3.2	-	Interleukin-4	
IL-4	is	produced	mainly	by	activated	T	cells	but	also	by	mast	cells,	basophils,	and	eosinophils	
(Nelms	et	al.,	1999).	A	typical	cytokine	structurally,	with	molecular	weight	varying	between	
12	and	20	kDa	because	of	variable	natural	glycosylation.	(Luzina	et	al,	2012).	Functionally,	IL-
4	regulates	cell	proliferation,	apoptosis,	and	expression	of	numerous	genes	in	various	cell	
types,	including	lymphocytes,	macrophages,	and	fibroblasts,	as	well	as	epithelial	and	
endothelial	cells	(Luzina	et	al,	2012).		
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IL-4	is	a	key	cytokine	in	the	development	of	allergic	inflammation.	It	is	associated	with	
induction	of	the	epsilon	isotype	switch	and	secretion	of	IgE	by	B	lymphocytes	(Steinke	&	
Borish,	2001).	It	is	also	involved	in	the	differentiation	of	Th-2	lymphocytes	leading	to	Th-2	
cytokine	release	(Vella	et	al.,	1997)	and	the	induction	of	VCAM-1	expression	on	the	vascular	
epithelium	(Moser,	Fehr	&	Bruijnzeel,	1992).	Interleukin-4	can	subsequently	produce	further	
IL-4	through	a	positive	feedback	loop	on	Th2	cells.	
	
1.3.3	-	Interleukin-6	
Interleukin-6	(IL-6)	is	a	polyfunctional	cytokine	that	plays	a	key	role	in	host	defence.	IL-6	was	
first	identified	in	the	mid-1980’s	as	a	small	glycoprotein	that	is	relatively	unique	compared	
to	other	cytokines,	due	to	it	being	produced	by	a	broad	spectrum	of	cells	in	response	to	a	
variety	of	different	stimuli	(Rincon,	2012).		
	
Human	Interleukin-6	is	encoded	for	by	a	gene,	located	on	chromosome	7p21,	spanning	
approximately	5	kilobases	(Kb)	in	length	and	is	composed	of	four	introns	and	five	exons	
(Keller	et	al.,	1996).	These	exons	encode	for	an	1197	base	pair	mRNA	transcript,	which	is	
then	translated	into	the	Inteleukin-6	protein	(NCBI	GenBank,	2017).	This	protein	is	made	up	
of	212	amino	acids	including	a	28-amino	acid	signalling	peptide	(Tanaka	et	al.,	2014).		The	
core	protein	is	20kDa	in	mass,	however,	it	has	varying	degrees	of	glycosylation	leading	to	a	
natural	product	with	a	mass	of	between	21-26kDa	(Tanaka	et	al.,	2014).		
	
Interleukin-6	was	first	identified	in	1986	and	was	initially	called	B-cell	stimulatory	factor-2	
before	further	analysis	was	conducted	and	identified	that	Interleukin-6	had	the	same	
protein	structure	as	several	other	molecules,	allowing	it	to	be	known	as	a	pleiotropic	
cytokine	with	a	wide	range	of	functions	(Kishimoto,	2010).	Interleukin-6	has	been	described	
as	relatively	unique	compared	to	other	cytokines,	in	that	it	is	produced	by	a	broad	spectrum	
of	cells	in	response	to	a	variety	of	different	stimuli	(Rincon,	2012).		
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Under	normal	physiological	conditions,	the	concentration	of	interleukin-6	is	relatively	low	at	
a	concentration	of	between	0-5pg/ml	in	human	serum	(Hunter	&	Jones,	2015).	However,	
under	disease	conditions,	such	as	post	trauma,	the	concentration	can	rapidly	rise	to	
significantly	higher	levels	than	normal,	allowing	a	disease	condition	to	be	determined	
compared	to	homeostatic	conditions	(Hunter	&	Jones,	2015).		
	
Interleukin-6	is	mainly	secreted	by	T	cells	and	macrophages,	to	stimulate	an	immune	
response	following	events	such	as:	during	infection	and	after	traumatic	events,	namely	
burns	and	tissue	damage	leading	to	inflammation.	However,	it	is	also	secreted	from	other	
lymphoid	and	non-lymphoid	cells	including	B	cells,	fibroblasts,	keratinocytes,	endothelial	
cells,	astrocytes	and	mesangial	cells	(Figure	12)	(Kishimoto,	1989).	It	has	several	functions	
within	the	body	that	allow	IL-6	to	control	systemic	responses	such	as	the	acute	phase	
response,	the	regulation	of	leukocyte	recruitment,	numerous	effector	functions	and	
increasing	the	retention	of	inflammatory	cells	within	inflamed	tissue	(Liu	et	al.,	2016).	
Figure	12)	The	range	of	cells,	which	produce	interleukin-6.	
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Interleukin-6	has	also	been	shown	to	act	as	a	warning	signal	to	the	immune	system,	by	
indirectly	acting	as	a	DAMP	due	to	its	rapid	synthesis	following	the	damage	to	cells	or	the	
presence	of	a	pathogenic	organism	(Tanaka	et	al.,	2014).	The	presence	of	Interleukin-6	tells	
the	body	that	there	has	been	damage	and	triggering	an	immune	response	at	the	location	at	
which	the	causative	factor	has	bound	to	the	PRR	(Tanaka	et	al.,	2014).	
	
Interleukin-6	yields	its	biological	activity	on	cells	through	interaction	with	two	receptors:	IL-
6R	and	Glycoprotein	130	(Gp130)	(Figure	13).	Initial	binding	of	interleukin-6	to	IL-6R	cannot	
itself	initiate	a	signalling	cascade	due	to	its	short	cytoplasmic	domain	(Hassan	et	al.,	2014).	
Thus,	the	IL-6/IL-6R	complex	needs	to	bind	to	another	cell	membrane	receptor	known	as	
Gp130.	The	dimerization	of	Gp130,	following	the	binding	of	the	IL-6/IL-6R	complex,	allowing	
the	activation	of	protein	kinases	promoting	the	phosphorylation	of	downstream	signalling	
molecules	(Hunter	&	Jones,	2015).	
	
The	cytoplasmic	domain	of	Gp130	is	significantly	larger	than	IL-6R,	therefore	it	can	contain	
many	potential	motifs	that	induce	signal	transduction	such	as	the	Signal	transducer	and	
activator	of	transcription	(STAT)	and	Mitogen-activated	protein	kinase	(MAPK)	pathways	
(Kishimoto,	2010).	However,	Gp130	requires	the	further	addition	of	a	protein	kinase	such	as	
Janus	kinase	(JAK)	to	deliver	downstream	signalling	through	these	two	pathways	(Hassan	et	
al.,	2014).		
	
Once	phosphorylated	by	the	JAK,	STAT	can	dimerise	and	pass	into	the	nucleus,	leading	to	
the	expression	of	genes	by	binding	to	promoter	regions	of	target	genes	(Horn	et	al.,	2000).	
Gp130	is	expressed	on	all	cell	types,	while	IL-6R	is	limited	to	a	group	of	lymphoid	cells	
including	monocytes,	macrophages,	neutrophils,	B-cells	and	some	populations	of	T-cells,	
along	with	non-lymphoid	cells	such	as	hepatocytes	(Chalaris	et	al.,	2011).		
	
	
	
	
	
42	
However,	IL-6	signalling	can	take	place	on	cells	that	do	not	possess	IL-6R	due	to	a	process	
called	trans-signalling	through	a	soluble	version	of	IL-6R	(sIL-6R),	produced	following	
proteolytic	cleavage	or	alternative	splicing	of	the	IL-6R	molecule	(Drutskaya	et	al.,	2015).	
This	process	of	trans-signalling	allows	significant	expansion	of	the	types	of	cells	that	IL-6	can	
interact	with,	preventing	it	from	exclusively	acting	on	cells	of	the	immune	system	(Drutskaya	
et	al.,	2015).	
	
The	binding	of	interleukin-6	to	cells	can	induce	several	functional	effects	mainly	to	control	
the	systemic	response	during	inflammation,	namely:	the	recruitment	of	leukocytes,	effector	
functions	and	the	retention	of	inflammatory	cells	within	inflamed	tissues	(Liu	et	al.,	2016).	
Interleukin-6	causes	the	recruitment	of	leukocytes	due	to	the	binding	of	the	IL-6/IL-6R	
complex	to	endothelial	cells,	activating	them,	resulting	in	the	secretion	of	Interleukin-8	and	
monocyte	chemoattractant	protein	1	(MCP-1),	and	leading	to	the	expression	of	adhesion	
molecules	on	the	endothelial	cells	(Gabay,	2006).		
Figure	13)	The	process	by	which	Interleukin-6	induces	gene	expression	within	cells	
possessing	Gp130	on	their	cell	membranes.	
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Another	key	function	of	Interleukin-6	is	to	act	as	a	regulator	of	the	acute	phase	response	
(Figure	14).	It	does	this	by	inducing	the	expression	of	acute	phase	response	proteins	such	as	
C-Reactive	Protein	(CRP),	Fibrinogen	and	Serum	Amyloid	A	(Chalaris	et	al.,	2011).	This	
process	aids	in	the	recruitment	of	immune	cells	to	the	site	of	inflammation	and	the	
clearance	of	any	causative	agent,	which	may	have	triggered	the	inflammatory	response.	
	
	
	
	
	
	
	
	
	
Figure	14)	The	key	biological	functions	of	Interleukin-6	and	its	effects	on	cell	functions	
throughout	the	body.	Image	from	Rincon,	2012.	
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Figure	15)	The	types	of	cells	that	secrete	interleukin-10	and	the	factors	required	to	activate	
secretion	from	each	of	the	cells	(Nagpal	et	al.,	2017)	
1.3.5	-	Interleukin-10	
Interleukin-10	(IL-10)	is	a	major	anti-inflammatory	cytokine.	It	is	classed	as	a	type	II	cytokine	
(Th-2)	and	is	a	founding	member	of	a	family	of	cytokines	including,	interleukins-19,	20,	22,	
24,	26,	28	and	29	(Mosser	&	Zhang,	2008).	Interleukin-10	was	first	described	as	a	product	of	
T-helper	class	II	cells,	to	inhibit	cytokine	synthesis	in	class	I	T-helper	cells	(Th-1)	(Couper,	
Blount	&	Riley,	2008).		
	
IL-10	is	known	to	be	produced	by	a	variety	of	cells	both	immune	and	non-immune	cells.	It	is	
produced	by	macrophages,	dendritic	cells,	B	cells	and	various	subsets	of	CD4+	and	CD8+	
cells	(Figure	15)	(Couper,	Blount	&	Riley,	2008).	Additionally,	non-immune	effector	cells,	
such	as	epithelial	cells	and	keratinocytes	are	also	capable	of	producing	IL-10	in	a	response	to	
infection	or	tissue	damage	(Iyer	&	Cheng,	2012).	
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The	gene	that	encodes	the	IL-10	protein	spans	approximately	4.7	kilobases	on	chromosome	
1	21-32	(Iyer	&	Cheng,	2012).	The	gene	coding	IL-10	contains	5	exons	and	4	introns	(Iyer	&	
Cheng,	2012).	This	gene	encodes	a	biologically	active	form	of	IL-10,	which	is	36	kiloDaltons	
homodimer,	composed	of	two	non-covalently	bonded	monomers	each	made	up	of	160	
amino	acid	chains	(Verma	et	al.,	2016).	Two	disulphide	bridges	link	the	two	monomers,	
allowing	the	molecule	to	maintain	its	biological	and	structural	activity	(Verma	et	al.,	2016).	
	
Due	to	being	derived	from	numerous	different	cell	types,	IL-10	has	effector	functions	in	
numerous	different	cell	types	including,	mast	cells,	eosinophils,	dendritic	cells,	T-helper	cells	
and	IL-10	secreting	regulatory	T	cells	(Hawrylowicz	&	O’Garra,	2005).	IL-10	also	plays	a	
critical	role	as	a	feedback	regulator	of	diverse	immune	responses	(Ouyang	et	al.,	2011;	
Saraiva	&	O’Garra,	2010).		
	
Interleukin-10	invokes	its	anti-inflammatory	effects	
through	its	effect	on	antigen	presenting	cells	(Figure	
16).	This	prevents	the	production	of	Th-1	associated	
cytokines	such	as	IL-2	and	interferon	gamma,	and	the	
Th-2	cytokines,	IL-4	and	IL-5	(Mosser	&	Zhang,	2008).	
The	other	effect	of	IL-10	is	the	inhibition	of	pro-
inflammatory	cytokine	and	mediator	production	from	
macrophages	and	dendritic	cells	(Sabat	et	al.,	2010).	
This	dramatically	represses	IL-1,	IL-6,	IL-12	and	TNFα,	
following	exposure	to	IL-10	(Keel	et	al.,	1997;	Sabat	et	
al.,	2010).	
	
Not	all	IL-10	activity	is	immunosuppressive.	IL-10	
can	stimulate	B-cell	activation,	prolong	B-	cell	
survival	and	contribute	to	inducing	antibody	class	switching	in	B-cells	(Moore	et	al.,	2001).	It	
can	also	stimulate	natural	killer	cells	proliferation	and	cytokine	production	(Mosser	&	Zhang,	
2008).		
	
Figure	16)	The	main	functions	of	
interleukin-10	and	the	cells	on	which	it	
acts	(Hawrylowicz	&	O’Garra,	2005).	
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Interelukin-10	has	also	been	shown	to	enhance	the	differentiation	of	IL-10	secreting	T-
regulatory	cells	(Treg),	thus	providing	a	positive	regulatory	feedback	loop	for	the	induction	
of	IL-10	(Saraiva	&	O’Garra,	2010).	However,	in	vivo,	Tregs	must	receive	signals	to	induce	IL-
10	secretion.	In	vitro	analysis	has	shown	that	IL-2,	IL-4	and	TGFβ	have	been	shown	to	induce	
IL-10	expression	(Saraiva	&	O’Garra,	2010).	
	
To	invoke	these	immunomodulatory	and	anti-inflammatory	effects,	IL-10	needs	to	trigger	
signalling	pathways	within	cells	(Figure	17).	This	occurs	through	the	binding	of	IL-10	to	a	
two-receptor	complex,	consisting	of	interleukin-10	receptor	1	(IL-10R1)	and	interleukin-10	
receptor	2	(IL-10R2)	(Mosser	&	Zhang,	2010).	IL-10R1	binds	to	IL-10	with	a	high	affinity	and	
causes	a	conformational	change	that	leads	to	the	recruitment	and	oligomerisation	of	IL-
10R2	to	the	receptor	(Hutchins	et	al.,	2013).	The	binding	of	IL-10R2	and	formation	of	the	IL-
10	receptor	complex	enables	signal	transduction	following	the	binding	of	the	IL-10	ligand	
(Verma	et	al.,	2016).	
	
Ligation	of	IL-10	to	the	receptor	complex,	activates	the	Janus-associated	kinase	(JAK)/signal	
transducer	and	activator	of	transcription	(STAT)	pathway,	leading	to	large-scale	changes	in	
transcription	and	expression	of	immunomodulatory	genes	(Murray,	2006).	This	ligation	
causes	phosphorylation	of	the	receptor-associated	JAK.	This	leads	to	phosphorylation	of	
tyrosine	residues	on	the	intracellular	domain	of	IL-10R1	(Verma	et	al.,	2016).	This	
phosphorylation	allows	STAT	3	to	bind	to	IL-10R1	and	itself	become	phosphorylated.	The	
phosphorylated	STAT	3	molecules	can	then	dimerise	to	one	another,	allowing	it	to	
translocate	through	the	nuclear	membrane	(Verma	et	al.,	2016).	Once	in	the	nucleus,	STAT	
3	dimers	can	bind	to	STAT	3	binding	elements	in	the	promoters	of	various	IL-10	responsive	
genes	(Verma	et	al.,	2016).	
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Figure	17)	The	Interleukin-10	signalling	pathway.	The	binding	of	interleukin-10	to	the	IL-
10R1	receptor,	triggers	the	recruitment	of	IL-10R2,	causing	the	downstream	signalling	
through	the	JAK/STAT	pathway.	This	ultimately	results	in	changes	in	gene	expression,	
enhancing	the	expression	of	anti-inflammatory	genes.	
	
	
The	binding	of	STAT	3	dimers	induces	transcription	of	target	genes.	The	activation	and	
transcription	of	these	genes	invoke	the	immunomodulatory	and	anti-inflammatory	effects	
associated	with	IL-10	(Mosser	&	Zhang,	2008).	These	effects	are	caused	by	inducing	
downregulation	of	pro-inflammatory	cytokine	gene	expression	or	by	increasing	the	
expression	of	pro-inflammatory	cytokine	“mopping”	molecules	(Saraiva	&	O’Garra,	2010).	
The	binding	of	STAT	3	can	also	induce	the	expression	of	the	suppressor	of	cytokine	signalling	
3	(SOCS	3)	(Iyer	&	Cheng,	2012).	This	molecule	inhibits	pathogen	and	damage	recognition	
receptors,	such	as	Toll-like	receptors,	ultimately	leading	to	decreased	expression	of	pro-
inflammatory	cytokines,	including	TNFα,	IL-6	and	IL-1β	(Ouyang	et	al.,	2011).	
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Despite	the	ability	of	interleukin-10	to	decrease	pro-inflammatory	responses,	if	the	
production	of	interleukin-10	is	too	strong,	immunodeficiency	can	occur	(Taylor	et	al.,	2006).	
It	has	been	shown	that	overexpression	of	IL-10	results	in	significant	elevation	in	bacteraemia	
(Dolgachev	et	al.,	2014).	Experiments	have	also	shown	that	elevated	levels	of	interleukin-10	
in	trauma	patients	appears	to	be	a	predictor	of	poor	prognosis,	as	it	is	associated	with	
immunosuppressive	complications,	resulting	in	higher	risk	of	infection,	the	development	of	
multi-organ	failure	and	death	(Schneider	et	al.,	2004).		
	
Interleukin-10	is	a	key	anti-inflammatory	cytokine,	that	plays	an	important	role	in	
preventing	an	overactive	pro-inflammatory	response.	However,	if	the	anti-inflammatory	
response	is	too	strong,	it	can	lead	to	immune	suppression	and	the	development	of	adverse	
complications.	
	
1.3.6	-	Tumour	Necrosis	Factor	alpha	
Tumour	Necrosis	Factor	alpha	(TNF	α),	is	a	multifunctional	cytokine	playing	a	key	role	in	
apoptosis	and	cell	survival	as	well	as	in	inflammation	and	immunity	(van	Horssen,	ten	Hagen	
&	Eggermont,	2006).	TNFα	is	best	known	as	an	inflammatory	cytokine	produced	
predominantly	by	macrophages/monocytes,	but	can	also	be	produced	CD4+	
lymphocytes,	NK	cells,	neutrophils,	mast	cells,	eosinophils,	and	neurones	during	acute	
inflammation	and	is	responsible	for	a	diverse	range	of	signalling	events	within	cells	(Idriss	&	
Naismith,	2000).	Despite	being	predominantly	a	pro-inflammatory	cytokine,	TNFα	has	an	
optional	capacity	to	induce	apoptosis	(Marques-Fernandez	et	al.,	2013).	Under	
pathophysiological	conditions,	TNFα	shows	dual	functions,	being	strongly	engaged	in	both	
tissue	regeneration/expansion	and	destruction	(Wajant,	Pfizenmaier	&	Scheurich,	2003).	
	
TNFα	interacts	with	cells	through	two	main	receptors	TNF	receptor	1	(TNFR1)	and	TNF	
receptor	2	(TNFR2)	(MacEwan,	2002).		TNFR1	is	constitutively	expressed	in	most	tissues,	
where	TNFR2	expression	is	highly	regulated	and	is	typically	located	on	cells	of	the	immune	
system	(Wajant,	Pfizenmaier	&	Scheurich,	2003).	TNFα	induces	the	NF-κβ	signalling	
pathway.	NF-κβ	is	a	global	trans-activator	of	numerous	pro-inflammatory	cytokines	(IL-1,	IL-
2,	IL-6,	IL-8,	IL-12	and	TNFα),	chemokines,	adhesion	molecules	and	cell	survival	molecules	
(Sedger	&	McDermott,	2014;	Bradley,	2008).	
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If	TNFα	is	produced	in	high	amounts	and	present	in	systemic	circulation,	it	can	stimulate	the	
production	of	pro-inflammatory	cytokines	IL-1	and	IL-6	by	leukocytes	(Cereda	et	al.,	2012).		
It	also	results	in	the	synthesis	of	acute	phase	proteins	in	the	liver,	causing	an	acute	phase	
response	and	intracellular	clotting	(Cereda	et	al.,	2012).	Following	traumatic	injury,	TNFα	
has	been	shown	to	become	elevated	in	the	initial	period	after	the	injury	(Spielmann	et	al.,	
2001;	Namas	et	al.,	2009).	It	has	also	been	described	that	an	elevated	concentration	of	
TNFα	has	protective	properties,	as	it	has	been	shown	to	be	elevated	in	survivors	of	major	
trauma	compared	to	non-survivors	(Surbatovic	et	al.,	2013).		
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Figure	18)	The	four	main	types	of	ELISA	commonly	used	in	research.	Primary	antibody	
(orange);	Secondary	antibody	(blue);	reporter	molecule	(yellow);	Substrate	pre-reaction	
(green);	Substrate	post-reaction	(purple);	Red	triangle	represents	incorrect	antigen	bound	
to	antibody.	
1.3.7	-	Methods	of	cytokine	detection	
The	measurement	of	proteins	within	biological	fluids	is	vitally	important	within	scientific	
research.	It	plays	a	major	role	in	the	research	of	a	variety	of	diseases	ranging	from	cancer	to	
inflammation,	to	vaccine	development	(Noble	&	Bailey,	2009).	Methods	used	to	measure	
the	proteins	include	Western	blots,	Enzyme-linked	immunosorbent	assays	(ELISA)	and	
modern	flow	cytometry	based	cytometric	bead	array.	
	
1.3.7.1	-	Enzyme-linked	immunosorbent	assay	
Enzyme-linked	immunosorbent	assays	(ELISA’s)	are	a	commonly	used	method	in	the	
scientific	research	field.	It	was	first	developed	in	1971,	following	the	modification	of	the	
radioimmunoassay.	It	uses	the	basic	immunological	concept	of	antigens	binding	to	specific	
antibodies	to	detect	molecules	within	a	sample	(Gan	&	Patel,	2013).		
	
Several	variations	of	the	ELISA	method	have	been	developed	since	its	creation	in	1971,	
these	mainly	involve	the	use	of	different	reporter	molecules,	or	the	position	in	the	method	
where	the	antibody	is	added	to	the	sample,	either	before	or	after	the	addition	of	the	
primary	antibody.	The	main	variations	of	the	ELISA	method	are	A	direct	ELISA,	an	indirect	
ELISA,	sandwich	ELISA’s	and	competitive	ELISA’s	(Figure	18).	
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ELISA	methods	are	similar	throughout	the	variations	that	have	arisen	in	the	years	since	the	
development	of	the	method.	They	all	involve	the	initial	binding	of	the	desired	antigen	to	a	
primary	antibody	before	a	secondary	antibody	is	added	that	either	binds	to	the	primary	
antibody	or	the	antigen	(Bidwell	et	al.,	1976).	The	secondary	antibodies	are	commonly	
linked	to	a	reporter	molecule,	which	exhibits	a	significant	change	when	a	substrate	or	the	
correct	wavelength	of	light	is	added.	The	labels	linked	to	antibodies	are	enzymes	or	
fluorescent	molecules	that	when	provoked	yield	a	visible	colour	change	following	the	
addition	of	a	chromogenic	substrate	or	the	appropriate	wavelength	of	light	to	stimulate	the	
fluorescent	molecule	(Bidwell	et	al.,	1976).	The	amount	of	change	that	occurs	can	be	
correlated	to	the	amount	of	antigen	within	a	sample,	with	qualitative	or	quantitative	
measures	can	be	assessed	based	upon	the	colorimetric	reading	(Gan	&	Patel,	2013).	
	
The	primary	antibody	can	be	directly	conjugated	with	a	reporter	molecule,	however	this	
method	is	less	reliable	and	more	expensive	than	the	use	of	the	secondary	antibody,	as	the	
reporter	must	be	conjugated	directly	to	a	specific	antibody	for	the	antigen,	rather	than	
against	a	primary	antibody,	which	can	be	used	in	the	detection	of	several	antigens	that	are	
bound	to	the	same	type	of	antibody.	
	
The	ELISA	method	has	both	its	positives	and	negatives,	which	impact	its	current	use	in	
diagnostics	and	research.	The	ELISA	assay	shows	both	good	reproducibility,	along	with	good	
specificity	and	high	sensitivity.	Another	benefit	is	that	the	method	has	been	used	in	a	vast	
amount	of	research	journals	and	publications,	meaning	that	both	methods	and	results	are	
available	to	review	and	compare.	Due	to	this	vast	array	of	research	a	wide	variety	of	ELISA	
kits	are	available	for	most	molecules,	and	if	kits	are	unavailable,	primary	antibodies	can	be	
created	using	animal	models.	
	
The	ELISA	method	does	have	its	drawbacks,	mainly	in	the	fact	that	it	uses	a	relatively	large	
volume	of	the	sample	compared	to	other	methods	available,	this	may	prevent	analysis	being	
conducted	if	the	sample	size	is	small.		Another	negative	to	the	ELISA	method	is	that	it	is	
labour	intensive	and	time	consuming	compared	to	other	methods,	as	it	requires	multiple	
washing	steps	and	incubation	times.	These	washing	steps	can	also	lead	to	the	development	
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of	false	positives	arising	as	the	excess	antibodies	are	not	correctly	removed	or	false	
negatives	through	over-washing.	
	
1.3.7.2	-	Flow	cytometry	and	the	cytometric	bead	array	
Flow	cytometry	is	described	as	the	measurement	of	physical	and/or	chemical	characteristics	
of	cells	as	they	travel	through	a	liquid	stream	(Shapirio,	2005).	This	liquid	stream	forces	the	
cells	into	a	single	file	line	before	they	are	passed	through	a	light	source,	i.e.	a	laser.	By	
passing	through	the	source	of	light	a	cells	size,	granularity,	roughness	and	internal	
structures	can	be	analysed	(Shapirio,	2005).	
	
When	cells	pass	through	the	light	source,	they	cause	the	light	to	scatter,	which	can	be	
measured	by	detectors	(Figure	19).	This	scattering	can	be	either	forward	scattering	or	side	
scattering.		The	greater	the	amount	of	light	side	scatter	produced,	the	more	granular	a	cell	
is,	while	the	forward	scatter	of	light	relates	to	the	size	of	the	cell.	The	detectors	that	record	
changes	in	side	scatter,	forward	scatter	and	fluorescence,	relay	the	changes	back	to	a	
computer,	which	analyses	and	visualises	the	data	(Givan,	2013).		
	
	
	
	
Figure	19)	The	process	of	measuring	cell	size	and	granularity	using	flow	cytometry.	
Fluorescence	of	cellular	structures	can	also	be	measured	using	specific	monoclonal	
antibody	fluorescent	dye	conjugates.	
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Both	internal	and	external	cellular	components	can	be	stained	using	monoclonal	antibodies,	
conjugated	with	fluorescent	dyes.	This	allows	the	presence	of	internal	cellular	components	
to	be	identified	and	quantified	within	a	cell	(Givan,	2013).	This	ability	to	measure	the	
internal	cellular	structures	provides	a	variety	of	uses	such	as	measuring	cell	death,	the	
effectiveness	of	cancer	treatments,	quantification	of	cellular	structures	or	receptors	and	the	
measurement	of	proteins	and	other	molecules	within	biological	fluids.	
	
Flow	cytometry	based	methods	are	advancing	each	year,	with	the	invention	of	more	stable	
staining	antibodies,	better	fluorophores	and	increasing	the	power	of	the	flow	cytometry	
software,	allowing	it	to	more	accurately	distinguish	cells	and	measure	changes	in	cellular	
fluorescence.	Further	inventions,	such	as	novel	approaches	for	the	measurement	of	protein	
concentration	in	biological	fluids,	have	allowed	the	measurement	of	proteins	in	biological	
fluids	to	continue	to	advance.	One	of	these	approaches	is	the	cytometric	bead	array.	
	
Cytometric	bead	arrays	are	a	flow	cytometry	based	method	that	allows	multiple	different	
analytes,	namely	proteins	and	cytokines,	within	a	sample	to	be	analysed	simultaneously	
during	a	single	test.	Cytometric	bead	arrays	use	the	broad	range	of	fluorescence	available	
using	flow	cytometry	and	antibody	coated	beads,	to	determine	the	concentration	of	
analytes	within	a	sample.	Each	analyte	has	its	own	antibody-coated	bead,	with	its	own	
unique	fluorescence	intensity	allowing	several	different	antibody	coated	beads	to	be	
analysed	simultaneously	in	a	single	tube,	termed	a	multiplex	assay.	
	
The	cytometric	bead	array	method	employs	the	use	of	antibody	coated	beads	to	capture	the	
chosen	analytes	(Figure	20-1	and	Figure	20-2).	During	a	multiplex	assay,	each	type	of	
capture	bead	will	have	its	own	light	scatter	characteristics	allowing	it	to	be	differentiated	
from	capture	beads	for	a	different	analyte.	Once	the	analytes	have	been	captured,	a	
fluorescent	conjugate	is	added	(Figure	20-3),	which	allows	detection	of	the	captured	
analytes	during	analysis	using	flow	cytometry	(Morgan	et	al.,	2004).		
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As	the	conjugated	beads	pass	through	the	flow	cytometer	laser,	set	to	the	excitation	
wavelength	of	the	fluorophore	attached	to	the	conjugate,	the	fluorophore	is	excited	by	the	
laser	and	emits	a	signal,	which	is	detected	by	the	flow	cytometer	and	recorded	(Figure	20-
4).	The	amount	of	excitation	that	occurs,	correlates	with	the	concentration	of	the	analytes	
within	the	sample,	based	on	the	results	of	known	concentrations	and	the	development	of	a	
standard	curve.	
The	ability	to	multiplex	the	capture	beads	allows	the	simplification	of	panel	assays,	as	only	a	
single	sample	is	required	to	detect	and	quantify	numerous	analytes	within	a	sample	
(Morgan	et	al.,	2004).		This	is	beneficial	when	sample	volume	is	limited,	for	example	during	
analysis	of	paediatric	samples,	Clinical	studies	and	studies	involving	animal	models.	
Cytometric	bead	arrays	also	save	significant	time	compared	to	conventional	methods	due	to	
the	ability	to	analyse	multiple	analytes	at	once.	
	
The	cytometric	bead	array	provides	a	highly	sensitive	way	of	detecting	a	large	number	
cytokines	found	at	low	concentrations	in	pathogenic	conditions	(Jimenez	et	al.,	2005).	It	also	
is	an	attractive	method	to	study	immune	response	and	biomarkers	in	large-scale	studies	due	
to	the	requirement	of	reduced	sample	volume	and	time-saving	benefits	for	the	researcher	
(Moncunill	et	al.,	2013).			
	
	
	
Figure	20)	The	cytometric	bead	array	method	for	the	detection	of	a	specific	analyte.	
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However,	the	initial	investment	in	equipment,	namely	the	flow	cytometer,	to	conduct	the	
cytometric	bead	array	method	is	significantly	more	expensive	than	the	instruments	required	
to	conduct	the	ELISA	method.	Therefore,	this	may	act	as	a	barrier	to	entry	for	institutions,	
organisations	and	researchers	to	use	the	cytometric	bead	array	method	over	the	ELISA	
method.	
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1.4	-	Clinical	response	to	trauma	
The	clinical	response	to	trauma	involves	several	organ	and	metabolic	systems	including	
inflammatory,	cytokine,	coagulation	and	cellular	responses.	These	responses	are	invoked	by	
the	initial	injury	and	further	exacerbated	by	secondary	insults	in	the	form	of	a	biphasic	
response	to	trauma	(Butt	&	Shrestha,	2008).		
	
The	first	trauma	impact	determines	the	severity	of	the	initial	injury.	This	invokes	the	primary	
response,	termed	the	first	hit	and	acts	to	prime	the	immune	system	(Godinho	et	al.,	2015).	
Further	exogenous	and	endogenous	factors,	such	as	surgery,	bacterial	infection,	respiratory	
distress	and	ischemia,	can	cause	secondary	activation	of	the	immune	response.		The	
reactivation	of	the	immune	system	invokes	a	significantly	stronger	response,	compared	to	
the	response	following	the	initial	response	(Harwood	et	al.,	2005).	This	secondary	activation	
of	the	immune	system	plays	a	key	role	in	the	initiation	and	severity	of	post	traumatic	
complications	(Keel	&	Trentz,	2005).		
	
During	trauma,	the	balance	of	the	inflammatory	response	plays	a	key	role	in	the	ability	of	
the	body	to	recover	following	a	traumatic	insult.	The	initial	immune	response	to	trauma	is	to	
initiate	a	pro-inflammatory	response	at	the	focus	of	the	injury.	However,	in	major	trauma,	
this	pro-inflammatory	response	can	occur	systemically	and	induce	a	vast	pro-inflammatory	
response	throughout	the	whole	body.	If	unregulated,	this	response	can	invoke	damage	to	
the	body	and	induce	early	multi-organ	failure.		
	
The	pro-inflammatory	response	is	downregulated	by	an	anti-inflammatory	response.	This	
response	is	the	body	attempting	to	maintain	homoeostasis	and	prevent	damage	from	an	
overactive	pro-inflammatory	response.	But	this	anti-inflammatory	response	can	cause	
damage	to	the	body	if	it	becomes	overactive	and	dominates	the	inflammatory	response	to	
trauma.	This	overactive	anti-inflammatory	response	can	cause	the	body	to	develop	a	state	
of	immunosuppression,	leading	to	the	susceptibility	to	nosocomial	infections	and	the	risk	of	
developing	systemic	infections	in	the	form	of	septic	complications	and	late	stage	organ	
failure	(Figure	21).	
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In	trauma,	the	inflammatory	response	to	trauma	is	split	into	two	main	responses,	the	
systemic	inflammatory	response	syndrome	(SIRS)	and	the	compensatory	pro-inflammatory	
response	syndrome	(CARS).	These	responses	aim	to	balance	each	other	to	maintain	
homoeostasis,	prevent	complications	and	allow	the	initiation	of	optimised	wound	healing	
(Figure	21).	It	has	long	been	thought	that	CARS	follow	SIRS,	however,	it	has	now	been	
identified	that	both	responses	occur	simultaneously	(Rosenthal	&	Moore,	2016).	
	
	
	
	
	
	
	
	
	
	
	
Figure	21)	The	balance	between	the	systemic	inflammatory	response	syndrome	and	the	
compensatory	anti-inflammatory	response,	with	the	complications	that	arise	of	one	
response	becomes	dominant	over	the	other.	
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1.4.1	-	Systemic	inflammatory	response	syndrome	
The	concept	of	the	systemic	inflammatory	response	syndrome	was	first	developed	in	1991	
at	the	sepsis	definitions	consensus	conference	(Bone	et	al.,	1992).	This	concept	was	used	to	
describe	the	complex	chain	of	events	involved	in	the	response	to	numerous	different	
pathologic	disorders	including,	infection,	traumatic	injury,	burns	and	pancreatitis	(Balk,	
2014).			
	
Systemic	inflammatory	response	syndrome	is	a	result	of	systemic	activation	of	the	innate	
immune	system,	regardless	of	the	causative	agent	(Hoesel	&	Ward,	2004).	This	response	is	
differentiated	from	the	response	involved	in	sepsis	and	septic	shock,	by	the	need	for	an	
infectious	stimulus	to	be	present	in	sepsis	and	septic	shock	(Hoesel	&	Ward,	2004).		
Many	factors	have	been	postulated	to	trigger	SIRS,	including	products	released	from	
bacteria	in	the	form	of	PAMPS,	as	well	as	intracellular	products	released	during	necrotic	cell	
damage,	induced	following	traumatic	injury	(Bosmann	&	Ward,	2013).	
	
Systemic	inflammatory	response	syndrome	manifests	itself	as	two	of	the	following	criteria	in	
a	clinical	setting	(Table	1).	SIRS	can	clinically	manifest	itself	as,	hyperthermia	or	
hypothermia,	tachycardia,	tachypnea	or	hyperventilation,	or	leukocytosis	or	leukopenia	
(Robertson	&	Coopersmith,	2006).		
	
Table	1)	The	definitions	for	systemic	inflammatory	response	syndrome	and	sepsis.	
Systemic	inflammatory	response	syndrome	
Temperature	 >38oC	or	36oC	
Heart	rate	 >90	beats	per	minute	
Respiratory	rate	 >20	breaths	per	minute	
White	blood	cell	count	 >12x109	or	<4x109	
Sepsis	
SIRS	plus	evidence	of	infection	
	
These	criteria	used	to	describe	SIRS	are	general,	due	to	it	requiring	clinical	criteria	that	are	
commonly	abnormal	in	a	variety	of	different	pathological	conditions	(Robertson	&	
Coopersmith,	2006).		Due	to	this	the	criteria	for	describing	SIRS	has	been	widely	criticised	
due	to	it	being	too	non-specific	for	widespread	use.		
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Due	to	these	criteria,	the	incidence	of	SIRS	is	extremely	high	within	hospitals.	With	33%	of	
all	hospital	admissions	meeting	the	criteria	of	undergoing	SIRS.	This	rises	even	further	in	ICU	
patients	(50%),	and	up	to	80%	of	surgical	ICU	patients	(Brun-Buisson,	2000).	
	
The	inducement	of	the	systemic	inflammatory	response	stimulates	a	variety	of	changes	to	
immune	cells.	The	hyper-inflammation	associated	with	SIRS	causes	the	enhanced	expression	
of	cellular	adhesion	molecules	on	blood	leukocytes	and	endothelial	cells,	allowing	the	
migration	of	monocytes	and	neutrophils	into	inflamed	tissue	(van	der	Poll	&	Meijers,	2010;	
Bosmann	&	Ward,	2013).		This	inflammatory	response	also	activates	neutrophils	and	
macrophages,	which	generate	abnormally	high	amounts	of	reactive	oxygen	species	(ROS)	
and	reactive	nitrogen	species	(RNS)	(Van	Berlo	et	al.,	2010;	Bosmann	&	Ward,	2013).	The	
greater	the	amount	of	these	reactive	oxygen	and	nitrogen	species,	the	more	extensive	the	
chemical	changes	that	can	occur	to	cells	at	the	site	of	inflammation	(Storr	et	al.,	2013).		
These	reactive	species	can	induce	DNA	damage	and	ultimately	DNA	fragmentation.	This	
fragmentation	causes	cell	death	in	cells	exposed	to	high	levels	of	reactive	oxygen	and	
nitrogen	species	(Storr	et	al.,	2013;	Bosmann	&	Ward,	2013).	Cell	death	induced	by	reactive	
species,	potentially	further	amplifies	cell	death	following	traumatic	injury,	causing	additional	
damage	to	tissue	and	organs,	rather	than	initiating	the	repair	process	following	traumatic	
injury.	
	
During	the	systemic	pro-inflammatory	response,	there	is	a	fierce	interplay	between	
cytokines.	In	cases	where	pro-inflammatory	cytokines	are	rapidly	produced	with	no	or	a	
delayed	compensatory	mechanism,	can	induce	the	development	of	a	pro-inflammatory	
cytokine	storm	(Matsuda	&	Hattori,	2006).		Cytokine	storms	have	potential	to	do	significant	
damage	to	body	tissues	and	organs.	If	this	occurs	in	the	lungs,	for	example,	it	causes	fluids	
and	immune	cells	to	accumulate	within	the	organ,	this	can	result	in	the	blockage	of	airways	
and	organ	failure	because	of	the	adaptions	induced	by	the	cytokine	storm.		
These	pro-inflammatory	cytokines	also	activate	the	recruitment	of	phagocytic	cells	to	the	
site	of	inflammation	(Tisoncik	et	al.,	2013).	These	cells	release	proteases	and	free	oxygen	
radicals,	which	further	increase	the	tissue	damage	induced	by	the	traumatic	injury.	
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A	compensatory	anti-inflammatory	response	commonly	occurs	immediately	following	the	
initiation	of	a	systemic	inflammatory	response,	to	avoid	the	potential	complications	
associated	with	an	overactive	pro-inflammatory	response	with	no	opposing	response.	
	
1.4.2	-	Compensatory	anti-inflammatory	response	syndrome	
The	compensatory	anti-inflammatory	response	is	the	mechanism	used	to	dampen	the	pro-
inflammatory	response	induced	by	traumatic	injury.	This	allows	the	body	to	return	to	
normal	levels	of	inflammation	and	maintain	homoeostasis.	The	compensatory	anti-
inflammatory	response	was	first	described	in	1996,	by	the	presence	of	anti-inflammatory	
cytokines	and	pro-inflammatory	antagonist	receptors	(Bone,	1996;	Gentile	et	al.,	2012).		
	
Compensatory	anti-inflammatory	response	induces	a	state,	characterised	by	altered	
cytokine	production,	decreased	antigen	presentation,	decreased	lymphocyte	proliferation	
and	increased	immune	cell	apoptosis	(Zarjou	&	Agarwal,	2011).	An	exaggerated	anti-
inflammatory	response	can	make	individuals	susceptible	to	nosocomial	infection	or	
secondary	infection,	which	can	initiate	the	septic	cascade	(Balk,	2014).	The	compensatory	
anti-inflammatory	response	involves	cellular	adaptions,	characterised	by	lymphocyte	
dysfunction,	including	reduced	proliferation	and	Th-1	cytokine	production	in	response	to	
antigens.	Other	responses	involve	lymphocyte	apoptosis,	downregulation	of	monocyte	
human	leukocyte	antigen	receptors	and	monocyte	deactivation,	reduced	pro-inflammatory	
cytokine	production	in	response	to	stimuli,	and	increased	interleukin-10	production	(Ward,	
Casserly	&	Ayala,	2008).		
	
The	global	down-regulation	of	the	immune	system	has	been	observed	through	the	down-
regulation	of	both	Th-1	and	Th-2	responses	in	patients	with	severe	burns	and	major	trauma	
(Puyana	et	al.,	1998).	Lymphocytes	from	trauma	and	burns	patients	have	reduced	levels	of	
Th1	cytokines	but	elevated	Th-2	cytokines	(IL-4	and	IL-10).	The	reversal	of	this	response	has	
been	shown	to	increase	patient	survival	in	patients	who	developed	sepsis	(Ward,	Casserly	&	
Ayala,	2008;	O’Sullivan	et	al.,	1995).		
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Genome-wide	expression	of	blood	leukocytes	from	severe	blunt	trauma	patients	identified	
the	down-regulation	of	genes	involved	in	T	cell	responses	(Xiao	et	al.,	2011).	However,	it	
also	showed	that	antigen	presentation	and	the	upregulation	of	anti-inflammatory	gene	
expression	increased	in	parallel	with	the	elevation	in	pro-inflammatory	genes	(Xiao	et	al.,	
2011;	Gentile	et	al.,	2012).	This	research	confirmed	that	the	systemic	inflammatory	
response	and	compensatory	anti-inflammatory	response	occur	simultaneously,	and	the	
balance	between	these	two	responses	is	a	key	factor	in	optimal	recovery	following	trauma.	
	
The	host	defence	response	tries	to	strike	a	balance	between	SIRS	and	CARS	to	induce	
reparative	mechanisms	and	limit	the	entry	and	potential	overload	of	microbes	(Keel	&	
Trentz,	2005).	This	balance	avoids	a	potential	autoimmune	inflammatory	response,	whilst	
also	avoiding	anti-inflammatory	immunosuppression	(Keel	&	Trentz,	2005).			
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1.5	-	Complications	of	traumatic	injury	
The	complications	of	traumatic	injury	have	a	major	impact	on	patients	in	the	period	
following	trauma.	There	are	two	main	peaks	in	trauma	related	deaths,	the	first,	which	
occurs	due	to	damage	caused	by	the	injury	and	a	second	peak	of	trauma	related	deaths,	
which	happens	because	of	conditions	that	arise	in	the	period	following	injury.		If	the	patient	
survives	the	initial	traumatic	insult,	they	are	still	at	risk	of	developing	complications,	
because	of	the	inflammatory	response	that	occurs	to	repair	damage	caused	by	the	injury.	
This	inflammation	can	become	overactive	and	result	in	damage	to	tissue	vascularity,	
resulting	in	ischemia	and	organ	damage.	Alternatively,	the	anti-inflammatory	response	can	
dominate	and	lead	to	immunosuppression.	Anti-inflammatory	immunosuppression	causes	
the	body	to	become	susceptible	to	nosocomial	infection,	and	potentially	result	in	septic	
complications.	These	complications	result	in	increased	length	of	stay	in	the	ICU	and	have	
major	financial	impacts	on	health	services	worldwide.	Therefore,	the	ability	to	predict	
patients	likely	to	develop	these	complications	is	of	great	importance.	
	
1.5.1	-	Acute	respiratory	distress	syndrome	
Since	its	first	description	in	1967,	acute	respiratory	distress	syndrome	(ARDS)	has	been	
widely	recognised	as	a	major	clinical	problem	worldwide,	due	to	its	high	morbidity	and	
mortality	burden	on	the	population	(Ashbaugh	et	al.,	1967;	Confalonieri	et	al.,	2017).	The	
development	of	ARDS	is	commonly	associated	with	blunt	chest	trauma	(Salim	et	al.,	2006),	
septic	complications,	aspiration	of	gastric	contents	and	complications	of	long	bone	
fractures.		
	
The	estimated	incidence	of	ARDS	ranges	from	17-64	cases	per	100,000	of	the	population	per	
year	(Monahan,	2013)	(Blank	&	Napolitino,	2011).	The	associated	mortality	of	ARDS	is	high,	
ranging	from	11%	to	68%	worldwide.	However,	many	of	the	patients	included	in	these	
statistics	die	from	multi-organ	dysfunction	opposed	to	directly	for	ARDS	induced	hypoxemia	
(Young	&	O’Sullivan,	2016).	The	development	of	ARDS	is	a	major	burden	on	health	services,	
through	the	additional	cost	of	treating	the	complication	alongside	the	main	cause	of	injury	
and	the	increased	length	of	stay	in	the	hospital	to	manage	and	treat	the	ARDS	symptoms	
(Salim	et	al.,	2006).	
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The	extent	to	which	ARDS	has	developed	was	originally	measured	using	the	American-
European	consensus	conference	(AECC)	definition	of	ARDS.	The	definition,	first	described	in	
1994	states	defines	ARDS	as;	the	acute	onset	of	hypoxemia	(Arterial	pressure	of	oxygen	to	
fraction	of	inspired	oxygen	[PaO2/FiO2]	<200mmHg),	with	bilateral,	infiltrates	on	frontal	
chest	radiographs,	with	no	evidence	of	hypertension	(Table	2)	(Force,	2012).		
	
Table	2)	The	American-European	Consensus	Criteria	for	defining	ARDS	
The	American-European	Consensus	Criteria	
All	the	following	features	must	be	present.	
1. Acute	onset	(<7	days)	
2. Hypoxemia	
PaO2/FiO2	<200	mmHg	
3. Diffuse	bilateral	pulmonary	infiltrates	on	frontal	chest	radiograph,	consistent	pulmonary	
oedema;	infiltrates	can	be	patchy	and/or	asymmetric.	
4. The	absence	of	left	atrial	hypertension	based	upon	clinical	assessment	or	PCWP	<	18mmHg	if	
measured.	
Abbreviations:	PaO2,	partial	pressure	of	oxygen;	FiO2,	fraction	of	inspired	oxygen;	mmHg,	
millimetres	of	Mercury;	PCWP,	pulmonary	capillary	wedge	pressure.	
	
This	definition	of	ARDS	has	received	criticism,	due	to	it	not	considering	the	relevance	of	
precipitating	conditions	to	prognosis,	no	uniform	system	of	interpreting	the	radiograph	
results	and	no	standardisation	of	mechanical	ventilation	support	strategies	to	be	used	when	
hypoxemia	is	quantified	(Leaver	&	Evans,	2007).	These	criticisms	led	to	a	modified	version	of	
the	AECC	criteria	to	be	developed.	Termed	the	Berlin	definition	of	ARDS,	this	addressed	
most	of	the	criticisms	that	the	AECC	definition	received.	This	definition	(Table	3),	is	now	
commonly	used	to	identify	the	development	of	ARDS	in	patients	who	have	suffered	an	
injury	to	their	chest	cavity	or	lung	tissue.	
	
Acute	respiratory	distress	syndrome	is	a	syndrome	of	inflammation	and	increased	the	
permeability	of	pulmonary	tissue,	associated	with	the	development	of	clinical	and	
physiological	abnormalities	(Sharma,	2010).		The	pathophysiology	of	ARDS	progresses	
through	three	main	stages,	an	acute	stage,	a	proliferative	stage	and	a	fibrotic	stage	(Mackay	
&	Al-Haddad,	2009).		
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Table	3)	The	Berlin	definition	of	defining	ARDS	
The	Berlin	Definition	
Timing	 Within	one	week	of	a	known	clinical	insult	or	new	or	worsening	respiratory	symptoms.	
Chest	imaging	 Bilateral	opacities	–	not	fully	explained	by	effusions,	lobar/lung	collapse,	or	nodules.	
Origin	of	oedema	
Respiratory	failure	not	fully	explained	by	cardiac	failure	of	fluid	overload.	
Need	objective	assessment	(e.g.,	echocardiogram)	to	exclude	hydrostatic	
oedema	if	no	risk	factor	present.	
Oxygenation	
Mild	
Moderate	
Severe	
	
200	mmHg	<	PaO2/FiO2,	<300	mmHg	with	PEEP	or	CPAP	>	5cmH2O	
100	mmHg	<	PaO2/FiO2,	<200	mmHg	with	PEEP	
PaO2/FiO2	<	100	mmHg	with	PEEP	
Abbreviations:	CPAP,	continuous	positive	airway	pressure;	PaO2,	partial	pressure	of	oxygen;	FiO2,	
fraction	of	inspired	oxygen;	PEEP,	positive	end-expiratory	pressure.	
	
The	acute	or	exudative	phase	of	ARDS	is	characterised	by	the	rapid	onset	of	acute	
respiratory	failure	within	the	first	week	following	injury	(Villar,	2011).	The	pathogenesis	of	
this	stage	is	a	result	of	a	combination	of	factors	including	damage	from	the	initial	injury	and	
the	activation	of	both	local	and	systemic	inflammatory	responses	(Villar,	2011).	The	initial	
insult	triggers	a	series	of	cell-mediated	responses,	resulting	in	damage	to	the	capillary	
endothelium	and	impaired	fluid	removal	from	the	alveolar	space	(Villar,	2011).	The	pro-
inflammatory	response	is	invoked	by	the	release	of	numerous	pro-inflammatory	cytokines	
including,	TNFα,	IL-1,	and	IL-6.	This	results	in	an	escalation	of	neutrophil	response,	the	
accumulation	of	leukocytes	and	erythrocytes,	along	with	platelet	activation	(Figure	22)	
(Bhatia	&	Moochhala,	2004).		
	
These	factors	all	result	in	increasing	of	vascular	permeability,	expansion	of	gaps	in	the	
alveolar	epithelial	membrane	and	triggering	the	necrosis	of	type	I	and	II	pneumocytes	
(Pierrakos	et	al.,	2012;	Monahan,	2013).	This	allows	fluid	to	pass	through	into	the	lungs,	
leading	to	pulmonary	oedema	(Figure	22).	Pulmonary	oedema	and	damage	to	the	alveolar	
membrane,	cause	the	main	symptoms	of	acute	phase	ARDS,	including	hypoxemia,	
decreased	lung	compliance,	poor	air	exchange	and	pulmonary	hypertension	(Ware,	Matthay	
&	Zimmerman,	2012;	Pierrakos	et	al.,	2012;	Monahan,	2013).	
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Although	most	survivors	of	ARDS	return	to	normal	lung	function	within	6-12	months,	
following	the	proliferative	phase	(Ware,	Matthay	&	Zimmerman,	2012).	Proliferation	allows	
pneumocytes	and	pulmonary	epithelial	cells	to	replenish	following	the	damage	caused	
during	the	acute	phase.	This	resolution	of	tissue	damage	causes	complications	during	the	
period	where	the	tissue	recovers.	Symptoms	of	lung	tissue	resolution	involve,	exercise	
intolerance,	muscle	weakness	and	diminished	mental	function	following	prolonged	
hypoxemia	(Monahan,	2013).		
	
	
	
	
Figure	22)	The	cellular	pathology	cycle	of	ARDS.	a)	Normal	alveolar	tissue,	filled	with	air.	
b)	The	alveoli	begin	to	fill	with	proteinaceous	fluid,	shown	by	the	green	arrow.	c)	
Leukocytes,	mainly	neutrophils,	begin	to	infiltrate	the	alveoli,	shown	by	the	green	arrow.	
d)	Macrophages,	erythrocytes	and	fibrin	strands	are	now	found	in	the	alveoli.	Adapted	
from	Short	et	al.,	2013.	
a)	
b)	c)	
d)	
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However,	if	the	lungs	cannot	resolve	the	damage,	fibrotic	methods	are	used	to	repair	
damage	(Ware,	Matthay	&	Zimmerman,	2012).	Patients	undergoing	fibrotic	repair	exhibit	
persistent	hypoxemia,	and	a	further	decrease	in	pulmonary	compliance	(Herridge	et	al.,	
2011;	Monahan,	2013).	They	become	reliant	on	external	mechanical	ventilation	and	have	
significant	levels	of	disability	and	mortality	compared	to	ARDS	patients	who	successfully	
resolve	the	damage	caused	by	ARDS	(Herridge	et	al.,	2011).		
	
1.5.2	-	Multiple	Organ	Dysfunction	and	Multiple	Organ	Failure	
Multiple	organ	dysfunction	syndrome	(MODS)	is	defined	as	the	development	of	potentially	
reversible	physiological	derangements,	involving	two	or	more	organ	systems,	which	are	not	
directly	involved	in	the	admission	to	the	intensive	care	unit	and	arise	in	the	wake	of	a	
potentially	life	threatening	insult	(Holzheimer	&	Mannick,	2001).	This	organ	dysfunction	
ultimately	leads	to	organ	failure	and	the	development	of	multiple	organ	failure	(MOF),	if	
two	or	more	organ	systems	fail.	
	
The	incidence	of	MODS	ranges	anywhere	from	11%	to	40%	in	patients	admitted	to	the	ICU	
(Ramirez,	2013;	Osterbur	et	al.,	2014).		This	is	the	most	common	cause	of	death	in	the	ICU,	
being	responsible	for	80%	of	all	intensive	care	deaths	(Osterbur	et	al.,	2014).	Multiple	organ	
dysfunction	is	also	the	leading	cause	of	mortality	in	trauma	patients,	who	survive	the	initial	
traumatic	injury	(El-Menyar	et	al.,	2012;	Maier	et	al.,	2007).	The	mortality	rate	of	intensive	
care	related	MODS	increases	based	on	a	number	of	organ	systems	which	are	undergoing	
dysfunction	or	have	failed	(Table	4)	(Balk	&	Goyette,	2002).	The	ICU	mortality	rate	is	lowest	
in	patients	who	have	no	organ	dysfunction	(9%),	increasing	progressively	with	the	number	
of	organs	which	have	developed	dysfunction	and	begun	to	fail	(Balk	&	Goyette,	2002).		The	
failure	of	two	organ	systems	to	meet	the	criteria	of	MOF	has	an	associated	mortality	rate	of	
38%	(Balk	&	Goyette,	2002).	This	increases	to	a	mortality	rate	of	83%	in	patients	who	
develop	organ	failure	in	four	or	more	organ	systems	(Balk	&	Goyette,	2002).	
	
Patients	who	develop	MODS	or	MOF	commonly	develop	pulmonary	MODS	before	any	other	
organ	system,	with	this	occurring	in	99%	of	all	MODS	ICU	patients	(Ceisla	et	al.,	2004;	Dewar	
et	al.,	2009).	This	is	due	to	capillary	leakage,	resulting	in	alveolar	flooding	and	deactivation	
of	pulmonary	surfactant	production	(Ramirez,	2013).	
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Table	4)	The	Multiple	organ	dysfunction	score	criteria	(Marshall	et	al.,	1995)	
Organ	system	 Score	points	0	 1	 2	 3	 4	
Respiratory	
(PaO2/FiO2)	
>300	 226-300	 151-225	 76-150	 <75	
Renal	(Serum	Creatinine)	
(umol/L)	 <100	 101-200	 201-350	 351-500	 >500	
Hepatic	(Serum	Bilirubin)	
(umol/L)	 <20	 21-60	 61-120	 121-240	 >240	
Cardiovascular	(PAR)	
(HRxCVP/MAP)	 <10	 10.1-15	 15.1-20	 20.1-30	 >30	
Haematological	(Platelet	count)	
(x103/ml)	 >120	 81-120	 51-80	 21-50	 <20	
Neurological	
(Glasgow	Coma	Scale)	 15	 13-14	 10-12	 7-9	 <6	
Abbreviations:	PaO2,	partial	pressure	of	oxygen;	FiO2,	fraction	of	inspired	oxygen;	µmol/L,	micromole/litre;	
HR,	heart	rate;	CVP,	central	venous	pressure;	MAP,	mean	arterial	pressure. 
	
Multiple	organ	failure	can	occur	during	two	main	periods	following	traumatic	injury.	It	can	
be	classed	as	either	early	MOF	where	it	occurs	within	48	hours	of	injury,	or	be	termed	late	
MOF,	which	occurs	after	72	hours	from	the	time	of	injury	(Dewar	et	al.,	2011;	Maier	et	al.,	
2007).	Early	organ	failure	is	commonly	a	direct	result	of	the	traumatic	injury,	which	has	led	
to	ischemic	and	necrotic	damage	to	the	organ,	triggering	the	organ	to	fail	(Dewar	et	al.,	
2011).	Late	organ	failure	is	a	consequence	of	a	secondary	inflammatory	insult,	such	as	
infective	complications,	which	cause	the	body	to	invoke	a	rapid	and	strong	inflammatory	
response.	This	strong	inflammatory	response	is	associated	with	the	dysfunction	of	the	
immune	system,	caused	by	an	excessive	pro-inflammatory	response	with	normal	or	
decreased	compensatory	anti-inflammatory	response	(Ramirez,	2013).	This	leads	to	the	loss	
of	homoeostasis	between	the	pro	and	anti-inflammatory	responses	(Ramirez,	2013).			
	
The	loss	of	homoeostasis	is	a	common	result	of	the	two-hit	hypothesis	of	inflammation,	
meaning	that	the	second	hit,	which	triggers	the	loss	of	homoeostasis	in	the	ICU.	This	can	be	
caused	by	an	otherwise	innocuous	nosocomial	infection	such	as	pneumonia	(Jin	et	al.,	
2016).	This	immune	dysregulation	can	result	in	hyper-inflammation,	causing	damage	
surrounding	microvessels	resulting	in	ischemia	to	regions	of	the	organ/tissue	(Rendy,	Sapan	
&	Kalesaran,	2017).		
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The	reperfusion	of	these	ischemic	regions	to	re-oxygenate	the	tissue	can	have	a	major	
impact	on	the	development	of	multiple	organ	failure,	through	the	flushing	of	pro-
inflammatory	mediators,	cellular	micro-aggregates	and	reactive	oxygen	species	(Baue,	2000;	
Dewar	et	al.,	2009;	Balk	&	Goyette,	2002).	The	release	of	pro-inflammatory	mediators,	
following	ischemia,	can	invoke	an	inflammatory	response	within	tissues	and	organs	away	
from	the	initial	site	of	ischemia.	This	results	in	the	expansion	of	the	ischemia,	allowing	the	
generation	of	further	inflammatory	mediators,	which	can	be	released	following	further	
tissue	reperfusion	(Balk	&	Goyette,	2002).	These	inflammatory	mediators	induce	endothelial	
damage	and	increase	vascular	permeability,	allowing	the	leakage	of	fluid	out	of	the	blood	
vessels	and	enter	tissues,	resulting	in	oedema.	
	
Cellular	micro-aggregates	are	commonly	composed	of	neutrophils,	platelets,	red	blood	cells	
and	fibrin	(Sibinga	&	Cash,	2001).	These	aggregates	are	often	seen	following	the	transfusion	
of	blood	into	trauma	patients	(Sibinga	&	Cash,	2001).	These	can	impair	the	blood	flow	in	
capillaries	and	post-capillary	venules	resulting	in	tissue	hypoxia	and	ischemia	(Balk	&	
Goyette,	2002).	This	ischemic	damage	persists	after	reperfusion,	resulting	in	tissue/organ	
damage	and	dysfunction	(Balk	&	Goyette,	2002).	This	damage,	following	prolonged	
ischemia,	may	ultimately	result	in	organ	failure.	
	
Reactive	oxygen	species	are	released	from	damaged	tissues,	with	unregulated	elevations	in	
ROS	concentrations	causing	damage	to	lipids,	proteins	and	DNA	(Scheiber	&	Chandel,	2014).	
These	elevations	have	been	shown	to	increase	pro-inflammatory	cytokine	production	(Kong	
et	al.,	2011).	This	exacerbates	the	innate	immune	response	during	inflammation	to	
pathogens	and	DAMP’s	following	trauma,	resulting	in	impaired	clearance	of	pathogens	and	
the	enhancement	of	septic	complications	(Thimmulappa	et	al.,	2006;	Scheiber	&	Chandel,	
2014).	Each	of	these	substances	that	are	washed	through	the	body	can	act	as	a	secondary	
hit	inflammatory	insult.	However,	if	all	the	substances	released	at	once	from	ischemic	
tissue,	it	can	trigger	a	massive	systemic	inflammatory	insult	that	can	impact	multiple	organs	
throughout	the	body	simultaneously.	Despite	the	incidence	of	MODS	and	MOF	decreasing	in	
recent	years	due	to	the	advancement	of	ICU	care	methods	and	techniques	(Nost-Kolb	et	al.,	
2001),	it	remains	a	major	burden	of	the	world's	healthcare	systems,	due	to	it	increasing	
patient’s	length	of	stay,	hospital	resource	use	and	ICU	mortality	rate.	
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1.5.3	-	Infection	and	sepsis	
Sepsis	is	a	life-threatening	condition	that	arises	when	the	body’s	response	to	the	presence	
of	infection	causes	injury	to	its	own	tissues	and	organs.	It	is	defined	by	the	presence	
(confirmed	or	unconfirmed)	of	infection	that	can	result	in	acute	organ	dysfunction,	
hypotension	and	ultimately	death	(Dellinger	et	al.,	2013).	Sepsis	is	described	as	an	illness	
caused	by	the	presence	of	infection	in	a	normally	sterile	area	of	the	body	(Lever	&	
Mackenzie,	2007).	This	description	is	commonly	used	to	differentiate	conditions	that	share	
identical	symptoms	to	sepsis,	which	may	arise	from	non-microbial	conditions	such	as	
pancreatitis	(Lever	&	Mackenzie,	2007).	
	
Sepsis	is	the	leading	cause	of	complication	in	critically	ill	patients	worldwide,	this	is	despite	
continual	advances	in	antibiotics	and	resuscitation	therapies	(Pierrakos	&	Vincent,	2010).	
Sepsis	affects	3	in	1000	people	per	year,	accounting	for	over	750,000	cases	per	year	in	the	
United	States	and	is	responsible	for	more	than	65,000	admissions	annually	in	the	United	
Kingdom	(Angus	et	al.,	2001;	Gupta	&	Jonas,	2006).	In	the	United	Kingdom	sepsis	causes	
36,800	deaths	per	year,	making	it	the	second	highest	cause	of	death	in	the	UK	behind	
coronary	heart	disease	(Griffiths	&	Anderson,	2009).		
	
Sepsis	has	become	a	major	financial	burden	on	health	systems	worldwide	(Prucha,	Bellingan	
&	Zazula,	2015),	due	to	longer	lengths	of	stay	in	the	hospital,	increased	antibiotic	usage,	and	
the	necessity	for	patients	to	be	placed	in	intensive	care	units	(ICU’s).	There	are	varying	
degrees	of	severity	for	sepsis	conditions,	including	sepsis,	severe	sepsis	and	septic	shock.	
These	are	differentiated	based	on	the	type	of	symptoms	exhibited	by	the	patient.	Sepsis	is	
the	presence	of	a	microorganism	within	the	blood;	it	is	the	most	common	type	of	sepsis	
along	with	having	the	lowest	mortality	rate	(Singer	et	al.,	2016).			
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Severe	sepsis	occurs	when	a	septic	patient	develops	evidence	of	hypoperfusion	or	the	
dysfunction	of	at	least	one	organ	(Singer	et	al.,	2016).	This	condition	is	more	severe	than	
sepsis	and	has	a	higher	mortality	rate.	Septic	shock	is	the	most	severe	form	of	sepsis	and	
occurs	when	the	patient	suffers	from	hypotension	or	requires	vasopressors,	along	with	fluid	
resuscitation	having	no	or	minimal	effect	(Lever	&	Mackenzie,	2007).	
	
Sepsis	commonly	originates	following	a	breach	in	the	integrity	of	a	host	barrier	of	
protection,	such	as	the	skin	during	surgery	(Lever	&	Mackenzie,	2007).	The	entrance	of	a	
microbe	following	the	loss	of	barrier	integrity	causes	an	initial	host	response	to	try	to	clear	
the	organism.	However,	in	sepsis	cases	this	response	becomes	amplified	and	dysregulated,	
resulting	in	the	symptoms	associated	with	sepsis	(Cohen,	2002).			
	
The	septic	response	is	a	complex	chain	of	events	involving	inflammatory	processes,	humoral	
and	cellular	abnormalities	along	with	circulatory	aberrations	(Figure	23)	(Pierrakos	&	
Vincent,	2010).	These	events	result	in	tissue	hypoperfusion	and	hypoxia,	which	are	
dominant	factors	in	the	development	of	organ	failure	during	sepsis	(Cohen,	2002).		
Figure	23)	The	link	between	Infection	and	Inflammation	that	leads	to	the	development	of	
sepsis.	
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1.5.4	-	Coagulation	disorders	following	traumatic	injury	
The	human	body	possesses	intrinsic	mechanisms	to	regulate	haemostasis,	allowing	the	
balance	of	clot	formation	and	breakdown	to	be	maintained.	However,	an	imbalance	in	these	
mechanisms	can	result	in	the	development	of	coagulation	disorders.	Coagulation	disorders	
are	present	in	most	trauma	patients	in	the	form	of	haemorrhagic	disorders,	thrombosis	and	
in	the	case	of	disseminated	intravascular	coagulation	(Miniello	et	al.,	2004).	Coagulation	
abnormalities	occur	quickly	after	trauma	with	fibrinogen,	reaching	critical	levels,	with	
coagulation	abnormalities	being	present	within	25	minutes	of	injury	(Maegele,	Schochl	&	
Cohen,	2014;	Floccard	et	al.,	2012).	Coagulopathies	are	encountered	in	25-30%	of	trauma	
patients	and	are	associated	with	a	worse	outcome	(Rugeri	et	al.,	2007).	These	haemostatic	
manifestations	are	associated	with	increased	need	for	blood	transfusion,	a	longer	length	of	
hospital	stay	and	a	higher	mortality	rate	(Martini,	2016).	
	
In	cases	of	trauma	death	following	massive	haemorrhage,	commonly	due	to	non-surgical	
bleeding	or	trauma	related	coagulopathy	(MacLeod,	2008).	Trauma	induced	coagulopathy	
(TIC)	is	a	complex	disorder	and	is	not	fully	understood	(White,	2013).	It	involves	several	key	
processes	including	dysfunction	of	natural	anticoagulant	mechanisms,	platelet	dysfunction,	
fibrinogen	consumption	and	hyper-fibrinolysis,	which	have	all	been	identified	as	potential	
causative	factors	of	TIC	(White,	2013).	
	
In	the	immediate	period	following	traumatic	injury,	the	injury	exposes	tissue	factor	the	
circulation,	initiating	thrombin	generation	and	clot	formation.	Platelets	also	become	
activated	through	cellular	signalling	mechanisms	including	collagen,	glycoprotein	VI,	von	
Willebrand	Factor	(vWF)	and	glycoprotein	Ib.	The	activation	of	platelets	amplifies	thrombin	
generation	and	the	clotting	process,	causing	the	consumption	of	coagulation	factors.	
Patients	who	develop	massive	haemorrhage	due	to	major	trauma,	often	develop	metabolic	
failure,	commonly	referred	to	as	“the	triad	of	death”	(Figure	24)	(Maani,	DeSocio	&	
Holcomb,	2009).	This	triad	is	composed	of	hypothermia,	acidosis	and	coagulopathy	
(MacLeod,	2008).	
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Hypothermia	is	a	decrease	in	core	body	temperature,	which	is	caused	by	blood	loss	or	
exposure	at	the	point	of	traumatic	injury.	Hypothermia	can	result	in	impaired	stability	of	
fibrin	clots,	as	well	as	slowing	the	initiation	and	propagation	of	the	coagulation	cascade	
(Dirkmann	et	al.,	2008).	The	hypothermic	insult	is	associated	with	a	decrease	in	thrombin	
generation,	as	well	as	compromised	formation	of	platelet	plugs	and	fibrin	clots	(Maani,	
DeSocio	&	Holcomb,	2009).	Johnston,	Chen	&	Reed,	1994,	observed	that	a	decrease	in	body	
temperature	caused	a	decrease	in	all	coagulation	factors,	lowering	the	temperatures	further	
reduced	the	amount	of	functional	clotting	factors.		
	
Acidosis	is	the	decrease	in	blood	pH	caused	by	an	increase	in	metabolic	acids	due	to	
hypoxemia	and	hypo-perfusion.	Acidosis	can	worsen	existing	coagulopathies	by	inhibiting	
enzyme	complexes,	which	are	vital	to	clot	formation	(Dirkmann	et	al.,	2008).		This	inhibition	
of	enzyme	complexes	by	blocking	the	binding	enzyme	complexes	to	positively	charged	lipid	
membranes	(Tieu,	Holcomb	&	Schreiber,	2007).		
Figure	24)	The	lethal	triad	of	coagulopathy	disorders	following	traumatic	injury.	
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Acidosis	was	found	to	have	a	profound	inhibitory	effect	on	the	thrombin	generation	rate;	
this	was	further	exacerbated	when	combined	with	hypothermia	(Martini	et	al.,	2005).	A	
reduction	of	blood	pH	from	7.4	to	7.0	decreased	the	activity	of	Factor	VIIa	by	90%,	and	the	
rate	of	prothrombin	activation	by	70%	(Meng	et	al.,	2003).	In	a	clinical	setting,	significant	
bleeding	was	found	to	occur	in	patients	with	acidosis	and	hypothermic	complications,	
despite	adequate	blood,	platelet	and	plasma	replacement	(Tieu,	Holcomb	&	Schreiber,	
2007).		
	
Coagulation	factors	can	be	depleted	or	diluted,	resulting	in	an	impaired	clotting	response.	
The	direct	loss	of	coagulation	factors	through	haemorrhage	can	quickly	deplete	the	bodies	
stores	of	fibrinogen	and	platelets	(Martini	et	al.,	2005).	As	a	part	of	the	response	to	
traumatic	haemorrhage	clinicians	and	paramedics	often	give	patients	intravenous	fluids	to	
maintain	blood	volume	(Iijima	et	al.,	2013).	These	intravenous	fluids	dilute	the	remaining	
blood	components	including	clotting	factors	decreasing	the	effectiveness	of	the	clotting	
cascade	and	resulting	in	impaired	coagulation	(Maegele,	Schochl	&	Cohen,	2014).	
	
As	a	part	of	the	response	to	traumatic	injury,	an	inflammatory	response	occurs.	This	
inflammatory	response	can	increase	procoagulant	activity	(Pierce	&	Pitlet,	2014).	
Inflammatory	cytokines	may	also	activate	platelets	and	increase	their	expression	of	
procoagulants	(MacLeod,	2008).	This	reaction	along	with	suppression	of	anticoagulant	
activity	and	fibrinolysis	results	in	the	development	of	disseminated	intravascular	
coagulopathy	(DIC)	(ten	Cate,	2000).		
	
The	development	of	DIC	is	partly	explained	by	the	early	activation	of	protein	C,	resulting	in	
its	depletion	(Brohi,	Cohen	&	Davenport,	2007).	As	protein	C	is	re-synthesised,	it	returns	to	
normal	concentrations,	during	which	a	hypercoagulable	state	exists	(Brohi,	Cohen	&	
Davenport,	2007).	Several	studies	have	identified	a	late	hypercoagulable	state,	increasing	
the	risk	of	thromboembolic	complications	(Shreiber	et	al.,	2005;	Engelman	et	al.,	1996).	
These	complications	can	trigger	the	blockage	of	post	capillary	venules,	resulting	in	hypoxia	
to	organs	and	tissues,	which	may	lead	to	multiple	organ	failure	(Kidokoro,	Iba	and	Hong,	
1999).	
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1.6	-	Clinical	measurements	of	traumatic	injury	severity	
Trauma	centres	around	the	world	use	a	variety	of	different	systems	to	identify	and	stratify	
patients	based	upon	the	types	of	injury	that	they	receive	during	trauma.	These	scoring	
systems	are	used	to	identify	patients	who	have	the	most	severe	injuries	and	provide	insight	
into	potential	therapeutic	interventions	that	are	required	to	treat	them	or	identify	those	
patients	who	are	at	the	greatest	risk	of	developing	complications	in	the	days	and	weeks	
after	the	traumatic	injury.	
	
The	most	commonly	used	scoring	systems	used	in	trauma	are,	the	Acute	Physiology	and	
Chronic	Health	Evaluation	(APACHE)	system,	Injury	severity	score	(ISS),	Sequential	Organ	
Failure	Assessment	(SOFA)	score	and	the	Glasgow	Coma	Scale	(GCS).	Each	of	these	systems	
has	its	own	positives	and	negatives	as	they	each	identify	factors	that	other	systems	do	not.	
Each	scoring	system	will	be	further	explained	within	this	section.	
	
1.6.1	-	Acute	Physiology	and	Chronic	Health	Evaluation	score	
The	APACHE	scoring	system,	first	developed	in	1985,	is	used	to	predict	mortality	and	
measure	injury	severity	in	critically	ill	patients	who	have	been	admitted	to	the	Intensive	
Care	Unit	of	a	hospital	(Knaus	et	al.,	1985).	The	patient’s	APACHE	score	is	calculated	within	
24	hours	of	admission	to	the	ICU,	with	the	score	being	calculated	based	upon	13	
physiological	factors	measured	within	the	24	hours	following	admission.	The	13	factors	used	
in	the	APACHE	calculation	are	PaO2,	temperature,	mean	arterial	pressure,	arterial	pH,	heart	
rate,	respiratory	rate,	serum	sodium	concentration,	serum	potassium	concentration,	
creatinine,	haematocrit,	white	blood	cell	count	and	the	Glasgow	Coma	Scale	score	(Knaus	et	
al.,	1985).		From	these	physiological	variables,	an	overall	score	ranging	from	0	to	71	is	
calculated	(Figure	25).		
	
Patients	who	score	higher	on	the	APACHE	scale,	have	more	severe	injuries	and	a	greater	risk	
of	in-hospital	mortality	due	to	their	injuries	(Rapsang	&	Shyam,	2014).	APACHE	scores	have	
been	shown	to	inform	on	patient	prognosis	and	assist	the	investigator	in	comparing	and	
evaluating	different	forms	of	treatment	or	therapeutic	options	(Rapsang	&	Shyam,	2014).	
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The	APACHE	score	has	shown	a	good	calibration	and	discriminatory	value	across	a	range	of	
disease	processes	and	remains	a	commonly	used	international	severity	scoring	system	
worldwide	(Bouch	&	Thompson,	2008).	Several	variants	of	the	APACHE	scoring	system	have	
been	developed	since	its	inception,	to	enhance	the	predictive	and	diagnostic	power	of	the	
scoring	system.	Overall,	the	APACHE	scoring	system	provides	a	robust	predictor	of	patient	
outcomes,	due	to	the	use	of	a	high	number	of	physiological	variables	and	the	identification	
of	patient’s	co-morbidity	status	to	determine	the	risk	of	complications	or	mortality	to	the	
patient.	
	
	
	
	
	
	
	
	
Figure	25)	The	scoring	criteria	used	to	generate	the	APACHE	II	score.	It	is	a	measure	of	11	
physiological	criteria,	along	with	age	and	patient	chronic	health	status.	The	points	for	
each	of	these	categories	are	added	together	to	generate	the	APACHE	II	score.	
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1.6.2	-	Injury	Severity	Score	
The	Injury	severity	score	(ISS)	is	a	method	of	scoring	the	severity	of	injury	in	polytrauma	
patients.	It	has	become	the	most	common	and	widely	used	scoring	system	worldwide	since	
its	creation	in	1976	(Baker	et	al.,	1976).	The	score	is	calculated	based	upon	the	description	
of	six	regions	of	the	body,	namely:	a)	External,	skin	injuries;	b)	Limbs;	Abdomen,	including	
organs	and	lumbar	spine;	c)	Chest,	including	organs,	diaphragm,	rib	cage,	thoracic	spine;	
Face;	Head	and	neck,	including	the	brain	and	cervical	spine	(Restrepo-Álvarez	et	al.,	2016).		
	
The	injury	severity	score	is	calculated	from	the	sum	of	the	squares	of	the	single	highest	
Abbreviated	Injury	Scale	(AIS)	score	for	each	of	the	three	most	severely	injured	body	regions	
(Deng	et	al.,	2016).		The	injury	severity	is	purely	based	on	the	anatomical	findings	defined	by	
the	AIS	(Paffrath	et	al.,2014).	The	most	recent	version	of	the	AIS,	adapted	in	2008,	lists	
approximately	2000	different	injuries	to	nine	regions	of	the	body	(Lossius	et	al.,	2012).		
	
The	severity	of	each	injury	is	graded	on	a	scale	from	1	to	6	(Table	5),	where	a	score	of	1	
describes	a	minor	injury,	while	a	score	of	6	is	given	for	untreatable,	mostly	lethal	injuries	
(Paffrath	et	al.,	2014).	Most	clinical	studies	describe	patients	who	are	critically	ill	trauma	
patients	as	having	an	ISS	of	>16,	these	patients	had	an	associated	10%	increase	in	mortality	
rate	(Champion	et	al.,	1990).	
	
Table	5)	The	Abbreviated	Injury	Scale	injury	scoring	table,	used	to	enumerate	the	severity	of	
trauma	injuries	and	calculate	trauma	patient’s	injury	severity	score.	
Injury	severity	 Abbreviated	injury	score	
Minor	 1	
Moderate	 2	
Serious	 3	
Severe	 4	
Critical	 5	
Probably	lethal	 6	
	
The	ISS	is	limited	in	the	fact	that	it	is	calculated	based	on	the	squared	values	of	three	body	
regions.	This	means	that	if	a	person	suffers	multiple	injuries	but	they	all	occur	in	one	region	
of	the	body,	then	the	ISS	will	be	significantly	lower	and	not	accurately	reflect	the	severity	of	
the	person’s	injuries	(Osler	et	al.,	1997).		
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Since	the	inception	of	the	ISS,	modifications	have	been	made	to	make	the	method	to	be	
more	accurate	in	predicting	patient	mortality	following	trauma.	These	modifications	have	
resulted	in	a	new	scale	called	the	new	injury	severity	score	(NISS),	which	uses	the	three	
most	injured	body	parts	regardless	of	body	region	(Deng	et	al.,	2016).	This	modification	to	
the	ISS	allows	a	more	accurate	representation	of	a	person’s	injuries,	allowing	a	more	precise	
prediction	of	patient	outcomes,	thus	allowing	optimised	treatment	strategies	to	be	adopted	
and	utilised.	
	
Despite	the	example	patient	(Table	6),	having	identical	injuries	for	each	scoring	system,	the	
scores	from	each	ISS	based	system	are	significantly	different.	This	is	because	the	NISS	
considers	the	three	highest	scoring	injuries,	irrespective	of	the	organ	system	involved.	This	
allows	a	greater	representation	of	overall	injury	severity,	as	the	most	severe	injuries	are	
accounted	for,	rather	than	using	a	relatively	minor	injury	because	it	occurs	in	a	different	
organ	system.	
	
1.6.3	-	Sequential	Organ	Failure	Assessment	score	
The	SOFA	scoring	system	was	developed	in	1994	and	analyses	six	organ	systems	
(respiratory,	cardiovascular,	renal,	hepatic,	central	nervous	system	and	coagulation)	and	
scores	them	based	on	their	function.	The	function	of	these	organ	systems	is	scored	on	a	
scale	of	0,	which	is	normal	function	up	to	4,	which	indicates	mostly	abnormal	function.	The	
SOFA	score	uses	physiological	and	laboratory	variables;	however,	it	does	not	consider:	age,	
ethnicity	and	co-morbidity	disease,	which	are	key	drivers	in	the	mortality	related	to	sepsis	
(Macdonald	et	al.,	2014).	The	specific	criteria	used	to	develop	the	overall	SOFA	score	are	
detailed	in	Table	7.	
Table	6)	The	difference	between	the	Injury	severity	score	and	the	New	Injury	Severity	Score	for	a	
patient	with	multiple	injuries	following	trauma.	
Organ	system	 Injury	description	 AIS	score	 ISS	score	 NISS	score	
Head/neck	 Cerebral	Contusion	 3	 9	 9	
Face	 None	 0	 	 	
Chest	 Flail	chest	
Haemothorax	
Pericardial	injury	
4	
3	
4	
	
	
16	
16	
	
16	
Abdomen	 Minor	splenic	contusion	 2	 4	 	
Extremities	 None	 0	 	 	
External	 None	 0	 	 	
	 Sum	of	top	3	AIS	scores	 29	 41	
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Table	7)	The	criteria	used	to	develop	an	overall	SOFA	score	for	trauma	patients	based	upon	the	function	
of	six	organ	systems.	
System	
	
Score	
0	 1	 2	 3	 4	
Respiration	
PaO2/FiO2,	mmHg	
(kPa)	 >400	(53.3)	 <400	(53.3)	 <300	(40)	
<200	(26.7)	with	
respiratory	support	
<100	(13.3)	with	
respiratory	support	
Coagulation	
Platelets	(x103/µl)	 >150	 <150	 <100	 <50	 <20	
Hepatic	
Bilirubin,	mg/dL	
(µmol/L)	 <1.2	(20)	 1.2-1.9	(20-32)	 2.0-5.9	(33-101)	 6.0-11.9	(102-204)	 >12.0	(204)	
Cardiovascular	
	
MAP	>70	mm	Hg	 MAP	<70	mm	Hg	
Dopamine	<5	or	
any	dose	
dobutamine	
Dopamine	5.1-15	
Or	epinephrine	<0.1	
Or	norepinephrine	
<0.1	
Dopamine	>15	
Or	epinephrine	>0.1	
Or	norepinephrine	
>0.1	
Central	nervous	system	
Glasgow	coma	
scale	score	 15	 13-14	 10-12	 6-9	 <6	
Renal	
Creatinine,	mg/dL	
(umol/L)	
<1.2	
(110)	
1.2-1.9	
(110-170)	
2.0-3.4	
(171-299)	
3.5-4.9	
(300-440)	
>5.0	
(440)	
Urine	output,	
ml/d	 	 	 	 <500	 <200	
Abbreviations:	FiO2,	Fraction	of	Inspired	Oxygen;	MAP,	Mean	Arterial	Pressure;	PaO2,	Partial	pressure	of	oxygen.	
	
	
	
An	alternative	to	the	SOFA	scoring	
method	has	been	developed	to	
allow	an	initial	assessment	of	
overall	SOFA	score	to	be	conducted	
at	the	patient’s	bedside	as	soon	as	
they	are	admitted	to	hospital.	The	
system	termed	quick	Sequential	Organ	Failure	Assessment	(qSOFA),	is	comprised	of	only	
three	factors	that	are	used	to	rapidly	evaluate	the	risk	of	a	patient	having	more	severe	
outcomes	before	a	complete	SOFA	score	can	be	calculated	(Table	8)	(Singer	et	al.,	2016).		
	
These	criteria	can	be	determined	within	minutes	of	admission	and	may	direct	initial	
treatments	by	permitting	the	identification	of	patients	at	high	risk	of	infection,	while	a	
complete	SOFA	score	is	calculated	as	this	requires	more	complex	tests	and	further	scoring	
systems	such	as	the	Glasgow	Coma	Scale	and	a	full	calculation	of	the	injury	severity	score	
(Singer	et	al.,	2016).	
Table	8)	The	criteria	required	to	calculate	the	
qSOFA	score	and	quickly	identify	patients	at	higher	
risk	of	developing	an	infection	and	further	
complications	while	in	the	hospital.	
Criteria	 Measurement	
Respiratory	rate	 >22/min	
Systolic	blood	pressure	 <100	mg	Hg	
Mentation	 Abnormal	
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1.6.4	-	Glasgow	Coma	Scale	
The	Glasgow	Coma	Scale	is	a	system	of	scoring	the	severity	of	trauma.	First	described	in	
1974,	the	system	is	used	to	quantify	the	severity	of	head	injury	and	measures	several	
responses	to	stimuli	to	determine	the	level	of	consciousness	(Restrepo-Álvarez	et	al.,	2016).	
It	evaluates	a	patient’s	neurological	status	by	recording	eye	opening,	verbal	response	and	
motor	response	to	standardised	verbal	and	physical	stimuli,	to	indicate	the	severity	of	head	
trauma	(Smith	&	Smith,	2017).		
	
The	Glasgow	Coma	Scale	is	scored	up	to	a	maximum	combined	score	of	15.	A	score	of	15	
indicated	a	fully	awake	person	and	a	low	score	of	3	signifying	a	deep	coma,	(Table	9)	
(Teasdale	et	al.,	2014).	A	score	of	less	than	or	equal	to	8,	is	the	traditionally	used	value	for	
differentiating	between	severe	and	moderate	to	mild	head	injury	for	management	and	
treatment	purposes	(Balestreri	et	al.,	2004).	
	
Table	9)	The	scoring	criteria	used	to	develop	a	Glasgow	Coma	Scale	using	eye	opening	response,	
verbal	response	and	motor	response,	to	measure	the	cognitive	function	of	trauma	patients.	
Eye	opening	response	 Verbal	response	 Motor	response	
4	-	Spontaneous	 5	-	Orientated	 6	-	Obeys	commands	
3	-	To	verbal	stimuli	 4	-	Confused	 5	-	Localises	pain	
2	-	To	pain	 3	-	Inappropriate	words	 4	-	Withdraws	from	pain	
1	-	None	 2	-	Incoherent	 3	-	Flexion	to	pain	or	
decorticate	
	 1	-	None	 2	-	Extension	to	pain	or	
decorticate	
	 	 1	-	None	
	
The	GCS	was	originally	developed	to	gauge	a	patient’s	neurological	deterioration	or	
impairment,	as	well	as	act	as	a	predictor	for	patient	outcome.	However,	it	is	now	commonly	
used	as	a	clinical	indicator,	and	a	tool	to	manage	patients	(Sternbach,	2000).	The	main	
limitation	of	using	the	Glasgow	Coma	Scale	is	that	a	patient’s	verbal	response	is	unable	to	
be	determined	in	a	patient	who	has	been	intubated	(Smith	&	Smith,	2017).	Thus,	a	complete	
GCS	cannot	be	calculated	or	the	value	is	significantly	lower	than	if	the	patient	was	not	
intubated	(Smith	&	Smith,	2017).	Despite	attempts	to	modify	the	GCS	methodology	to	offer	
improvements	and	eliminate	limitations	in	the	method,	the	criteria	are	still	the	same	as	
when	the	method	was	first	developed	in	1974.	
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1.7	-	The	role	of	omics	in	biomarker	development	
Omics	technologies	are	a	component	of	the	evolving	field	of	systems	biology,	with	the	aim	
of	providing	a	complete	insight	into	highly	complex	models	of	disease	(Farid	&	Morris-Stiff,	
2015).	They	are	termed	omics	technologies,	related	to	the	suffix	-ome,	which	is	defined	as	
“all	constituents	considered	collectively”	(Rotoff	&	Motsinger-Reif,	2016).	Omics	
technologies	are	used	in	the	detection	of	genes	(genomics),	messenger	ribonucleic	acid	
(mRNA)	(transcriptomics),	proteins	(Proteomics)	and	metabolites	(metabolomics),	in	a	
biological	sample	(Wheelock	et	al.,	2013;	Horgan	&	Kenny,	2011).	These	are	conducted	in	a	
non-targeted	and	non-biased	manner	(Kell,	2007;	Horgan	&	Kenny,	2011).		
	 	
The	basic	aspect	of	these	approaches	is	that	a	complex	system	can	be	understood	more	
thoroughly	if	all	considered	together	(Horgan	&	Kenny,	2011).	Omics	technologies	are	
commonly	used	in	scientific	research	to	generate	hypotheses,	as	large	outputs	of	data	can	
be	mined	to	identify	potential	molecules	to	further	analyse	and	generate	a	hypothesis	
around	(Horgan	&	Kenny,	2011;	Brown	et	al.,	2005).	Omics	has	already	utilised	in	key	areas	
of	basic	science,	including	drug	and	biomarker	discovery	(Matthews,	Hanison	&	Nirmalan,	
2016).	
	
Advancements	in	biotechnology	and	computational	performance	in	recent	years	have	
allowed	omics	technologies	to	rapidly	develop	alongside	these	advancements	(Farid	&	
Morris-Stiff,	2015).	This	has	permitted	vast	amounts	of	information	to	be	collected	and	
analysed	simultaneously,	allowing	a	complete	disease	profile	to	be	developed.	This	data	
analysis	is	conducted	through	a	process	known	as	bioinformatics,	which	compares	the	
results	of	scientific	research	analysis	to	a	computer	database,	to	determine	the	identity	of	
molecules	in	biological	samples	(Wheelock	et	al.,	2013;	Krug	et	al.,	2012).			
	
Since	the	development	of	genomics,	the	completion	of	the	human	genome	(Venter	et	al.,	
2001;	Lander	et	al.,	2001)	and	the	rapid	advancement	in	technology	and	medical	research	
that	has	been	a	result,	advancements	have	begun	into	developing	an	understanding	of	
humans	at	a	proteomic	and	metabolomic	level,	to	ascertain	the	importance	of	these	
systems	on	biological	functions	and	in	disease	states,	and	to	provide	a	complete	
representation	of	human	beings	as	a	biological	system.	
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1.7.1	-	Proteomics	
The	proteome	consists	of	all	proteins	expressed	by	a	certain	species	(Lovric,	2011).	
Proteomics	follows	on	from	the	genomic	and	transcriptomic	systems,	as	proteins	are	
created	from	the	transcription	of	mRNA.	However,	all	individuals	of	a	species	do	not	have	
identical	proteomes,	due	to	internal	and	external	factors,	such	as	post-transcriptional	
modification,	health	conditions	and	environmental	factors	(Lovric,	2011;	Graves	&	Haystead,	
2002).		
	
Proteomic	analysis	can	be	classified	into	three	main	groups,	expression	proteomics,	
structural	proteomics	and	functional	proteomics	(Chandrasekhar	et	al.,	2014).	Expression	
analysis	is	used	to	quantify	expression	of	proteins	under	two	conditions,	normally	healthy	
against	disease	states	(Wright	et	al.,	2012).	Structural	analysis	aims	to	identify	the	three-
dimensional	structure	of	proteins,	using	x-ray	crystallography,	allowing	the	complexities	of	
functional	proteins	to	be	determined	(Manjasetty	et	al.,	2012).	Functional	proteomics	
develops	knowledge	of	protein	function	and	the	molecular	mechanism	of	protein	
interaction,	allowing	the	role	of	proteins	in	disease	conditions	to	be	determined	(Monti	et	
al.,	2005).	
	
Numerous	different	methods	can	be	used	to	undertake	proteomic	analysis.	Initially,	
separation	based	proteomics	is	to	identify	the	different	proteins	within	a	sample	based	on	
their	molecular	weight	(Abdallah	et	al.,	2012).	Electrophoresis	based	methods	can	be	used	
to	analyse	expression	and	qualitative	expression	(Yan	et	al.,	2002).	However,	these	methods	
do	not	provide	high	enough	resolution	to	conduct	a	complete	proteomic	analysis	of	
biological	samples	(Wright	et	al.,	2012).	Higher	resolution	analysis	can	be	achieved	by	
employing	alternative	methods,	such	as	mass	spectrometry.	
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1.7.2	-	Metabolomics	
Metabolomics	is	the	study	of	the	metabolites	within	a	biological	system	(Horgan	&	Kenny,	
2011).	Metabolites	are	the	substrates	and	products	of	essential	cellular	functions,	such	as	
energy	production	and	storage,	signal	transduction	and	apoptosis	(Johnson,	Ivanisevic	&	
Siuzdak,	2016).	
	
Metabolites	can	also	be	derived	from	exogenous	substances	including	microorganism,	
xenobiotic	and	dietary	metabolites	(Johnson,	Ivanisevic	&	Siuzdak,	2016).	Metabolites	have	
been	described	as	proximal	reporters	of	disease	because	of	their	abundance	within	
biological	fluids	under	pathological	conditions	(Gerszten	&	Wang,	2008;	Clish,	2015).	
During	biomarker	discovery	studies	involving	metabolomic	analysis,	there	are	commonly	
two	main	stages,	a	discovery	stage,	in	which	a	group	of	novel	biomarker	candidates	are	
identified,	and	a	validation	phase,	where	potential	biomarkers	are	validated	in	a	different	
patient	cohort	or	using	an	alternative	methodology	(Barderas	et	al.,	2011).	
	
Metabolites	can	be	identified	within	many	biological	fluids	or	tissues,	with	blood	plasma	and	
urine	the	most	commonly	used	biological	matrices,	due	to	their	relatively	uncomplicated	
availability	and	high	relevance	within	a	clinical	setting	(Barderas	et	al.,	2011;	Darde,	
Barderas	&	Vivanco,	2007).	There	are	two	main	methods	of	generating	metabolomics	data;	
these	are	nuclear	magnetic	resonance	(NMR)	and	mass	spectrometry	(MS)	(Alonso,	Marsal	
&	Julià,	2015).	Mass	spectrometry	is	commonly	preferred	over	NMR	for	metabolomic	
analysis	of	biological	fluids,	due	to	its	sensitivity	and	its	ability	identify	thousands	of	
metabolites	in	a	single	analysis	(Vuckovic,	Issaq	&	Veenstra,	2013;	Jardine,	2012).		
	
A	greater	knowledge	of	metabolic	pathways	also	offers	the	ability	to	develop	new	
biomarkers	for	disease	states,	by	identifying	changes	between	healthy	and	disease	states.	
This	allows	diseases	to	be	identified	earlier,	providing	quicker,	specific	therapeutic	
intervention	to	provided,	before	the	disease	can	progress.	
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1.7.3	-	Mass	spectrometry	and	bioinformatics	
Mass	spectrometry	(MS)	is	an	analytical	technique	that	acquires	spectral	data	based	on	the	
mass	to	charge	ratio	and	relative	intensity	of	molecules	(Alonso,	Marsal	&	Julià,	2015).	It	
involves	several	steps	including	ionisation,	transportation,	deflection	and	detection.	
However,	before	MS	analysis	can	be	conducted	the	biological	sample	needs	to	be	separated	
using	chromatography	based	methods	(Alonso,	Marsal	&	Julia,	2015).	These	methods	
involve	the	interaction	of	molecules	within	a	sample	to	an	adsorbent	material	within	a	
separation	column	(François,	Sandra	&	Sandra,	2009).		
Following	separation,	the	compounds	and	molecules	need	to	be	ionised	to	give	them	a	
positive	charge	and	convert	them	to	the	gaseous	phase	without	causing	degradation	to	the	
analytes	(Yates,	Ruse	&	Nakorchevsky,	2009).		
	
The	choice	of	ion	source	used	to	ionise	molecules	is	of	importance	when	conducting	MS	
analysis.	This	is	due	to	different	ionisation	techniques	fragmenting	molecules	to	different	
extents	(Lössl,	van	de	Waterbeemd	&	Heck,	2016).	Several	ionisation	methods	are	available	
to	generate	the	positively	charged	fragments.	These	methods	can	be	conducted	in	a	
vacuum,	such	as	electron	impact	ionisation	(EI)	and	matrix-assisted	laser	desorption	
ionisation	(MALDI)	(Yates,	Ruse	&	Nakorchevsky,	2009),	or	at	atmospheric	pressure	through	
chemical	ionisation	and	electro	spray	ionisation	(ESI)	(Mumtaz	et	al.,	2017).			
	
Ions	are	transported	through	the	spectrometer;	they	pass	through	a	strong	magnetic	or	
electrical	field	(Hoffmann	&	Stroobant,	2007).	These	fields	are	used	to	separate	and	analyse	
ions	based	on	their	mass.	This	involves	the	amount	of	deflection	caused	by	the	field	or	the	
time	taken	to	reach	the	detector	(time	of	flight	instruments)	(Domon	&	Aebersold,	2006).	
Ions	with	lower	masses	will	reach	the	detector	first,	and	as	the	strength	of	the	field	is	
increased	higher	mass	ions	can	be	detected	(Burinsky,	2006).	
	
The	detection	of	ions	involves	the	measurement	of	charged	ions	when	they	hit	the	surface	
of	the	detector	(Yerlekar	&	Kshirsagar,	2014).	This	charge	is	then	converted	by	a	computer	
to	develop	the	mass	to	charge	ratio	and	abundance	of	an	ion.	The	mass	to	charge	ratio	can	
then	be	compared	to	those	of	known	molecules	using	bioinformatics	analysis.	This	
determines	the	identity	of	analytes	and	their	function	within	a	biological	system.		
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Bioinformatics	analysis	is	commonly	compared	to	publically	available	databases	such	as	the	
Research	Collaboratory	for	Structural	Bioinformatics	protein	database	and	the	National	
Center	for	Biotechnology	Information	protein	database.	
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1.8	-	Aims	of	the	study	
The	study	was	designed	for	a	cohort	of	200	patients,	to	meet	the	statistical	powering	target.	
This	MSc	by	research	position	acted	as	a	50-patient	pilot	study	to	determine	if	interleukin-6	
and	interleukin-10	showed	positive	trends	in	predicting	patient	outcome	and	could	be	used	
to	stratify	patients.		
	
The	main	aim	of	this	pilot	study	is	to	identify	if	interleukin-6	and	interleukin-10	
concentrations	play	a	key	role	and	be	utilised	to	predict	the	development	of	poor	patient	
outcome,	following	traumatic	injury	requiring	immediate	surgery	or	direct	admission	to	the	
ICU.	From	this	main	overall	aim,	several	sub-aims	can	be	generated:		
	
• To	optimise	the	cytometric	bead	array	to	simultaneously	detect	interleukin-6	and	
interleukin-10	in	trauma	patient	serum	samples.		
• The	measurement	of	both	interleukin-6	and	interleukin-10	in	a	large	patient	cohort	to	
identify	the	changes	in	concentration	over	a	5-day	period	following	traumatic	injury.	
• To	identify	if	the	concentrations	of	interleukin-6	and	interleukin-10	differ	in	patient	
populations	with	a	poor	outcome	compared	to	a	good	outcome.	
	
These	aims	will	be	met	using	a	variety	of	different	methods	and	techniques	including,	flow	
cytometry	based	cytometric	bead	arrays,	metabolomics	analysis	and	clinical	data	
management	and	examination.	
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Chapter	2	-	Methods	
2.1	-	Study	design	
The	overall	study	is	designed	to	identify	the	interplay	between	immune	and	metabolic	
systems,	to	identify	a	panel	of	markers	that	can	predict	patient	outcome,	in	a	large	cohort	of	
patients.	The	study	was	granted	UKCRN-NIHR	Portfolio	status	(BIT	19377),	which	supported	
research	nurse	funding	for	clinical	activities	in	Manchester	Royal	Infirmary	(MRI)	and	Salford	
Royal	Hospital	(SR).	
	
As	a	part	of	study	development,	a	statistical	power	calculation	was	conducted	by	
statisticians	at	Manchester	Royal	Infirmary	to	identify	the	number	of	patients	required	for	
statistically	significant	results	to	be	achieved.	This	was	based	on	a	power	calculation	was	
based	on	90%	confidence	of	falsely	rejecting	the	null	hypothesis.	This	calculation	identified	
the	need	for	200	patients,	accounting	for	withdrawals.	For	the	period	of	the	MSc	by	
research	position,	an	aim	of	analysing	approximately	50	patient	samples	for	interleukin-6	
and	interleukin-10.	
	
2.1.1	-	Ethical	considerations	 	
The	description	of	the	project	required	ethical	approval	to	be	required	from	Local	Ethics	
Commit	Manchester,	NHS/HSC	Research	and	Development	offices	(IRAS	ID	172620)	and	the	
ethical	committee	at	the	University	of	Salford,	under	ethics	code	ST1617-17. 
	
2.1.2	-	Patient	recruitment	
Patients	were	recruited	from	MRI	and	SR.	Patients	who	were	suitable	to	participate	in	the	
study	were	identified	using	the	criteria	in	Table	10.	
	
Table	10)	The	criteria	used	to	identify	suitable	patients	for	the	study.	Patients	are	required	
to	meet	all	three	primary	criteria	and	be	either	directly	admitted	to	the	intensive	care	unit	
or	require	immediate	surgical	intervention.	
Requirement	 Yes/No	
Age	>16	and	<90	 Yes	
Male	and	Female	 Yes	
ISS	>15	 Yes	
Immediate	surgical	intervention	 	
ICU	admission	 Yes	
Abbreviations:	ISS,	Injury	Severity	Score;	ICU,	Intensive	Care	Unit.	
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Suitable	patients	were	required	to	consent	as	soon	as	possible	before	taking	and	storage	of	
samples	using	the	consent	form	(Appendix	1).	Once	recruited,	20mls	of	blood	was	taken	
from	patients	at	three	time	points.	These	samples	were	taken	on	day	1	(within	24	hours	of	
admission),	day	3	(third	day	after	admission)	and	day	5	(the	fifth	day	after	admission)	after	
the	traumatic	injury	(Table	11).		
	
Table	11)	The	time	points	at	which	blood	samples	and	clinical	data	were	collected.	
	 D1	 D2	 D3	 D4	 D5	 D6	 D7	 D8	
Blood	sample	 X	 	 X	 	 X	 	 	 	
Data	collection	 X	 	 X	 	 X	 	 	 X	
	
Alongside	blood	sampling,	a	series	of	clinical	information	was	collected	(Table	12).	
	
Table	12)	The	clinical	data	collection	sheet	used	for	each	of	the	four	clinical	data	collection	
points.	
Day		 Date	
HR	 	 BP	 ___/__	 Temp	 _____°C	
Hb	 	 WCC	 	 PLT	 	
eGFR	 	 Creatinine	 	 Bilirubin	 	
PT	 	 Intubated	 Y	/	N	 NIV/CPAP	 Y/N	
FiO2	 ____%	 P/F	Ratio	 _____kPA	 Lactate	 ___mmol/L	
Noradrenaline	 ___µg/kg/min	 CRP	 _______mg/L	 CVVH/IHD	 Y/N	
Sedated	 	 GCS	 ____/N/A	 	 	
Treated	with	antibiotics	 Y	/	N	 Source	of	sepsis	 ______/empirical/unknown	
Abbreviations:	HR,	Heart	rate;	Hb,	Heamoglobin;	eGFR,	Estimated	glomerular	filtration	rate;	FiO2,	Fraction	of	Inspired	Oxygen;	
BP,	Blood	pressure;	WCC,	White	cell	count;	CRP,	C	Reactive	Protein;	GCS,	Glasgow	Coma	Score;	PLT,	Platelet	count;	CVVH,	
Continuous	Veno-Venous	Heamofiltration.	
	
This	clinical	data	was	then	used	to	calculate	patient	SOFA	scores,	which	would	be	used	as	a	
predictor	of	patient	outcome.	These	criteria	and	clinical	scoring	systems	were	then	
compared	to	IL-6	and	IL-10	concentration	determined	using	methods	2.3	and	2.4.	From	this	
comparison,	it	identified	if	patient’s	outcome	and	injury	severity	correlated	with	IL-6	and	IL-
10	concentration.	
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2.1.3	-	Evaluation	of	good	and	poor	outcome	
Patients	were	grouped	into	those	with	a	good	and	poor	outcome	following	traumatic	injury.	
To	distinguish	between	good	and	poor	outcome	patients	the	criteria	in	Table	13	was	used.	
	
Table	13)	The	definitions	of	good	and	poor	outcome	for	trauma	patients	used	in	this	study.	
Good	Patient	Outcome	
• A	SOFA	score	of	<3	5	days	after	traumatic	injury.	
Poor	Patient	Outcome	
• A	SOFA	score	of	>3	5	days	after	traumatic	injury.	
• The	patient	remaining	hospitalised	8	days	after	injury.		
Abbreviations:	SOFA,	Sequential	organ	failure	assessment.	
	
These	criteria	were	then	compared	to	interleukin-6	and	interleukin-10	concentration,	to	
analyse	if	the	concentration	of	these	cytokines	correlated	with	a	good	or	poor	outcome	
following	traumatic	injury.	
	
2.2	-	Sample	preparation	
Initially,	10mls	of	blood	was	removed	from	blood	containers	and	added	to	two	15ml	
centrifuge	tubes,	which	were	then	centrifuged	at	644xg	(2000rpm)	for	5	minutes.	Once	
centrifuged,	the	top	layer	of	serum	was	removed	and	1ml	aliquots	transferred	to	cryovials,	
before	storage	at	-80oC	for	later	analysis.	
	
A	further	10mls	of	patient	blood	was	carefully	layered	over	Ficoll	Histopaque,	before	being	
centrifuged	for	20minutes	at	522xg	(1800rpm).	Following	centrifugation,	the	serum	was	
extracted	and	transferred	to	cryovials	and	stored	at	-80oC.	
	
Peripheral	Blood	Mononuclear	Cells	(PBMC’s)	were	also	extracted	from	the	Ficoll	
Histopaque	and	washed	in	Phosphate	Buffered	Saline	(PBS)	by	centrifuging	at	272xg	
(1300rpm)	for	10	minutes.	After	washing,	the	supernatant	was	discarded	and	the	cell	pellet	
was	re-suspended	using	1ml	of	freezing	media	(90%	Fetal	Bovine	Serum	(FBS)	and	10%	
Dimethyl	sulfoxide	(DMSO)).	The	mixture	was	then	transferred	to	cryovials	and	stored	in	the	
‘Mr	Frosty’	freezing	container	for	24	hours,	before	being	moved	to	long-term	sample	
storage.	
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2.3	-	Cytometric	bead	array	for	standard,	known	concentrations	
Before	the	cytometric	bead	array	assay	was	conducted	three	different	reagents	were	
required	to	be	prepared.	These	reagents	were	the	standard	concentrations,	the	mixed	
capture	beads	and	the	PE	detection	reagent.	
	
The	preparation	of	known	standard	concentrations	was	then	used	to	create	a	standard	
curve,	which	was	used	to	determine	the	concentration	of	Interleukin-6	and	Interleukin-10	in	
unknown	samples.	The	standards	were	prepared	by	opening	phials	of	lypholysed	standard	
spheres	from	each	BD	Bioscience	cytometric	bead	array	flex	sets	to	be	used	in	the	analysis	
and	pooling	them	in	one	tube.	The	standard	spheres	were	then	reconstituted	in	4mls	of	
assay	diluent	and	left	to	equilibrate	at	room	temperature	for	15	minutes.			
	
During	this	period,	nine	additional	tubes	were	filled	with	500µl	of	assay	diluent	and	labelled	
with	the	standard	concentrations,	shown	in	Table	10).	After	this	period,	the	standard	
spheres	were	mixed	with	a	pipette	and	a	serial	dilution	was	then	conducted	in	the	pattern	
shown	in	Table	13).	A	negative	control	was	also	prepared,	which	was	filled	with	just	assay	
diluent,	created	independently	from	the	serial	dilution.	
	
Table	14)	Standard	concentrations	created	following	serial	dilution	of	standard	spheres	from	the	BD	
Bioscience	Interleukin-6	and	Interleukin-10	Flex	sets.	
Tube	label	 Standard	Dilution	 Concentration	(pg/ml)	
1	(Top	Standard)	 1:1	 2500	
2	 1:2	 1250	
3	 1:4	 625	
4	 1:8	 312	
5	 1:16	 156	
6	 1:32	 80	
7	 1:64	 40	
8	 1:128	 20	
9	 1:256	 10	
10	(Negative	control)	 No	Dilution	 0		
	
Subsequently,	the	preparation	of	the	standard	concentrations,	the	capture	beads	were	
prepared.	This	was	done	by	initially	calculating	the	number	of	tests	to	be	conducted	as	this	
was	used	to	determine	the	volume	of	capture	beads	required,	as	1	test	equals	1µl	of	
capture	bead	stock	required.		
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Once	calculated,	the	phial	of	capture	bead	stock	was	vortexed	for	15	seconds	to	re-suspend	
the	beads	and	the	required	volume	of	capture	beads	was	pipetted	into	a	tube.	The	capture	
beads	were	then	washed,	by	adding	500µl	of	wash	buffer	into	the	tube	and	centrifuging	for	
5	minutes	at	200xg.		
	
After	washing,	the	supernatant	was	aspirated	and	discarded,	with	the	pellet	being	
resuspended	in	capture	bead	diluent	to	a	concentration	of	50µl	per	test.	Before	the	assay	
procedure	was	done,	the	capture	beads	were	vortexed	and	incubated	for	15	minutes.	
In	the	preparation	of	the	PE	detection	reagent,	the	stock	PE	detection	reagent	was	diluted	
using	detection	reagent	diluent	to	a	1	in	50	dilutions,	therefore	to	a	concentration	of	1µl	of	
detection	reagent	with	49µl	of	detection	reagent	diluent.	Once	prepared,	the	diluted	PE	
detection	reagent	was	stored	at	4oC,	protected	from	light.		
	
Once	the	standard	concentrations	and	reagents	were	made	50µl	of	each	standard	
concentration	was	placed	into	individual	Eppendorf	tubes.	50µl	of	the	mixed	capture	beads	
were	then	added	to	each	tube	containing	the	serum	sample,	the	contents	of	the	tubes	were	
then	mixed	and	left	to	incubate	at	room	temperature	for	one	hour.	
	
Following	the	one	hour	incubation,	50µl	of	the	diluted	PE	detection	reagent	was	added	to	
each	tube	and	left	to	incubate	at	room	temperature	in	the	dark,	for	two	hours.	After	two	
hours,	1ml	of	wash	buffer	was	placed	into	each	tube	before	they	were	centrifuged	for	5	
minutes	at	200xg.	After	centrifugation,	the	supernatant	from	each	tube	was	discarded,	
being	careful	not	to	disturb	the	pellet	and	the	pellet	was	re-suspended	in	300µl	of	wash	
buffer	before	analysis	by	flow	cytometry.	
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2.4	-	The	cytometric	bead	array	for	the	analysis	of	interleukin-6	and	interleukin-10	in	
unknown	patient	samples	
Patient	serum	samples	were	removed	from	the	-80oC	freezer	and	defrosted	at	room	
temperature.	Once	defrosted,	50µl	of	the	serum	was	aliquoted	into	triplicate	Eppendorf	
tubes.	Following	this,	50µl	of	prepared	mixed	capture	beads	(See	Page	62)	were	added	to	
the	patient	serum	samples	and	mixed	by	gentle	pipetting,	before	being	incubated	at	room	
temperature	for	one	hour.	
	
After	one	hour,	50µl	of	the	prepared	PE	detection	reagent	(See	Page	62)	was	added	to	each	
sample	containing	tube,	before	being	incubated	in	the	dark,	at	room	temperature,	for	two	
hours.		Subsequently,	1ml	of	wash	buffer	was	added	to	each	tube	and	centrifuged	at	200xg	
for	five	minutes.	The	supernatant	was	then	discarded	and	the	pellet	was	re-suspended	using	
300µl	of	wash	buffer,	and	then	analysed	using	flow	cytometry.	
	
2.5	-	Flow	cytometry	analysis	of	the	cytometric	bead	array	
Once	prepared,	the	cytometric	bead	array	was	analysed	using	flow	cytometry.	During	this	
analysis,	the	different	capture	beads	for	IL-6	and	IL-10	were	distinguished	from	the	general	
bead	population	and	the	median	PE	fluorescence	for	each	capture	bead	population	was	
measured.		
	
The	median	fluorescence	of	PE	was	then	converted	to	the	concentration	of	IL-6	and	IL-10	
using	the	standard	curves	generated	during	optimisation	of	the	cytometric	bead	array	
method	(See	Chapter	2.8	for	further	information).	The	concentrations	were	then	compared	
to	patient	clinical	parameters,	to	determine	if	they	have	potential	to	predict	patient	
outcome	and	the	development	of	complications.	
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2.6	-	Methods	for	metabolomics	analysis	in	trauma	patient	samples	
Metabolomics	analysis	was	conducted	by	Waters	Corporation,	grouped	using	interleukin-10	
concentrations	generated	using	methods	2.4	–	2.5,	using	the	following	method.	An	initial	
cohort	of	35	patients	was	selected	at	presentation	to	hospital	based	on	injury	severity	
scoring	obtained	in	theatre	or	during	ICU	care.		The	metabolome	and	lipidome	profiles	of	
the	35-patient	cohort	were	developed	using	the	following	liquid	chromatography,	mass	
spectrometry	approach.	
	
Patient	serum	samples	were	subjected	to	a	methonal	based	extraction	process	to	extract	
metabolites	and	lipids	from	the	samples.	The	metabolites	were	then	separated	using	an	
Acquity	UPLC	system.	Data	was	then	acquired	using	a	VION	(IMS-Q-ToF)	mass	spectrometer	
operating	in	positive	and	negative	resolution	modes,	offering	independent	analysis.	Each	
sample	was	analysed	in	triplicate	using	this	method.	Metabolite	data	obtained	following	
mass	spectrometry	analysis	were	searched	against	the	human	metabolite	database	and	
quantified	using	Progenesis	QI	v2.3	LC/MS	analysis	software.	Any	metabolites	of	statistical	
significance	(CV	<30%;	ANOVA	(p)	<0.05)	were	considered	for	further	investigation.		
	
These	patients	were	then	grouped	based	upon	their	cytokine	profile,	examined	using	a	
cytometric	bead	array	method	described	in	chapter	2.4.	The	patient’s	metabolomic	and	
lipidomic	profiles	were	then	grouped	based	on	patients	with	a	day	1	interleukin-10	
concentration	of	>12	pg/ml	and	those	with	a	concentration	of	<12	pg/ml.	Metabolomic	data	
generated	by	Waters	Corporation	was	then	analysed	at	the	University	of	Salford	to	identify	
metabolites	with	significantly	differentiated	expression	between	the	two	patient	groups.	
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Chapter	3	-	Results	
3.1	-	Optimisation	of	the	cytometric	bead	array	
The	optimisation	of	the	cytometric	bead	array	for	interleukin-6	and	interleukin-10	involved	
several	experiments	to	set	up	the	correct	flow	cytometry	gating	for	the	capture	beads	to	
differentiate	each	population	of	capture	bead	and	develop	the	standard	curves	used	to	
calculate	the	concentration	of	IL-6	and	IL-10	within	patient	serum	samples.	
	
3.1.1	-	Optimisation	of	the	interleukin-6	cytometric	bead	array	
Firstly,	interleukin-6	capture	beads	were	analysed	independently,	to	optimise	the	gating	for	
this	population	of	capture	bead.	Gates	were	added	around	the	general	bead	population	
before	identifying	the	IL-6	capture	beads	(Figure	26).	
	
	
	
Once	the	gating	was	optimised	for	interleukin-6,	a	standard	curve	was	generated	using	
standard	concentrations	of	IL-6	(See	Chapter	2.3	for	the	full	method)	(Figure	27).		
Figure	26)	The	flow	cytometry	gating	used	to	identify	the	interleukin-6	capture	bead	
population	used	to	measure	the	median	PE	fluorescence.	
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3.1.2	-	Optimisation	of	the	interleukin-10	cytometric	bead	array	
Following	the	generation	of	a	standard	curve	for	interleukin-6,	this	method	was	repeated	
for	interleukin-10	cytometric	bead	arrays	(Figure	28-29).		
	
	
	
	
	
	
Figure	28)	The	flow	cytometry	gating	used	to	identify	the	interleukin-10	capture	bead	
population	used	to	measure	the	median	PE	fluorescence.	
Figure	27)	The	standard	curve	generated	for	interleukin-6	from	a	single	capture	bead	
population.	
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Figure	29)	The	standard	curve	generated	for	interleukin-10	from	a	single	capture	bead	
population.	
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3.1.3	-	Optimisation	of	the	multiplexed	interleukin-6	and	interleukin-10	cytometric	bead	
array	
After	both	interleukin-6	and	interleukin-10	had	been	individually	optimised,	a	multiplex	
assay	containing	both	types	of	capture	beads	was	conducted.	This	allowed	gating	of	both	
cytokine	capture	beads	when	simultaneously	analysed	using	flow	cytometry	(Figure	30).	
	
	
Following	the	optimisation	of	the	multiplex	assay	gating,	standard	curves	for	IL-6	and	IL-10	
were	then	generated	using	this	multiplex	assay	method	(Figure	31-32).	
	
Figure	30)	The	flow	cytometry	gating	used	to	identify	interleukin-6	and	interleukin-10	
capture	bead	populations	during	the	multiplex	assay.	The	individual	median	PE	
fluorescence	for	each	capture	bead	population	can	be	measured.	
Figure	31)	The	interleukin-6	standard	curve	generated	during	a	multiplex	assay	containing	
both	interleukin-6	and	interleukin-10	capture	beads.	
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Figure	32)	The	interleukin-10	standard	curve	generated	during	a	multiplex	assay	containing	
both	interleukin-6	and	interleukin-10	capture	beads.	
	
	
	
	
	
	
	
	
	
	
	
	
	
These	standard	curves	were	then	used	to	interpolate	the	concentration	of	interleukin-6	and	
interleukin-10	in	trauma	patient	samples.	
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3.2	-	Analysis	of	the	patient	cohort	
Patient	samples	were	received	from	Manchester	Royal	Infirmary	and	Salford	Royal	Hospital.	
As	of	the	15th	June	2017,	the	study	has	received	samples	from	110	patients,	with	69	
remaining	in	hospital	to	provide	all	three	samples.	The	patients	who	did	not	provide	all	
three	samples	were	discharged,	refused	to	consent	or	were	transferred	to	a	different	
hospital	(Figure	33).	
	
	
Following	receipt	of	patient’s	day	5	sample,	the	patients	were	grouped	based	on	whether	
they	had	a	good	or	a	poor	outcome	following	traumatic	injury.	These	groupings	were	
decided	based	upon	the	patient’s	day	5	SOFA	score	and	if	they	remained	in	hospital	past	day	
8	following	traumatic	injury.	The	criteria	used	to	distinguish	good	and	poor	outcome	
patients	are	shown	in	Table	13).	
	
	
	
63% 
27% 
5% 
2% 3% 
Complete	triplicate Refused	consent Discharged Transferred No	sample	taken
Figure	33)	Analysis	of	patient	samples	received	from	Manchester	Royal	Infirmary	and	
Salford	Royal	Hospitals	to	determine	the	percentage	of	patients	who	completed	all	three	
days’	samples	and	those	who	did	not,	with	the	reasons	why.	
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Using	the	criteria	in	table	13,	the	patient	cohort	was	further	analysed	to	compare	good	and	
poor	outcome	for	all	triplicate	samples	received	from	both	Manchester	Royal	Infirmary	and	
Salford	Royal	Hospital.	The	results	of	this	analysis	are	shown	in	Figures	34	-36).	
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Figure	34)	The	number	of	patients	who	had	a	poor	outcome	from	complete	triplicate	
samples	received	from	Manchester	Royal	Infirmary	(MRI)	and	Salford	Royal	Hospital	(SRFT).	
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Figure	35)	A	comparison	of	good	and	poor	outcome	patients	from	Manchester	Royal	Infirmary.	
Figure	36)	A	comparison	of	good	and	poor	outcome	patients	from	Salford	Royal	Hospital.	
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Of	the	69	sample	triplicates	received	from	Manchester	Royal	infirmary	and	Salford	Royal	
Hospital,	the	first	50	triplicate	samples	were	analysed	for	their	Interleukin-6	and	Interleukin-
10	concentrations	as	a	part	of	the	pilot	study.	These	concentrations	were	then	compared	to	
clinical	scoring	methods	and	commonly	measured	biological	molecules,	to	determine	if	
interleukin-6	and	interleukin-10	could	be	used	as	biomarkers	for	predicting	patient	outcome	
and	the	development	of	complications,	before	they	arise.	
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3.3	-	Analysis	of	trauma	patient’s	clinical	data	
Patient	clinical	data	was	provided	on	each	selected	time	point	during	the	8-day	period	
(Table	11)	following	traumatic	injury,	by	the	research	teams	at	MRI	and	SR	(Appendices	2	-	
5).	This	was	used	to	calculate	patient	SOFA	scores	and	analyse	commonly	used	markers	for	
inflammation	and	the	development	of	sepsis.	The	markers	for	inflammation	and	sepsis	
development	that	were	used	for	comparison	was	C	Reactive	Protein	(Figure	37)	and	Lactate	
(Figure	38).	
	
Day	1	C	Reactive	Protein	was	found	to	have	an	average	concentration	of	50.92	±	73.06	mg/L	
(Figure	39),	with	the	concentrations	ranging	between	1	mg/L	and	345	mg/L.	On	average	C	
Reactive	Protein	was	found	to	be	at	its	highest	concentration	in	day	3	following	traumatic	
injury	at	201.52	±	108.29	mg/L	(Figure	39).	In	day	3	concentrations	ranged	between	15	mg/L	
and	438	mg/L.		In	day	5,	C	Reactive	Protein	was	found	at	an	average	concentration	of	149	±	
101.22	mg/L	(Figure	39),	with	concentrations	ranging	between	3	mg/L	and	350	mg/L.	Day	8	
trauma	patient	samples	were	found	to	contain	an	average	of	162.15	±	148.75	mg/L	(Figure	
39)	of	C	Reactive	Protein.	The	day	8	concentrations	ranged	between	1	mg/L	and	563	mg/L.	
	
The	lactate	concentration	peaked	in	day	1	was	found	at	an	average	of	2.72	±	1.78	mM/L	
(Figure	40),	with	concentrations	ranging	between	0.7	and	7.7	mM/L.	The	lactate	
concentration	then	decreased	in	day	3	to	an	average	concentration	of	1.14	±	0.44	mM/L	
(Figure	40),	with	day	3	concentrations	ranging	between	0.5	and	2.1	mM/L.	The	
concentration	further	decreased	to	an	average	of	1.01	±	0.30	mM/L	(Figure	40),	with	
concentrations	between	0.5	and	1.4	mM/L.	The	average	day	8	lactate	concentration	
increased	slightly	from	that	of	day	5	to	a	concentration	of	1.14	±	0.34	mM/L	(Figure	40).	In	
day	8,	lactate	concentrations	ranged	between	0.6	and	1.6	mM/L.	
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	 Figure	37)	The	C	Reactive	Protein	concentration	for	all	samples	(n=50)	analysed	during	the	pilot	study.	
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Figure	38)	The	concentration	of	lactate	for	all	samples	(n=50)	analysed	during	the	pilot	study.	
105	
	
	
	
	
	
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Lactate	Day	1 Lactate	Day	3 Lactate	Day	5 Lactate	Day	8
Av
er
ag
e	
La
ct
at
e	
co
nc
en
tra
tio
n	
(m
M
/L
)
-50 
0
50
100
150
200
250
300
350
CRP	Day	1 CRP	Day	3 CRP	Day	5 CRP	Day	8
Av
er
ag
e	
C	
re
ac
tiv
e	
pr
ot
ei
n	
co
nc
en
tra
tio
n	
(m
g/
L)
	
Figure	39)	The	average	C	Reactive	Protein	concentration	for	all	samples	(n=50),	at	each	
time	point	following	traumatic	injury.	
Figure	40)	The	average	concentration	of	lactate	for	all	samples	(n=50),	at	each	time	
point	following	traumatic	injury.	
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3.4	-	Interleukin-6	as	a	predictor	of	patient	outcome	
3.4.1	-	Interleukin-6	concentrations	in	trauma	patient	serum	samples	
The	pro-inflammatory	cytokine,	Interleukin-6	was	measured	in	patient	serum	samples	using	
the	cytometric	bead	array.	This	was	conducted	in	triplicate,	for	all	analysed	patient	day	1,	
day	3	and	day	5	samples	(Figure	41).	
	
Interleukin-6	concentration	in	the	46	triplicate	samples	varied	from	day	1	to	day	5	
(Appendix	2).	The	day	1	samples	ranged	from	1188.87	pg/ml	to	0.83	pg/ml	with	a	median	
value	of	54.28	pg/ml	and	a	mean	value	of	113.51	pg/ml.	The	day	3	samples	ranged	from	
421.36	pg/ml	to	0.25	pg/ml	with	a	median	value	of	29.43	pg/ml	and	a	mean	value	of	48.32	
pg/ml.	The	day	5	samples	ranged	from	4635.45	pg/ml	to	0.26	pg/ml	with	a	median	value	of	
10.90	pg/ml	and	a	mean	value	of	128.48	pg/ml.	
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Figure	41)	The	interleukin-6	concentration	of	all	analysed	patient	samples	(n=50),	showing	the	change	over	the	5-day	period.	
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3.4.2	-	A	comparison	between	interleukin-6	concentrations	and	patient	SOFA	score	
The	interleukin-6	concentrations	of	patient	samples	were	then	compared	to	SOFA	score	
(Appendix	3).	Patients	were	grouped	based	on	their	SOFA	score	for	each	day	and	the	
average	interleukin-6	concentration	for	each	group	was	compared	to	the	SOFA	score	
(Figures	42	-	44).	
	
	
Figure	42)	A	comparison	of	averaged	interleukin-6	against	day	1	SOFA	score,	in	patients	
grouped	based	upon	day	1	SOFA	score.	
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Figure	43)	A	comparison	of	averaged	interleukin-6	against	day	3	SOFA	score,	in	patients	
grouped	based	upon	day	3	SOFA	score.	
Figure	44)	A	comparison	of	averaged	interleukin-6	against	day	5	SOFA	score,	in	patients	
grouped	based	upon	day	5	SOFA	score.	
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Day	1	averaged	interleukin-6	concentrations	(Figure	42)	was	found	to	plateau	between	
SOFA	scores	0	to	8,	as	the	concentrations	fluctuate	between	48.39	pg/ml	and	95.15	pg/ml.		
The	average	concentration	then	rapidly	increased	to	462.39	pg/ml	in	SOFA	score	of	9	and	
increased	further	in	the	patients	with	a	SOFA	score	of	11	to	1188.87	pg/ml.	
	
Day	3	interleukin-6	concentrations	(Figure	43)	spiked	in	patients	with	a	SOFA	score	of	4	as	it	
rises	from	22.90	pg/ml	in	SOFA	score	of	3	to	1023.84	pg/ml	in	patients	with	a	SOFA	score	of	
4.	The	concentration	then	falls	to	105.87	pg/ml	in	patients	with	SOFA	scores	of	5.	
Interleukin-6	concentration	then	fluctuates	between	67.31	pg/ml	and	21.47	pg/ml,	in	SOFA	
scores	7,	8	and	9.	
	
Day	5	interleukin-6	concentrations	(Figure	44)	ranged	between	10.90	pg/ml	and	19.08	pg/ml	
in	patients	with	SOFA	scores	of	0	and	3.	The	concentration	then	increased	to	68.49	pg/ml	in	
patients	with	a	SOFA	score	of	4	and	increased	further	to	76.70	pg/ml	for	SOFA	scores	of	5.	
The	concentration	then	decreased	to	32.33	pg/ml	in	patients	with	a	day	5	SOFA	score	of	8.	
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3.4.3	-	Interleukin-6	as	a	predictor	of	patient	outcome	
Patients	were	grouped	further	into	good	and	poor	outcomes	using	the	criteria	in	Table	13).	
Good	and	poor	outcome	patient	groups	interleukin-6	concentrations	were	then	averaged	
for	each	of	the	three	sample	time	points	and	the	good	outcome	patients	were	then	
compared	to	those	with	a	poor	outcome	(Figure	45).	
	
	
	
	
	
The	results	of	good	versus	poor	outcome	patients	(Figure	45),	shows	a	substantial	variation	
between	poor	outcome	patients	and	good	outcome	patients.	In	Day	1	the	average	
concentration	of	interleukin-6	in	poor	outcome	patients	was	323.45	pg/ml	compared	to	
62.63	pg/ml	in	good	outcome	patients.	The	difference	increased	in	day	3	as	the	average	
interleukin-6	concentration	of	poor	outcome	patients	increased	to	344.41	pg/ml,	while	the	
good	outcome	patients	average	interlekin-6	concentration	decreased	to	33.03	pg/ml.	The	
day	5	average	interleukin-6	concentrations	for	both	good	and	poor	outcome	patients	
decreased	to	84.16	pg/ml	in	poor	outcome	patients	and	15.71	pg/ml	in	patients	with	a	good	
outcome.	
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Figure	45)	A	comparison	between	the	interleukin-6	concentrations	of	good	outcome	
patients	(n=	42)	and	poor	outcome	patients	(n=	8)	on	day	1	(Good	=	62.63±66.89)	(Poor	=	
323.45±474.94),	day	3	(Good	=	33.03±50.99)	(Poor	=	334.41±689.98)	and	day	5	(Good	=	
15.71±19.97)	(Poor	=	84.16±89.99)	following	traumatic	injury.	
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3.5	-	Interleukin-10	as	a	predictor	of	patient	outcome	
3.5.1	-	Interleukin-10	concentrations	in	trauma	patient	serum	samples	
The	anti-inflammatory	cytokine,	Interleukin-10	concentration	was	measured	in	triplicate,	
using	cytometric	bead	arrays	for	all	sample	time	points	(Appendix	4).	Once	measured,	
comparisons	were	made	between	patient	SOFA	scores	and,	good	and	poor	outcome	
following	traumatic	injury.	The	results	of	interleukin-10	concentrations	for	all	patient	
samples	are	shown	in	Figure	46.	
	
The	day	1	interleukin-10	concentration	for	all	measured	samples	ranged	from	128.64	pg/ml	
to	1.48	pg/ml,	with	a	median	value	of	5.87	pg/ml	and	a	mean	concentration	of	12.39	pg/ml.	
The	day	3	samples	ranged	from	10.72	pg/ml	to	0.70	pg/ml,	with	a	median	value	of	2.59	
pg/ml	and	a	mean	concentration	of	3.25	pg/ml.	Day	5	samples	ranged	from	57.58	pg/ml	to	
0.31	pg/ml,	with	a	median	value	of	1.99	pg/ml	and	a	mean	concentration	of	4.32	pg/ml.	
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Figure	46)	The	interleukin-10	concentration	of	all	analysed	patient	samples	(n=	50),	showing	the	change	in	concentration	over	the	5-day	
period.	
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3.5.2	-	A	comparison	between	interleukin-10	concentrations	and	patient	SOFA	scores	
The	interleukin-10	concentrations	of	patients	were	compared	to	SOFA	scores.	This	was	done	
by	grouping	patients	based	upon	SOFA	score	and	averaging	the	interleukin-10	concentration	
for	each	SOFA	score	group.	These	were	then	compared	to	determine	if	there	was	a	
correlation	between	interleukin-10	concentration	and	patient	SOFA	scores	(Figures	47-49).	
	
Figure	47)	A	comparison	of	averaged	interleukin-10	against	day	1	SOFA	score,	in	patients	
grouped	based	upon	day	1	SOFA	score.	
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Figure	49)	A	comparison	of	averaged	interleukin-10	against	day	5	SOFA	score,	in	patients	
grouped	based	upon	day	5	SOFA	score.	
Figure	48)	A	comparison	of	averaged	interleukin-10	against	day	3	SOFA	score,	in	patients	
grouped	based	upon	day	3	SOFA	score.	
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The	day	1	interleukin-10	concentration	(Figure	47)	fluctuated	between	4.45	pg/ml	and	12.83	
pg/ml	between	SOFA	scores	0	and	8,	before	sharply	rising	to	44.32	pg/ml	in	patients	with	a	
SOFA	score	of	9.	It	then	decreased	to	18.49	pg/ml	in	patients	with	a	SOFA	score	of	11	
In	day	3	interleukin-10	concentrations	(Figure	48)	ranged	between	1.74	pg/ml	and	3.41	
pg/ml	for	SOFA	scores	of	0	and	3.	In	patients	with	a	SOFA	score	of	4,	the	interleukin-10	
concentration	increased	to	18.21	pg/ml,	before	dropping	down	to	between	3.75	pg/ml	and	
2.02	pg/ml	between	SOFA	scores	5	and	9.	In	day	5	samples,	the	interleukin-10	concentration	
(Figure	49)	increased	alongside	SOFA	score.	It	increased	from	2.24	pg/ml	in	patients	with	a	
SOFA	score	of	0	to	a	concentration	of	8.47	pg/ml.		
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3.5.3	-	Interleukin-10	as	a	predictor	of	patient	outcome	
The	interleukin-10	concentration	of	patient	serum	samples	was	compared	to	their	patient	
outcome.	The	patients	were	grouped	into	good	and	poor	patient	outcomes	using	the	
criteria	shown	in	Table	13),	and	the	average	interleukin-10	concentration	for	each	group	
was	evaluated	over	the	three	sample	time	points	(Figure	50).	
	
	
	
Interleukin-10	concentration	differed	significantly	between	good	and	poor	outcome	
patients.	In	day	1,	patients	with	a	good	outcome	had	an	average	interleukin-10	
concentration	of	7.30	pg/ml	compared	to	22.16	pg/ml	in	patients	with	a	poor	outcome.	
Both	good	and	poor	outcome	patients	decreased	on	day	3,	with	poor	outcome	patients	
remaining	higher	than	in	good	outcome	patients.	In	patients	with	a	good	outcome,	the	
interleukin-10	concentration	decreased	to	2.98	pg/ml,	with	poor	outcome	patients	
decreasing	to	7.16	pg/ml.	In	day	5,	both	patient	groups	slightly	decreased.	Poor	outcome	
patients	decreased	to	7.06	pg/ml,	while	good	outcome	patients	decreased	to	2.30	pg/ml.	
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Figure	50)	A	comparison	of	interleukin-10	in	good	outcome	patients	(n=	42)	and	poor	
outcome	patients	(n=	8)	on	day	1	(Good	=	7.30±5.64)	(Poor	=	22.16±16.99),	day	3	(Good	
=	2.98±2.32)	(Poor	=	7.16±10.57)	and	day	5	(Good	=	2.29±2.71)	(Poor	=	7.06±6.85)	
following	traumatic	injury.	
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3.6	-	Interleukin-6/interleukin-10	ratio	as	a	predictor	of	patient	outcome	
3.6.1	-	Interleukin-6/interleukin-10	concentrations	in	trauma	patient	serum	samples	
Once	interleukin-6	and	interleukin-10	were	analysed,	a	ratio	between	the	pro	and	anti-
inflammatory	cytokines	was	developed.	Once	developed,	comparisons	were	made	between	
patient	SOFA	scores	and,	good	and	poor	patient	(Figure	51).	
	
The	day	1	interleukin-6/interleukin-10	ratio	ranged	from	a	high	of	64.30:1	to	a	low	0.28:1.	
The	day	1	median	ratio	was	7.86:1	with	a	mean	ratio	of	10.59:1.		In	day	3	the	maximum	
ratio	was	85.12:1	with	a	minimum	of	0.13:1.	The	day	3	median	ratio	was	10.72:1	with	a	
mean	ratio	of	15.54:1.	In	the	day	5	samples,	the	maximum	interleukin-6/interleukin-10	ratio	
was	80.51:1	with	a	minimum	ratio	of	0.13:1.	The	day	5	median	ratio	was	6.83:1,	with	a	
mean	value	of	10.69:1	.	
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Figure	51)	The	interleukin-6/Interleukin-10	ratio	for	all	analysed	patient	samples	(n=	50),	showing	the	change	in	ratio	over	the	5-day	period.	
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Figure	52)	A	comparison	of	averaged	interleukin-6/interleukin-10	ratio	against	day	1	
SOFA	score,	in	patients	grouped	based	upon	day	1	SOFA	score.	
3.6.2	-	A	comparison	between	interleukin-6/interleukin-10	ratio	and	patient	SOFA	scores	
Patients	were	then	grouped	based	on	their	SOFA	scores	and	compared	to	the	interleukin-
6/interleukin-10	ratio.	These	were	then	compared	to	determine	if	there	was	a	correlation	
between	interleukin-10	concentration	and	patient	SOFA	scores	(Figures	52	-	54).	
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Figure	53)	A	comparison	of	averaged	interleukin-6/interleukin-10	ratio	against	day	3	
SOFA	score,	in	patients	grouped	based	upon	day	3	SOFA	score.	
Figure	54)	A	comparison	of	averaged	interleukin-6/interleukin-10	ratio	against	day	5	
SOFA	score,	in	patients	grouped	based	upon	day	5	SOFA	score.	
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The	interleukin-6/interleukin-10	ratio	was	found	to	be	elevated	on	day	1	in	patients	with	
higher	SOFA	scores	(Figure	52).	With	patients	with	a	SOFA	score	of	11	having	a	ratio	of	
64.30:1	compared	to	between	6.08:1	and	17.60:1	in	patients	with	SOFA	scores	below	9.	In	
day	3	(Figure	53)	patient	ratios	ranged	from	10.65:1	to	49.67:1.	Patients	with	a	SOFA	score	
of	2	had	a	high	ratio	at	25.09:1,	while	Patients	with	a	SOFA	score	of	8	had	the	highest	ratio	
at	49.67:1.	In	day	5	(Figure	54),	interleukin-6/interleukin-10	ratio	ranged	between	25.50:1	
and	9.27:1.	The	ratio	decreased	from	patients	with	a	SOFA	score	of	0	to	those	with	a	SOFA	
score	of	8,	with	peaks	occurring	at	SOFA	scores	of	1	and	4,	with	ratios	of	25.50:1	and	20.66:1	
respectively.	
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Figure	55)	A	comparison	of	averaged	interleukin-6/interleukin-10	ratio	between	good	
outcome	patients	(n=	42)	and	poor	outcome	patients	(n=	8)	on	day	1	(Good	=	8.85±7.34)	
(Poor	=	14.68±22.78),	day	3	(Good	=	11.00±15.22)	(Poor	=	49.14±20.81)	and	day	5	(Good	
=	12.00±12.57)	(Poor	=	7.50±11.88)	following	traumatic	injury.	
3.6.3	-	Interleukin-6/interleukin-10	ratio	as	a	predictor	of	patient	outcome	
The	Interleukin-6/interleukin-10	ratio	was	compared	to	their	patient	outcome.	The	patients	
were	grouped	into	good	and	poor	patient	outcomes	using	the	criteria	shown	in	Table	13),	
and	the	average	interleukin-10	concentration	for	each	group	was	evaluated	over	the	three	
sample	time	points	(Figure	55).	
	
Figure	55	demonstrates	that	the	interleukin-6/interleukin-10	ratio	was	higher	in	patients	
with	a	poor	outcome	compared	to	those	with	a	good	outcome.	The	ratio	was	slightly	higher	
poor	outcome	patients	on	days	1	and	5,	whilst	being	considerably	elevated	on	day	3	
compared	to	good	outcome	patients.	
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3.7	-	Metabolomics	analysis	of	trauma	patient	serum	samples	
Further	analysis	was	conducted	to	identify	significantly	differentially	expressed	metabolites	
based	on	the	day	1	interleukin-10	concentration.	Patients	were	grouped	based	on	day	1	
interleukin-10	concentration	>12	and	<12	pg/ml.	
	
Metabolomics	analysis	using	LC/MS	identified	9249	individual	compounds	in	the	Progenesis	
QI	v2.3	analysis	of	the	positive	ion	dataset.	Their	reproducibility	and	biological	variability	
were	evaluated	through	replicate	injections	by	Progenesis	QI	v2.3,	with	further	data	analysis	
being	conducted	at	the	University	of	Salford	to	identify	differentially	regulated	metabolites.	
	
Following	patient	grouping	based	on	their	day	1	interleukin-10	concentration,	611	
metabolites	were	found	to	be	differentially	regulated	day	1,	day	3	and	day	5	trauma	patient	
serum	samples	(Appendices	5-7).	Metabolites	were	further	narrowed	to	those	with	a	fold	
change	of	>2,	to	identify	those	with	a	greater	potential	for	further	analysis.	
	
The	day	1	metabolite	profile	(Figure	56)	identified	22	metabolites.	Two	of	these	metabolites	
were	found	to	be	meaningfully	elevated	above	the	rest	of	the	metabolites	identified	in	day	
1.	These	metabolites	are	Dioxin	B	and	Sulfoglycolithocholic	acid.	
	
The	day	3	metabolite	profile	(Figure	57)	identified	49	metabolites.	Eight	of	the	49	
metabolites	were	discovered	to	be	elevated	higher	than	the	rest	of	the	metabolites.	These	
metabolites	are	cholic	acid,	ergosta-5,7,22,24(28)-tetraen-3beta-yl	acetate,	PG,	Chenodeoxy	
cholic	acid,	glycochenodeoxycholic	acid	7-sulfate,	geissospermine	and	PI.	
	
The	Day	5	metabolite	profile	(Figure	58)	identified	28	metabolites.	Two	of	these	metabolites	
were	found	to	be	notably	elevated	above	the	rest	of	the	metabolites	identified	in	day	5.	
These	metabolites	are	Amoxicillin	and	Geissospermine.	
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Figure	56)	The	significantly	expressed	Day	1	metabolites	(n=	22)	identified	in	patients	with	interleukin-10	concentrations	of	>12	pg/ml	
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Figure	57)	The	significantly	expressed	Day	3	metabolites	(n=	49)	identified	in	patients	with	interleukin-10	concentrations	of	>12	pg/ml	
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Figure	58)	The	significantly	expressed	Day	5	metabolites	(n=	28)	identified	in	patients	with	interleukin-10	concentrations	of	>12	pg/ml.	
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Chapter	4	-	Discussion	
Trauma	is	a	major	health	burden,	affecting	both	high	and	low-income	countries	and	is	
considered	one	of	the	main	causes	of	death	and	disability	worldwide	(World	Health	
Organisation,	2012).	This	is	due	to	trauma	being	the	main	cause	of	death	in	adults	under	the	
age	of	40	and	the	incidence	of	trauma	increasing	in	the	elderly	population	in	developed	
countries,	due	to	the	rapidly	growing	ageing	population	in	developed	countries	(Kehoe	et	
al.,	2015).	This	changing	trend	in	the	age	of	trauma	patients	has	resulted	in	falls	from	a	
height	of	<2m	becoming	the	main	cause	of	traumatic	injury	in	the	United	Kingdom.	The	
increasing	numbers	of	elderly	patients	suffering	trauma,	places	an	increasing	burden	health	
services	due	to	these	patients	having	significant	levels	of	comorbidities,	which	may	
exacerbate	or	impair	the	recovery	following	traumatic	injury.	
	
Trauma	related	injuries	are	often	complex	in	nature	with	patients	required	to	stay	in	the	
hospital	for	extended	periods	of	time,	often	involving	specialist	care	within	an	intensive	care	
unit	(ICU).	These	complex	care	needs	result	in	a	high	cost	to	health	services.	This	has	been	
shown	in	the	UK	National	Health	Service,	where	trauma	has	an	annual	estimated	cost	of	
£1.6	billion,	accounting	for	7%	of	the	total	NHS	budget	as	of	2008	(Christensen	et	al.,	2008).		
	
It	has	been	shown	that	inflammation	following	traumatic	injury	is	a	key	component	in	the	
recovery	of	traumatic	injury.	However,	this	response	has	been	shown	to	be	linked	to	the	
development	of	the	systemic	inflammatory	response	syndrome	and	septic	complications.	As	
both	interleukin-6	and	interleukin-10	have	been	demonstrated	to	play	major	roles	in	the	
inflammatory	response.	This	project	aims	to	determine	if	the	concentrations	of	these	two	
cytokines	can	be	used	as	biological	markers	to	predict	patient	outcome	and	the	
development	of	complications.	The	concentration	of	these	cytokines	would	then	be	used	to	
group	patient	metabolite	data	to	identify	significant	metabolites,	which	would	be	further	
examined	determine	if	they	had	any	diagnostic	or	prognostic	value	for	trauma	patients.	
Additional	analysis	of	identified	metabolites	along	with	interleukin-6	and	interleukin-10	
would	be	conducted,	to	determine	if	they	could	be	used	to	stratify	patient	cohorts,	and	
identify	those	at	risk	of	developing	complications	quickly	following	admission.	This	
stratification	would	allow	aggressive	treatment	to	be	provided	rapidly,	offering	patients	the	
best	opportunity	for	recovery	and	preventing	the	development	of	complications.	
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Patient	recruitment	analysis	
This	pilot	study	encompasses	a	variety	of	different	methods	to	identify	the	variations	in	
interleukin-6	and	interleukin-10	concentration,	along	with	analysis	of	metabolomics	profiles	
for	trauma	patients.	Initially,	the	patient	cohort	was	analysed	to	identify	and	group	patients	
based	upon	if	they	had	a	good	outcome	or	a	poor	outcome	following	trauma.	From	the	
cohort	who	provided	samples	for	all	three	time	points	(n=69),	50	patients	were	analysed	to	
identify	their	outcome	using	the	criteria	described	in	Table	13).	Of	the	50	patients,	42	had	a	
good	outcome,	whilst	88	patients	had	a	poor	outcome	per	the	distinguishing	criteria.	Of	the	
8	poor	outcome	patients,	three	patients	died	in	the	period	following	their	injury.		
	
When	the	analysed	patients	were	categorised	based	on	the	hospital	from	which	they	were	
admitted,	it	identified	a	difference	between	the	two	hospitals.	The	results	identified	that	
10%	of	the	trauma	patients	from	Manchester	Royal	Infirmary	developed	a	poor	outcome	
following	trauma,	compared	to	40%	of	the	patients	recruited	from	Salford	Royal	Hospital.	
This	difference	is	due	to	Salford	Royal	being	a	major	trauma	centre	for	cranial	based	injuries,	
indicating	that	the	patients	from	Salford	Royal	may	have	significantly	more	severe	injuries	
than	those	admitted	to	Manchester	Royal	Infirmary.	The	difference	may	also	be	a	result	of	
the	significantly	smaller	patient	cohort	recruited	from	Salford	Royal	Hospital	compared	to	
Manchester	Royal	Infirmary.	From	the	69	triplicate	samples	received,	50	triplicate	samples	
were	analysed	to	determine	their	interleukin-6	and	interleukin-10	concentrations	in	days	1,	
3	and	5	following	their	admission	to	hospital,	following	traumatic	injury.		
	
Cytokine	profile	of	trauma	patient	serum	samples	
The	analysis	of	interleukin-6	concentration	in	trauma	patient	samples	identified	the	highest	
concentration	to	be	found	in	day	1	following	trauma,	with	this	concentration	decreasing	in	
day	3	and	decreasing	further	in	day	5.	This	shows	that	the	pro-inflammatory	response	
following	trauma	is	at	its	peak	in	the	period	shortly	after	the	traumatic	injury	before	
decreasing	in	the	following	days,	as	the	patients	begin	to	recover	from	their	injuries.		
This	pattern	of	interleukin-6	has	previously	been	shown	in	research	by	Mörs	et	al.,	2016,	
Gebhard	et	al.,	2000,	and	Seekamp	et	al.,	2002.	Gebhard	et	al.,	2000	observed	the	peak	
concentration	to	occur	at	12	hours	after	injury,	increasing	from	the	site	of	injury	to	12	
hours,	before	decreasing	for	the	7	days	after	the	injury.	
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Interleukin-10	concentration	was	found	to	be	elevated	at	all	sample	time-points	with	the	
highest	concentration	on	day	1,	with	it	decreasing	in	days	3	and	5.	The	elevated	interleukin-
10	concentration	following	major	trauma	has	been	observed	in	other	studies	looking	at	
major	trauma	and	following	major	surgery	(Neidhardt	et	al.,	1997;	Giannoudis	et	al.,	2000;	
Smith	et	al.,	2000;	Easton	&	Balogh,	2014).	The	change	in	interleukin-10	concentration	over	
a	5-day	period	matches	that	shown	in	Sun	et	al.,	2011,	which	showed	interleukin-10	to	peak	
24	hours	after	the	initial	injury.		
	
Following	the	measurement	of	interleukin-6	and	interleukin-10	concentrations,	patients	
were	grouped	based	on	their	SOFA	scores	for	each	of	the	day’s	samples	were	taken.	The	
patient	SOFA	score	was	used	to	assess	the	likelihood	of	patients	developing	organ	failure	
and	further	complications.	When	patients	in	this	study	were	grouped	using	their	SOFA	
scores	their	interleukin-6	concentration	on	day	1	was	found	to	be	the	greatest	in	patients	
with	a	SOFA	score	of	11,	which	was	the	highest	observed	in	the	patient	cohort.	These	results	
are	like	those	of	Sousa	et	al.,	2015,	which	observed	a	correlation	between	clinical	scoring	
systems	and	interleukin-6	concentration	in	the	development	of	MODS	and	ultimately	death,	
with	patients	with	higher	interleukin-6	concentrations	having	a	greater	risk	of	developing	
complications	following	trauma.	
	
When	interleukin-10	was	compared	to	patient	SOFA	scores	was	found	to	peak	in	SOFA	score	
9	on	day	1	with	a	lower	concentration	in	SOFA	scores	0-8	and	a	decrease	in	patients	with	a	
SOFA	score	of	11.	In	day	3	the	interleukin-10	concentration	was	found	to	peak	in	patients	
with	a	SOFA	score	of	4	before	decreasing	in	higher	SOFA	scores.	Day	5	interleukin-10	
concentration	was	found	to	be	the	highest	at	higher	SOFA	scores.	This	showed	a	strong	
positive	correlation	between	interleukin-10	and	patient	SOFA	scores.	These	results	differ	
from	those	written	in	Liu	et	al.,	2017,	which	showed	a	positive	correlation	between	
interlukinin-10	and	SOFA	score	on	day	1	after	trauma.	Patients	were	further	grouped	into	
good	and	poor	outcome	based	on	criteria	including	SOFA	score	on	day	5	after	injury	and	
length	of	ICU	stay.		The	interleukin-6	concentrations	of	good	outcome	patients	were	notably	
lower	than	those	in	poor	outcome	patients	for	the	three	time	points	collected.		This	
indicates	an	elevated	interleukin-6	concentration	may	be	linked	to	the	development	of	a	
poor	outcome	in	trauma	patients.	
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The	results	of	this	study	resemble	those	observed	in	Gebhard	et	al.,	2000,	which	identified	
an	elevated	interleukin-6	concentration	in	more	severely	injured	patients	compared	to	ones	
with	less	severe	injuries.	This	idea	was	further	supported	by	Stensballe	et	al.,	2009,	which	
noted	that	serum	interleukin-6	concentration	was	higher	in	patients	who	did	not	survive	30	
days	following	injury.	They	also	identified	that	the	interleukin-6	concentration	of	non-
survivors	was	up	to	6	times	higher	than	those	observed	in	surviving	patients,	which	are	
comparable	to	that	observed	in	our	study	when	the	poor	outcome	groups	was	compared	to	
the	good	outcome	group	of	patients.		
	
In	interleukin-10	analysis	for	patients	grouped	based	on	their	outcome.	The	analysis	showed	
significant	differences	between	poor	outcome	and	good	outcome	patients.	In	day	1,	the	
interleukin-10	concentration	was	found	to	be	3	times	higher	in	poor	outcome	patients	than	
in	patients	who	had	a	good	outcome.	The	higher	interleukin-10	concentration	in	poor	
outcome	patients	has	been	similarly	observed	in	Mijatovic	et	al.,	2015,	in	which	non-
survivors	having	a	higher	interleukin-10	concentration	at	each	time	point	measured	
compared	to	good	outcome	patients.	
	
The	measurement	of	interleukin-6	and	interleukin-10	allowed	a	ratio	between	the	two	
cytokines	to	be	measured.	This	ratio	was	found	to	be	elevated	in	poor	outcome	patients	in	
day	3	following	traumatic	injury.	It	was	also	shown	to	decrease	in	day	5	in	patients	grouped	
on	their	SOFA	score.	These	results	differ	from	those	in	Sousa	et	al.,	2015,	which	observed	a	
low	interleukin-6/interleukin-10	ratio	at	24	and	72	hours	following	traumatic	injury	
correlated	with	negative	outcome,	namely	organ	dysfunction,	organ	failure	and	death.	
	
In	general,	these	results	determine	that	both	interleukin-6	and	interleukin-10	play	key	roles	
in	the	inflammatory	response	to	traumatic	injury	and	that	the	changes	in	both	cytokines	
occur	in	parallel	rather	than	the	previously	thought	pro-inflammatory	response	followed	by	
a	counter	anti-inflammatory	response.	It	also	identifies	that	both	interleukin-6	and	
interleukin-10	can	offer	advances	in	the	ability	to	predict	patient	outcome,	through	their	
correlation	with	commonly	used	clinical	scoring	systems,	calculated	after	patient	discharge	
or	at	a	point	when	the	modification	of	treatments	too	late	to	benefit	the	patient.	
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Metabolomic	analysis	of	trauma	patient	serum	samples	
Patient	serum	samples	were	further	analysed	to	identify	changes	in	the	metabolite	profile	
of	trauma	patients.	It	also	compared	the	changes	in	these	metabolite	profiles	over	the	5-day	
period	following	trauma	to	identify	modifications	in	the	profile,	which	may	act	as	a	
diagnostic	biomarker	for	the	prediction	of	patient	outcome	after	traumatic	injury.	This	
analysis	identified	611	metabolites	in	trauma	patient	serum	samples	grouped	based	on	day	
1	interleukin-10	concentration.	Of	these	metabolites,	twelve	key	molecules	were	identified	
as	potential	markers,	based	on	their	elevated	fold	change	in	the	metabolite	within	the	day	
1,	3	and	5	samples.	One	of	these	main	molecules	identified	in	the	day	5	trauma	patient	
samples	with	a	day	1	interleukin-10	concentration	of	>12	pg/ml	is	amoxicillin.		
This	is	a	penicillin	based	antibiotic,	used	in	the	treatment	of	various	types	of	bacterial	based	
infection.	The	presence	of	amoxicillin	in	the	day	5	metabolite	profile,	in	patients	with	higher	
day	1	interleukin-10	concentrations,	indicates	that	these	patients	have	prolonged	antibiotic	
usage.	The	potential	ability	of	interleukin-10	concentrations	to	detect	the	need	for	
prolonged	antibiotic	usage	may	act	as	an	early	signpost	for	patients	with	a	greater	risk	of	
bacterial	infection	and	therefore	act	as	a	potential	indicator	for	the	development	of	septic	
complications,	allowing	treatment	to	be	provided	earlier	following	admission	for	those	at	
greater	risk	and	limit	usage	to	those	patients	who	are	unlikely	to	acquire	infective	
complications.			
	
Metabolomic	analysis	provided	a	novel	approach	to	the	identification	of	altered	molecules	
in	trauma	patient	serum	samples.	The	identified	molecules	can	be	further	examined	to	
classify	if	they	can	be	effectively	measured	in	patient	biological	samples	and	if	they	
accurately	and	precisely	offer	predictive	value	for	patient	outcome	and	the	development	of	
complications.		
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Limitations	of	the	study	
This	study	had	factors	which	lead	to	limitations	in	the	effectiveness	of	the	study.	One	of	
these	limitations	was	due	to	the	study	using	a	heterogeneous	patient	cohort	containing	the	
diverse	population	found	in	the	Greater	Manchester	region,	resulting	in	a	large	range	in	
serum	cytokine	levels	identified	in	the	patient	cohort.	This	range	in	serum	cytokine	
concentration	is	a	result	of	patients,	gender,	ethnicity,	type	of	injury,	the	number	of	
transfusions	given,	genetic	polymorphisms	and	the	co-morbidity	status.		
	
These	potential	factors	could	be	controlled	by	increasing	the	size	of	the	patient	cohort	to	
allow	potential	outlying	patients	to	be	identified	and	further	examined	to	identify	the	cause	
of	the	outlying	result.	Patients	could	also	be	additionally	grouped	based	on	their	gender	and	
co-morbidities,	to	identify	if	they	have	an	impact	on	the	serum	levels	of	interleukin-6	and	
interleukin-10.	
	
The	results	of	the	pilot	study	have	identified	that	interleukin-6	and	interleukin-10	can	be	
used	to	identify	patient	outcome	early	after	admission	and	that	correlations	are	observed	in	
the	comparison	between	interleukin-10	concentration	on	day	5	and	patient’s	day	5	SOFA	
score.	However,	the	heterogeneity	of	the	population	along	with	the	sample	size	being	below	
the	target	for	statistical	powering	resulted	in	substantial	error	bars,	indicating	an	
uncertainty	in	the	data	points.	Further	data	collection	up	to	the	target	of	200	patients,	
would	decrease	the	uncertainty	in	the	results	and	allow	statistical	analysis	to	be	conducted,	
to	validate	any	differences	that	were	identified	during	this	pilot	study.	
	
The	size	of	the	patient	cohort	used	for	the	pilot	study	may	have	been	a	limiting	factor	in	this	
study,	due	to	the	study	being	statistically	powered	for	a	cohort	of	200	patients.	Therefore,	
statistical	analysis	cannot	be	conducted	as	the	cohort	used	for	the	pilot	study	is	not	large	
enough	to	represent	the	whole	patient	cohort	and	statistical	analysis	would	not	identify	
significant	differences	between	variables	until	the	target	of	200	patients	was	reached.	
Consequently,	the	results	of	the	study	so	far	can	only	offer	trends	for	the	data	analysed	
during	the	pilot	study	and	not	be	representative	of	a	full	cohort	of	200	patients.	
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The	retrieval	of	clinical	data	used	to	determine	if	patients	had	a	good	or	a	poor	outcome	
following	traumatic	injury	takes	a	prolonged	time	to	organise	and	collate.	This	delays	the	
ability	to	identify	poor	outcome	patients,	following	the	completion	of	sample	retrieval	from	
the	patients.	This	is	a	result	of	the	large	volume	of	work	conducted	by	research	nurses	and	
clinicians,	preventing	them	from	collating	all	the	information	required	to	generate	patient	
SOFA	scores,	ISS	and	length	of	hospital	stay.	The	clinical	data	also	did	not	provide	a	
description	of	the	type	of	injury,	either	penetrating	or	blunt.	Without	this	information,	it	
cannot	be	determined	if	the	patient	has	had	significant	blood	loss	due	to	their	injuries.	This	
lack	of	knowledge	regarding	blood	loss,	may	play	a	major	role	in	the	concentration	of	
cytokines	within	the	patient’s	serum.	Significant	blood	loss	at	the	initial	point	of	injury,	may	
require	the	use	of	intravenous	fluids	or	blood	transfusion	to	maintain	an	adequate	volume	
of	blood	in	the	patient.	These	interventions	may	dilute	the	concentrations	of	cytokines	and	
metabolites	within	the	serum,	causing	results	that	are	lower	than	expected	based	on	the	
severity	of	their	injuries.	This	may	account	for	anomalously	low	interleukin-6	and	
interleukin-10	concentrations	identified	in	this	study,	but	further	clinical	information	is	
required	to	confirm	this	assumption.	
	
Future	Research	and	potential	applications	of	the	study	
To	continue	this	study,	further	research	would	have	to	be	conducted.	The	first	piece	of	
research	to	be	conducted	would	be	to	continue	to	recruit	patients	and	process	these	
patients	triplicate	samples.	Once	the	statistical	target	of	200	patient	triplicates	is	reached	
the	samples	will	be	analysed	for	interleukin-6	and	interleukin-10.	The	continuation	of	the	
current	study	will	allow	the	trends	observed	in	this	pilot	study	to	be	statistically	validated	in	
the	complete	cohort	of	200	patients.	
	
During	this	study,	samples	were	taken	at	time	intervals	of	the	first	24	hours	after	injury	(day	
1),	72	hours	after	injury	(day	3)	and	120	hours	(day	5).	In	future	studies	these	time	points	
could	be	adjusted	to	add	more	samples	to	the	earlier	time	periods	following	trauma,	to	
identify	the	exact	point	at	which	the	concentrations	of	interleukin-6	and	interleukin-10	peak	
following	traumatic	injury.		
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This	will	identify	the	promptness	of	the	initiation	of	the	inflammatory	response	in	patients	
following	trauma	and	identify	if	a	delay	in	the	commencement	of	the	inflammatory	
response,	leaves	patients	at	risk	of	debilitating	complications.	The	time-points	for	sample	
collection	could	also	be	expanded	beyond	the	day	5	collection	point	to	analyse	if	there	is	a	
secondary	immune	response	as	described	to	occur	in	septic	complications	following	
traumatic	injury.	Samples	could	be	collected	on	day	8,	day	10	and	day	14	after	initial	injury	
and	hospital	admission.	However,	collection	of	samples	at	these	time-points	may	be	difficult	
for	many	patients	included	in	the	study	as	they	are	commonly	discharged	within	seven	days	
of	hospital	admission,	leaving	only	patients	with	major	or	life	threatening	injuries	for	
sampling,	limiting	the	size	of	patient	cohort	if	the	sample	collection	points	were	extended.		
	
Further	to	this,	the	panel	of	cytokines	will	be	expanded	to	generate	a	more	expansive	and	
detailed	cytokine	panel.	This	panel	will	be	made	up	of	additional	inflammatory	cytokine	that	
have	been	shown	to	play	key	roles	in	the	inflammatory	response.	This	panel	will	include	
cytokines	such	as	TGFβ,	IL-1,	IL-2,	IL-4,	IL-8,	TNFα	and	IFNγ.	This	panel	will	also	be	expanded	
to	include	other	molecules	that	have	been	found	to	have	modified	concentrations	during	an	
inflammatory	response	including	HMGB1,	heat	shock	proteins,	chemokines	and	cellular	
adhesion	molecules	involved	in	the	transmigration	of	leukocytes	during	the	inflammatory	
response.		
	
Metabolomic	analysis	could	also	be	continued	for	the	full	cohort	of	200	patients	to	identify	
any	additional	pathways	involved	in	the	response	to	trauma	that	were	not	identified	in	the	
initial	35	triplicate	samples	analysed	during	the	pilot	study.	Further	examination	of	the	
metabolomic	data	will	identify	additional	metabolites,	which	were	not	initially	identified	
and	remove	any	outlying	data	observed	in	the	pilot	study	patient	cohort.	This	additional	
analysis	will	also	validate	the	presence	of	the	penicillin	based	antibiotic	metabolites,	when	
patients	were	grouped	using	day	1	interleukin-10	concentrations,	in	a	larger	cohort.		
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Further	applications	of	this	research	may	involve	using	molecules	identified	through	
metabolomic	analysis	to	compare	trauma	patients	to	healthy	individuals.	This	research	will	
allow	the	identification	of	modified	pathways	involved	in	traumatic	injury.	The	identification	
of	these	modified	metabolic	pathways	has	the	potential	to	identify	therapeutic	targets	to	
potentially	decrease	the	impact	of	trauma	and	increase	the	effectiveness	of	currently	used	
therapeutic	options.	These	metabolites	can	also	be	used	as	biomarkers,	to	stratify	patients	
into	groups	based	on	the	likelihood	of	them	developing	complications.	Stratification	allows	
aggressive	treatment	to	be	provided	at	the	earliest	opportunity,	giving	the	patient	the	
greatest	opportunity	of	an	uncomplicated	recovery	from	traumatic	injury.	
	
The	findings	of	the	pilot	study	could	be	applied	in	the	development	of	an	assay,	to	rapidly	
and	cost	effectively	measure	the	concentration	of	both	interleukin-6	and	interleukin-10	at	
the	point	of	admission.		This	would	allow	a	specific	and	selective	test,	to	predict	if	the	
patient	was	going	to	have	a	poor	outcome	because	of	their	injuries,	and	allow	clinicians	to	
provide	optimal	care	and	treatment	strategies	early,	to	prevent	patients	developing	
complications	and	allow	them	the	best	chance	at	a	full	recovery	from	their	injuries.	
	
The	ultimate	long	term	goal	of	the	study	would	be	to	develop	a	panel	of	molecules	with	
known	concentrations,	to	differentiate	between	good	and	poor	outcome	in	trauma	patients.	
The	biomarker	panel	could	be	used	to	identify	the	patient	cohorts	with	poor	outcome	as	
early	as	possible	following	the	traumatic	injury.	This	would	allow	clinicians	to	provide	
aggressive	treatment	options	earlier,	allowing	the	patient	to	begin	the	recovery	process	
quicker	and	avoid	the	development	of	late	stage	complications	following	trauma.	The	ability	
to	rapidly	identify	patients	who	are	likely	to	have	complications	following	trauma	will	
enhance	patient’s	quality	of	care	during	and	after	their	hospitalisation.		
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Conclusion	
In	conclusion,	this	research	identifies	interleukin-6	and	interleukin-10	as	potential	
biomarkers	for	the	prediction	of	patient	outcome	following	traumatic	injury.	It	showed	that	
interleukin-10	concentration	can	be	used	to	identify	patient	outcome	at	an	early	stage	in	
the	period	following	traumatic	injury,	through	its	strong	correlation	with	patient	SOFA	
scores	and	the	significantly	elevated	penicillin	based	antibiotic	metabolites	identified	in	day	
5	samples,	using	day	1	interleukin-10	concentrations.	The	results	generated	so	far,	identify	
key	trends	in	the	data,	with	a	larger	patient	cohort	required	to	develop	a	statistically	
validated	interpretation	of	the	results.	
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Chapter	6	-	Appendices	
Appendix	1	-	Patient	recruitment	consent	form	
	
	
Investigator:	Prof	Kevin	Mackway-Jones	and	Dr	Richard	Body	
Patient	Information	Sheet	
	
You	are	being	invited	to	take	part	in	a	research	study.	Before	you	decide	it	is	important	for	
you	to	understand	why	the	research	is	being	done	and	what	it	will	involve.	Please	take	time	
to	read	the	following	information	carefully	and	discuss	it	with	others	if	you	wish.	
This	sheet	tells	you	the	purpose	of	this	study,	what	will	happen	to	you	if	you	take	part	and	
provides	more	detailed	information	about	how	the	study	will	be	carried	out.	Ask	us	if	there	
is	anything	that	is	not	clear	or	if	you	would	like	more	information.	Take	time	to	decide	
whether	or	not	you	wish	to	take	part.	Thank	you	for	reading	this.	
	
What	is	the	purpose	of	the	study?	
We	are	investigating	a	condition	called	major	trauma.	This	is	a	process	whereby	a	person	
becomes	severely	injured.	It	is	known	that,	after	a	major	injury,	the	body	activates	
inflammatory	mechanisms	that	are	designed	to	promote	healing.		This	inflammatory	
process	and	other	mechanisms	that	reverse	this	process	can	become	exaggerated	after	a	
significant	injury.	This	can	result	in	the	person	developing	further	illness	after	the	initial	
injury.	
	
We	are	investigating	the	levels	of	inflammation	proteins	called	cytokines	and	cells	in	the	
immune	system	called	T-regulatory	cells.	It	is	hoped	that	these	markers	in	the	blood	can	be	
used	to	predict	whether	someone	will	survive	after	a	major	trauma	and	be	of	use	in	
targeting	treatments	in	the	future	for	patients.	
	
Why	have	I	been	chosen?	
You	have	been	asked	to	take	part	in	this	study	as	you	have	suffered	a	major	injury	requiring	
hospitalisation.	We	are	planning	to	study	200	patients	in	total,	admitted	to	Manchester	
Royal	Infirmary.	
	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	or	not	to	take	part.	If	you	do	decide	to	take	part	in	the	
study,	you	will	be	given	this	information	sheet	to	keep	and	be	asked	to	sign	a	consent	form.	
If	you	decide	to	take	part,	you	are	still	free	to	withdraw	at	any	time	and	without	giving	a	
reason.	A	decision	to	withdraw	at	any	time,	or	a	decision	not	to	take	part	at	all,	will	not	
affect	the	standard	of	care	you	receive.	
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What	will	happen	to	me	if	I	take	part?	
You	will	be	asked	to	provide	a	20ml	blood	sample	on	the	day	of	your	injury	and	on	the	third	
and	fifth	days	afterwards.	The	blood	samples	will	be	sent	to	a	laboratory	to	estimate	the	
levels	of	inflammatory	cytokines	and	T	regulatory	cells.	We	request	that	blood	samples	are	
treated	as	a	gift	and	are	able	to	be	stored	at	the	University	of	Salford	after	the	completion	
of	this	study	in	order	to	perform	further	analysis	at	a	later	date.	
All	samples	will	be	coded	and	not	contain	any	personal	identifying	information.	These	
samples	will	initially	be	stored	at	this	hospital	and	then	be	sent	to	the	University	of	Salford	
for	storage	and	analysis.	Samples	will	be	stored	beyond	the	end	of	this	study	in	accordance	
with	the	Human	Tissue	Act.	
	
What	do	I	have	to	do?	
You	will	not	have	to	do	anything	different	if	you	decide	to	take	part.	The	medical	and	
nursing	staff	will	take	the	blood	samples	while	in	the	emergency	department	and	on	the	
ward.	We	will	continue	to	collect	daily	clinical	information	from	your	medical	notes	relating	
to	your	condition	throughout	your	stay	in	hospital.		
With	your	consent,	we	will	share	your	name,	postcode	and	date	of	birth	with	the	Health	and	
Social	Care	Information	Centre.	This	will	enable	the	Health	and	Social	Care	Information	
Centre	and	other	central	UK	NHS	bodies	to	provide	us	with	information	about	your	health	
status	after	hospital	discharge	for	up	to	6	months.	
If	you	do	not	wish	to	be	part	of	this	study,	no	further	information	will	be	collected	about	you	
for	the	trial	and	the	doctors	will	continue	to	provide	you	with	whatever	medical	treatment	
is	needed.	
	
Will	this	affect	the	way	I	am	treated	in	hospital?	
No.	Inclusion	in	the	study	will	not	change	the	care	that	you	receive	and	the	doctors	and	
nurses	caring	for	you	will	not	be	aware	of	the	results	of	the	tests	in	the	study.	
	
What	are	the	possible	benefits	of	taking	part?	
This	study	will	improve	our	understanding	of	why	some	people	survive	major	trauma	and	
others	do	not	and	hopefully	improve	our	care	for	people	with	major	trauma	in	the	future.	
However,	this	study	will	not	have	any	direct	benefits	to	your	health.	
	
What	are	the	possible	disadvantages	and	risks	of	taking	part?	
Blood	samples	will	need	to	be	collected.	This	will	usually	be	done	from	existing	lines,	but	it	
might	be	necessary	to	collect	a	sample	from	a	new	needle,	which	might	result	in	some	
minor	discomfort	during	collection	and	possibly	a	small	bruise.	
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Will	information	from	this	study	be	kept	confidential?	
All	information,	including	personal	information,	which	is	collected	about	you	during	the	
course	of	the	research	will	be	kept	password	protected	and	strictly	confidential.	Any	
information	about	you	which	leaves	the	hospital	will	have	your	name,	hospital	number	and	
address	removed	and	will	be	identified	only	by	your	Trial	subject	number,	date	of	birth	and	
initials,	so	that	you	cannot	be	recognised	from	it.	This	is	with	the	exception	of	information	
obtained	from	The	Health	and	Social	Care	Information	Centre	as	described	earlier.	Only	the	
researchers	and	representatives	of	regulatory	authorities	and	research	ethics	committees	
may	have	direct	access	to	it.	Other	doctors	in	this	hospital	treating	you	will	be	told	of	your	
participation	in	this	study.		
	
What	will	happen	to	the	results	of	the	research	study?	
The	results	of	this	study	will	be	presented	at	medical	meetings	and	published	in	scientific	
journals.	Only	group	information	and	no	personal	information	will	be	presented.	If	you	are	
interested	in	the	results	you	will	be	able	to	contact	the	investigators	for	further	information.	
	
Who	is	organising	and	funding	the	research?	
This	study	is	being	organised	by	doctors	and	scientists	at	Manchester	Royal	Infirmary	and	
the	University	of	Salford.	It	is	funded	by	the	University	of	Salford.		
	
Who	has	reviewed	the	study?	
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people	called	a	Research	
Ethics	Committee.		
	
Who	can	I	contact	for	independent	research	information?	
If	you	have	any	questions	about	being	in	a	research	study,	you	can	contact	the	Trust’s	
Patient	Advice	Liaison	Service	(PALS).	They	will	give	you	advice	about	who	you	can	talk	to	for	
independent	advice.	
	
Further	information	
Thank	you	for	considering	participation	in	this	study.		If	you	have	any	questions	about	this	
research,	the	local	study	staff	will	be	more	than	happy	to	answer	them.		Their	contact	
details	are:	
	
Study	Investigators	Contact	details	
Study	Investigator	 Prof	Kevin	Mackway-Jones	and	Dr	Richard	Body	
Study	Nurse	 Richard	Clark	
Day	time	Telephone	 0161	276	6777	
Emergency	Telephone	 0161	276	4712	
	
CONSENT	FORM	FOR	PATIENTS	ABLE	TO	GIVE	CONSENT	
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Patient	#	 	 Site	#	 	
Name	of	Research	Doctor	 	
	
Please	initial	each	box	if	you	agree	with	the	following:	
¨ I,	(forename	and	
surname)……………………………………………………………………………………………………	freely	agree	
to	take	part	in	the	study.	
¨ I	confirm	that	I	have	read	and	understood	the	patient	information	sheet	dated	
January	2015	Version	1.0	for	the	above	study	and	have	been	able	to	ask	questions	
which	have	been	answered	fully.		
	
¨ I	understand	that	my	participation	is	voluntary	and	I	am	free	to	withdraw	at	any	
time,	without	giving	any	reason,	without	my	medical	care	or	legal	rights	being	affected.	
	
¨ I	understand	my	identity	will	never	be	disclosed	and	any	information	collected	will	
remain	confidential.		
	
¨ I	agree	that	my	medical	records	and	other	personal	data	generated	during	the	study	
may	be	examined	by	the	research	team	and	by	representatives	of	Regulatory	
authorities,	where	it	is	relevant	to	my	taking	part	in	this	research.		
	
¨ I	agree	that	I	will	not	seek	to	restrict	the	use	to	which	the	results	of	the	study	may	be	
put.	
	
	
¨ I	agree	to	gift	my	samples	to	a	tissue	bank	for	future	scientific	study.	
	
¨ I	understand	that	information	held	and	managed	by	The	Health	and	Social	Care	
Information	Centre	and	other	central	UK	NHS	bodies	may	be	used	in	order	to	provide	
information	about	my	health	status.	To	do	this,	I	understand	that	my	name,	postcode	
and	date	of	birth	will	be	shared	with	The	Health	and	Social	Care	Information	Centre.	
	
	
	
Patient	
	
Person	responsible	for	collecting	the	informed	
consent	
Date:	
	
Signature:	
	
Printed	Name:	
Date:	
	
Signature:	
	
Printed	Name:	
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Appendix	2	-	Day	1	clinical	data	for	trauma	patients	selected	for	the	pilot	study	
	
	 	
HR Sys	BP Dia	BP MAP Temp Hb WCC PLT eGFR Creat Bili PT Intubated NIV	/	CPAP FiO2 P/F
BIT001 115 110 60 76.66667 37.8 134 31.6 356 42 132 34 15.6 N N 0.21 N
BIT002 125 122 84 96.66667 38 122 18.6 142 50 134 28 16.6 N N 0.28 38.2
BIT003 94 70 45 53.33333 36 123 11.5 180 55 116 6 15.4 N N 0.3 N
BIT004 129 101 61 74.33333 36.5 112 16.2 213 76 85 7 14.4 N N 0.21 63.1
BIT007 110 126 66 86 37.5 140 19 298 90 76 12 14.7 N N 0.35 48.3
BIT008 110 85 60 68.33333 37.7 99 5.9 152 65 69 13 20.8 Y N 0.21 58
BIT009 90 102 55 70.66667 37.9 108 22 232 81 101 15 16.3 N N 0.28 N
BIT010 116 99 35 56.33333 37.8 130 9.9 286 80 68 7 13.7 N N 0.3 21.6
BIT011 90 103 71 81.66667 36.4 114 15.4 318 27 158 8 19.7 N N 0.4 N
BIT014 112 102 56 71.33333 36.2 78 16.6 129 78 88 16.3 Y N 0.4 29.2
BIT016 117 72 48 56 36.3 115 26.6 150 50 126 9 15.7 N N 0.35 34.7
BIT017 127 94 63 73.33333 36.2 120 10.9 222 72 83 6 13.7 Y N 0.6 71.9
BIT018 109 175 90 118.3333 35.4 146 16.8 260 90 49 6 11.3 N N 1 N
BIT021 146 90 70 76.66667 35.2 109 33.5 235 50 146 10 14.2 Y N 0.3 50
BIT022 97 117 75 89 35.6 128 27.1 408 90 79 5 10.8 N N 0.28 N
BIT023 98 88 65 72.66667 35.7 112 22.1 156 83 91 18 12.3 N N 0.32 43.6
BIT024 115 74 40 51.33333 38.2 83 16.4 155 90 56 8 11.2 Y N 0.6 62.3
BIT025 122 85 45 58.33333 33.9 97 16.1 130 31 241 20 11.9 N Y 0.35 9.34
BIT027 129 163 65 97.66667 38 100 28.8 203 111 61 10.7 Y N 1 27.6
BIT029 94 159 84 109 35.5 119 6.8 132 90 74 28 11.2 N N 1 N
BIT035 89 168 93 118 36.2 139 14 295 67 83 15 11.2 N N 0.85 N
BIT040 110 109 88 95 36.1 131 33.2 226 80 99 11 11.4 N N 0.6 61.6
BIT042 99 135 67 89.66667 38.4 118 19.5 213 N 93 5 11.9 N N 0.21 N
BIT043 109 79 30 46.33333 37.7 117 19 194 81 101 9 12 N N 0.35 33.4
BIT046 92 80 50 60 35.5 73 29.6 78 59 81 16 13.4 N N 0.85 31.4
BIT047 160 77 56 63 35 147 28.7 248 67 114 12 12.4 Y N 0.7 41.9
BIT048 0 145 27.1 287 81 91 12 12.1 y n
BIT049 123 177 77 35.1 121 16.4 129 89 102 27 12 n n 0.32 39.2
BIT050 97 123 59 35/6 149 8.7 359 64 116 10 11.5 y n 0.28 0
BIT052 112 151 76 36.5 94 13.3 161 66 88 12 13 y n 0.35 40.3
BIT053 85 103 52 69 34.6 117 8.1 154 62 77 7 11.5 n n 0.85 30.6
BIT055 88 165 75 105 38.2 105 8.9 146 82 81 18 12.3 n n 0.28 49.8
BIT060 130 70 40 50 35.7 80 13.9 101 45 146 25 12.7 Y N 0.95 27.7
BIT061 116 180 105 130 38.1 128 14.4 220 89 63 10.9 11 y n 0.8 19.9
BIT066 22? 162 85 110.6667 35 138 13.2 178 81 83 8 11.9 n n 0.28 n
BIT067 82 146 81 102.6667 36.9 124 12.5 166 99 84 15 11.4 n n 0.35 n
BIT069 112 95 55 68.33333 35.5 104 19.7 257 79 104 15 11.9 y n 0.85
BIT070 110 178 117 137.3333 35.8 143 26.9 339 89 88 11 11.8 y n
BIT072 53 138 72 94 35.6 130 6.8 242 n 76 20 12.6 n n 0.21 n
BIT073 53 138 72 94 35.6 129 16 210 56 87 32 11.7 n n 0.7 9.79
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	 	Lactate Norad CRP CVVH/HD Sedated GCS Antibiotics Septic	source MAP	SOFA PLT	SOFA CREAT	SOFA BILI	SOFA RESP	SOFA GCS	SOFA SOFA	DAY	1
BIT001 1.2 0 19 N N 15 Y 0 0 1 2 0 0 3
BIT002 3.9 0 63 N N 15 Y 0 1 1 1 2 0 5
BIT003 N 0 2 N N 15 Y 1 0 1 0 0 0 2
BIT004 0.9 0 102 N N 15 N 0 0 0 0 0 0 0
BIT007 0.9 0 60 N N 15 Y 0 0 0 0 1 0 1
BIT008 2 0 23 N Y N Y 1 0 0 0 0 0 1
BIT009 N 0 6 N N 14 Y 0 0 0 0 0 1 1
BIT010 1.3 0 100 N N 15 N 1 0 0 0 3 0 4
BIT011 N 0 117 N N 15 N 0 0 1 0 0 0 1
BIT014 3.4 0 8 N Y N Y empirical 0 1 0 0 2 0 3
BIT016 3.5 0 5 N N 15 Y 1 1 1 0 2 0 5
BIT017 1.7 0 6 N Y N Y empirical 0 0 0 0 0 0 0
BIT018 0.7 0 89 N N 15 Y empirical 0 0 0 0 0 0 0
BIT021 3.4 0 1 N N 15 Y empirical 0 0 1 0 1 0 2
BIT022 N 0 3 N N 15 Y empirical 0 0 0 0 0 0 0
BIT023 1.1 0 17 N N 14 Y empirical 0 0 0 0 1 1 2
BIT024 3.8 0 170 N Y N Y 1 0 0 0 0 0 1
BIT025 6.3 0.07 345 N N 15 Y empirical 3 1 2 1 4 0 11
BIT027 1.4 0 30 N Y N Y empirical 0 0 1 2 2 0 5
BIT029 N 0 226 N N 15 Y empirical 0 1 0 1 0 0 2
BIT035 N 0 43 N N 15 N 0 0 0 0 0 0 0
BIT040 1.5 0 10 N N 15 Y empirical 0 0 0 0 0 0 0
BIT042 N 0 1 N N 15 Y empirical 0 0 0 0 0 0 0
BIT043 3.3 0 N N 15 N 1 0 0 0 2 0 3
BIT046 1.8 0 6 N N 15 Y empirical 1 2 0 0 2 0 5
BIT047 4.8 1.01 75 N Y N Y empirical 4 0 1 0 1 0 6
BIT048 71 n y N y e 1 0 0 0 4 0 5
BIT049 7.7 0 1 n n y15 y empirical 1 1 0 1 2 0 5
BIT050 2 0 20 n y N y empirical 1 0 1 0 4 0 6
BIT052 4.1 0 2 n y N y empirical 1 0 0 0 1 0 2
BIT053 1.7 0 32 n n 15 y empirical 1 0 0 0 2 0 3
BIT055 1.6 0 38 n n 15 y empirical 0 1 0 0 1 0 2
BIT060 5.4 0.19 N Y N Y empirical 4 1 1 1 2 0 9
BIT061 2 0 18 n y N y empirical 0 0 0 0 3 0 3
BIT066 n 0 3 n n 15 y empirical 0 0 0 0 0 0 0
BIT067 0 13 n n 15 y empirical 0 0 0 0 0 0 0
BIT069 0 4 n y N y empirical 1 0 0 0 4 0 5
BIT070 0 n n y N y empirical 0 0 0 0 4 0 4
BIT072 n 0 1 n n 14 y eye 0 0 0 1 0 1 2
BIT073 2 0 116 n 15 y empirical 0 0 0 1 4 0 5
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Appendix	3	-	Day	3	clinical	data	for	trauma	patients	selected	for	the	pilot	study	
		 	HR Sys	BP Dia	BP MAP Temp Hb WCC PLT eGFR Creat Bili PT Intubated NIV	/	CPAP FiO2 P/F
BIT001 98 124 91 102 37.5 77 18.1 194 90 78 9 16.7 N N 0.21 N
BIT002 126 136 76 96 36.2 96 10.8 157 75 94 12 15.7 N N 0.28 33.3
BIT003 115 89 55 66.33333 36.4 70 5.4 135 64 101 7 15.2 N N 0.21 N
BIT004 123 92 80 84 38.1 79 15.8 152 90 54 9 15 N N 0.21 51.2
BIT007 87 125 70 88.33333 37.6 112 6.8 144 90 52 16 13.1 N N 0.21 N
BIT008 130 140 90 106.6667 36.9 96 20.6 147 89 65 26 14.4 Y N 0.21 31
BIT009 82 112 43 66 36.8 80 8.2 156 79 104 11 15.7 N N 0.24 N
BIT010 133 136 78 97.33333 38.2 109 8.1 236 90 57 6 14 N N 0.5 32.4
BIT011 91 113 49 70.33333 38.2 78 13.5 190 36 137 11 17.9 N N 0.4 N
BIT014 112 103 60 74.33333 36.4 112 21 163 77 101 15 N N N
BIT016 95 109 82 91 36.5 86 11.5 96 45 137 11 18 N N 0.3 28.3
BIT017 130 170 90 116.6667 36.1 124 10.1 116 85 72 31 15.6 Y N 1 55.4
BIT018 100 142 81 101.3333 38 100 5.6 133 90 46 9 11.3 N N 0.4 N
BIT021 109 141 86 104.3333 36 94 13.1 154 90 80 16 10.9 N N 0.28 N
BIT022 87 136 82 100 37.2 97 8.6 278 90 62 6 11.4 N N 0.21 N
BIT023 90 100 56 70.66667 36.8 89 10 131 90 79 8 11.4 N N 0.33 N
BIT024 99 96 50 65.33333 37.3 69 15 166 90 147 3 10.2 Y N 0.4 47.2
BIT025 170 100 35 56.66667 36.9 97 17.2 142 63 100 10.4 N Y 0.6 18.24
BIT027 72 149 69 95.66667 37.5 94 13.3 138 90 73 6 10.2 N N 0.21 31.2
BIT029 98 107 69 81.66667 35.4 108 5.7 142 90 66 17 10.1 N N 0.24 N
BIT035 N N N N N N N N N N N N N N N N
BIT040 107 131 85 100.3333 37.3 96 10.7 350 90 80 14 N N N 0.28 N
BIT042 126 132 85 100.6667 38.4 103 11.1 177 N 73 9 12.3 N N 0.21 N
BIT043 N N N N N N N N N N N N N N N N
BIT046 105 110 62 78 35.5 75 32.3 78 51 92 15 13 N N 0.32 25.8
BIT047 125 107 49 68.33333 38.4 83 6.8 97 90 89 20 11.5 N N 0.28 40.6
BIT048 0 74 6.9 101 14 427 8 11.2 y n n
BIT049 99 146 76 99.33333 37.4 111 7.9 111 90 63 12 11.1 n n 0.32 n
BIT050 118 110 56 74 39 118 7 200 90 76 14 n n n 0.28 n
BIT052 110 151 100 117 37.4 84 6.4 110 90 66 10 11.3 n n 0.24 n
BIT053 103 160 88 112 37.6 107 6.4 116 90 47 17 11.9 n n 0.55 21.9
BIT055 87 137 62 87 37.7 105 5.9 113 90 72 114 12.3 n n 0.21 42.5
BIT060 87 100 50 66.66667 37.8 70 7.9 92 70 99 8 10.9 Y N 0.5 18.4
BIT061 100 85 64 71 38.2 91 11 164 90 48 12 11.6 y n 0.4 22.6
BIT066 87 147 77 100.3333 36.1 132 8.8 233 90 66 n n n n 0.21 n
BIT067 76 135 76 95.66667 36.6 n n n n n n n n n 0.21 n
BIT069 125 145 80 101.6667 37.1 125 8.2 192 90 65 23 11 n n 0.24 58.2
BIT070 54 139 63 88.33333 37.3 n n n n n n n n n 0.21 n
BIT072 98 153 70 97.66667 37 n n n n n n n n n 0.21 n
BIT073 98 153 70 37 122 4.5 208 75 68 n 11.9 n n 0.21 n
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Lactate Norad CRP CVVH/HD Sedated GCS Antibiotics Septic	source Steroids CAM	+ve MAP	SOFA PLT	SOFA CREAT	SOFA BILI	SOFA RESP	SOFA GCS	SOFA SOFA	DAY	3
BIT001 0 145 N N 15 Y N N 0 0 0 0 0 0 0
BIT002 1.3 0 349 N N 15 Y N N 0 0 0 0 2 0 2
BIT003 0 120 N N 15 Y N N 1 1 0 0 0 0 2
BIT004 0.5 0 279 N N 15 N N N 0 0 0 0 1 0 1
BIT007 0 97 N N 15 N N N 0 1 0 0 0 0 1
BIT008 2.1 0 239 N Y N Y Y 0 1 0 1 2 0 4
BIT009 0.7 0 127 N N 15 Y N N 1 0 0 0 0 0 1
BIT010 0.9 0 317 N N 15 N N N 0 0 0 0 2 0 2
BIT011 0 147 N N 15 N N N 0 0 1 0 0 0 1
BIT014 0 250 N N 15 Y empirical Y N 0 0 0 0 0 0 0
BIT016 1.2 0 318 N N 15 Y N N 0 2 1 0 2 0 5
BIT017 1.3 0 41 N Y N Y empirical N 0 1 0 1 0 0 2
BIT018 0 155 N N 15 N N N 0 1 0 0 0 0 1
BIT021 0.8 0 178 N N 15 N N N 0 0 0 0 0 0 0
BIT022 0 53 N N 15 N N N 0 0 0 0 0 0 0
BIT023 0 180 N N 15 Y empirical N N 0 1 0 0 0 0 1
BIT024 1.6 0 291 N Y Y Y N 1 0 1 0 1 4 7
BIT025 1.1 0 291 N N 15 Y empirical N N 1 1 0 0 3 0 5
BIT027 1 0 60 N N 15 Y empirical Y N 0 1 0 0 2 0 3
BIT029 N 0 174 N N 15 Y empirical N N 0 1 0 0 0 0 1
BIT035 N 0 N N N N N N N 0 0 0 0 0 0 0
BIT040 N 0 340 N N 15 Y empirical N N 0 0 0 0 0 0 0
BIT042 N 0 201 N N 15 N N N 0 0 0 0 0 0 0
BIT043 N 0 N N N N N N N N 0 0 0 0 0 0 0
BIT046 1.3 Norad 15 N N 15 Y empirical N N N 2 0 0 3 0 5
BIT047 0.9 0 291 N N 15 Y empirical N N 1 2 0 1 1 0 5
BIT048 273 y y N y e y 1 1 3 0 0 0 5
BIT049 n 0 55 n n 15 n n n 0 1 0 0 0 0 1
BIT050 n 0 438 n n 15 n n n 0 0 0 0 0 0 0
BIT052 1.5 0 n n n 15 y empirical n n 0 1 0 0 0 0 1
BIT053 0.8 0 197 n n 15 n n n 0 1 0 0 3 0 4
BIT055 0.5 0 n n n 15 y empirical n n 0 1 0 3 1 0 5
BIT060 1.9 0.05 N Y N Y empirical N N 3 2 0 0 3 0 8
BIT061 1.2 0 223 n y N y empirical n n 0 0 0 0 3 0 3
BIT066 n 0 n n n 15 n n n 0 0 0 0 0 0 0
BIT067 n n0 n n n 15 n n n 4 0 0 0 0 0 4
BIT069 0.7 0 n n n 14 y empirical n n 0 0 0 1 0 1 2
BIT070 n 0 n n n 15 y empirical n n 0 0 0 0 0 0 0
BIT072 n 0 n n n 15 y eye y n 0 0 0 0 0 0 0
BIT073 n 0 59 n n 15 y empirical y n 1 0 0 0 0 0 1
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Appendix	4	-	Day	5	clinical	data	for	trauma	patients	selected	for	the	pilot	study	
	 	
HR Sys	BP Dia	BP MAP Temp Hb WCC PLT eGFR Creat Bili PT Intubated NIV	/	CPAP FiO2 P/F
BIT001 94 111 78 89 37.2 102 10.1 356 90 84 N N N N 0.21 N
BIT002 107 131 79 96.33333 36.6 91 7.5 191 90 65 18 16.9 N N 0.28 45.2
BIT003 110 85 65 71.66667 36.6 83 6.3 211 86 78 13 14 N N 0.21 N
BIT004 117 92 76 81.33333 37.3 102 12 221 90 45 17 15 N N 0.21 53.6
BIT007 85 115 85 95 36.5 122 7.7 217 90 61 10 13.1 N N 0.21 N
BIT008 108 102 62 75.33333 35.7 85 20.3 199 90 48 22 12.5 Y N 0.28
BIT009 80 115 47 69.66667 37.1 83 7.6 233 90 91 15 14.7 N N 0.21 N
BIT010 124 126 94 104.6667 36.2 114 6.7 270 90 38 7 13.6 N N 0.4 N
BIT011 98 115 60 78.33333 36.9 N N N N N N N N N 0.32 N
BIT014 103 130 64 86 35.9 91 10.6 357 90 78 N N N N N N
BIT016 100 113 70 84.33333 36.4 83 10 125 58 111 11 14.1 N N 0.4 29.8
BIT017 112 140 65 90 37.7 82 6.2 85 90 60 8 13.6 N N N N
BIT018 113 176 96 122.6667 37.6 111 8.5 228 90 53 13 10.7 Y N 0.4 25.8
BIT021 98 133 78 96.33333 36 109 9.7 339 90 70 9 10.4 N N 0.21 N
BIT022 54 130 75 93.33333 36.1 N N N N N N N N N N N
BIT023 80 111 58 75.66667 37.1 N N N N N N N N N 0.21 N
BIT024 95 105 50 68.33333 36.7 82 9 198 90 52 6 9.9 Y N 0.3 45.4
BIT025 75 96 46 62.66667 34.7 92 14.9 166 83 79 16 11.1 N N 0.6 22.1
BIT027 66 116 80 92 36.4 118 11.9 350 90 75 N N N N 0.21 N
BIT029 86 107 69 81.66667 35.4 N N N N N N N N N 0.21 N
BIT035 N N N N N N N N N N N N N N N N
BIT040 117 134 82 99.33333 38.5 103 12.2 409 90 86 21 N N N 0.24 N
BIT042 106 127 73 91 37.4 101 8.6 239 N 64 8 11.3 N N 0.21 N
BIT043 N N N N N N N N N N N N N N N N
BIT046 110 86 37 53.33333 35.8 80 48.7 84 83 60 24 13.4 N N 0.5 23.5
BIT047 112 139 65 89.66667 38.2 86 7.1 179 90 76 22 11.4 N N 0.28 43.9
BIT048 0 74 12.7 245 19 321 12 11 y n n
BIT049 97 147 81 37.2 123 8.2 248 90 71 8 n n n 0.21 n
BIT050 98 115 74 87.66667 36.1 119 7.2 339 90 69 11 n n n 0.28 n
BIT052 98 132 87 102 35.9 n n n n n n n n n 0.21 n
BIT053 105 155 72 37.5 102 6.2 207 90 48 n 11 n n 0.32 n
BIT055 90 98 63 74.66667 37.5 n n n n n n n n n 0.21 n
BIT060 125 105 50 68.33333 37.7 77 6.5 165 75 94 15 10.8 Y N 0.6 11.3
BIT061 97 140 55 83.33333 35.8 82 8.8 213 90 38 14 11.1 n n 0.35 27.4
BIT066 87 145 72 35.7 129 9.9 261 90 62 13 n n n 0.21 n
BIT067 Discharged 0
BIT069 110 149 88 108.3333 37.1 125 8.4 242 90 67 7 11.1 n n 0.28 63.7
BIT070 56 145 63 90.33333 36 123 10.6 349 78 98 n n n n 0.21 n
BIT072 104 136 71 92.66667 35.7 n n n n n n n n n n n
BIT073 83 131 83 36.9 127 5.6 254 76 67 7 n n n 0.28 n
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Lactate Norad CRP CVVH/HD Sedated GCS Antibiotics Septic	source Steroids CAM	+ve MAP	SOFA PLT	SOFA CREAT	SOFA BILI	SOFA RESP	SOFA GCS	SOFA SOFA	DAY	5
BIT001 N 0 18 N N 15 Y N N 0 0 0 0 0 0 0
BIT002 0.8 0 244 N N 15 Y N N 0 0 0 0 1 0 1
BIT003 N 0 113 N N 15 Y N N 0 0 0 0 0 0 0
BIT004 0.5 0 329 N N 15 N N N 0 0 0 0 0 0 0
BIT007 N 0 55 N N 15 N N N 0 0 0 0 0 0 0
BIT008 1.3 0 210 N Y N Y Abdomen Y N 0 0 0 1 4 0 5
BIT009 N 0 95 N N 15 Y N N 1 0 0 0 0 0 1
BIT010 N 0 181 N N 15 Y Chest N N 0 0 0 0 0 0 0
BIT011 N 0 N N 15 N N N 0 0 0 0 0 0 0
BIT014 N 0 194 N N 15 N N N 0 0 0 0 0 0 0
BIT016 1.4 0 174 N N 15 Y N N 0 1 1 0 2 0 4
BIT017 N 0 124 N N 15 N N N 0 2 0 0 0 0 2
BIT018 1.2 0 92 N Y N Y empirical N N 0 0 0 0 3 0 3
BIT021 N 0 26 N N 15 N N N 0 0 0 0 0 0 0
BIT022 N 0 N N 15 N N N 0 0 0 0 0 0 0
BIT023 N 0 N N 15 N N N 0 0 0 0 0 0 0
BIT024 0.6 0 N Y N Y N Y 1 0 0 0 1 0 2
BIT025 1.4 0 N N 15 N N N 1 0 0 0 3 0 4
BIT027 N 0 33 N N 15 Y POST	OP N N 0 0 0 0 0 0 0
BIT029 N 0 N N N 15 N N N 0 0 0 0 0 0 0
BIT035 N 0 N N N N N N N N 0 0 0 0 0 0 0
BIT040 N 0 309 N N 15 Y empirical N N 0 0 0 1 0 0 1
BIT042 N 0 150 N N 15 N N N 0 0 0 0 0 0 0
BIT043 N 0 N N N N N N N N 0 0 0 0 0 0 0
BIT046 0.9 0 181 N N 13 N empirical N N 1 2 0 1 3 1 8
BIT047 0.8 0 227 N N 15 N N N 0 0 0 1 1 0 2
BIT048 350 n y N y empirical n n 1 0 3 0 0 0 4
BIT049 n 0 3 n n 15 n n n 1 0 0 0 0 0 1
BIT050 n 0 267 n n 15 n n n 0 0 0 0 0 0 0
BIT052 n 0 n n n 15 n n n 0 0 0 0 0 0 0
BIT053 n 0 123 n n 15 n n n 1 0 0 0 0 0 1
BIT055 n 0 n n n 15 n n n 0 0 0 0 0 0 0
BIT060 1.2 0 N Y N Y empirical Y Y 1 0 0 0 4 0 5
BIT061 0.9 0 152 n n 15 y empirical n n 0 0 0 0 2 0 2
BIT066 n 0 53 n n n n n n 1 0 0 0 0 0 1
BIT067 1 0 0 0 0 0 1
BIT069 1.1 0 n n n 15 n n n 0 0 0 0 0 0 0
BIT070 n 0 n n n 15 y empirical n n 0 0 0 0 0 0 0
BIT072 n 0 n n n 15 y eye y n 0 0 0 0 0 0 0
BIT073 n 0 22 n y 15 y empirical y n 1 0 0 0 0 0 1
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Appendix	5	-	Day	8	clinical	data	for	trauma	patients	selected	for	the	pilot	study	
		 	HR Sys	BP Dia	BP MAP Temp Hb WCC PLT eGFR Creat Bili PT Intubated NIV	/	CPAP FiO2 P/F
BIT001 80 117 78 91 36.9 108 27.5 460 90 86 N N N N 0.21 N
BIT002 111 134 95 108 36.6 91 12.5 184 90 64 29 16.9 N N 0.35 N
BIT003 89 93 53 66.33333 37.1 N N N N N N N N N 0.21 N
BIT004 92 114 64 80.66667 36.6 N N N N N N N N N 0.21 N
BIT007 75 134 65 88 36.3 N N N N N N N N N 0.21 N
BIT008 113 121 68 85.66667 36 94 29.5 241 90 36 23 13.8 Y N 0.4 N
BIT009 80 119 63 81.66667 36.9 96 10.5 337 90 79 19 15.2 N N 0.21 N
BIT010 125 134 100 111.3333 37.3 121 9.6 546 90 44 6 14.2 N N 0.35 N
BIT011 91 121 68 85.66667 36.9 73 15.8 123 59 79 15.1 N N 0.21 N
BIT014 100 112 72 85.33333 36.2 101 15.2 481 88 90 N N N N N N
BIT016 93 97 66 76.33333 35.9 105 11.9 233 64 101 16 14.4 N N 0.28 43.3
BIT017 N N N N N N N N N N N N N N N N
BIT018 105 151 94 113 35.7 94 6.4 193 90 41 9 11.4 N N 0.28 N
BIT021 N N N N N N N N N N N N N N N N
BIT022 N N N N N N N N N N N N N N N N
BIT023 90 105 57 73 37.8 N N N N N N N N N 21 N
BIT024 99 110 65 80 37.3 107 N N N N N N N N 0.21 N
BIT025 87 83 45 57.66667 35.3 80 14.2 329 75 86 9 10.7 N N 8 19.2
BIT027 N N N N N N N N N N N N N N N N
BIT029 N 104 68 80 36 N N N N N N N N N 0.21 N
BIT035 N N N N N N N N N N N N N N N N
BIT040 112 149 73 98.33333 39 100 17.3 708 90 82 26 N N N 0.28 N
BIT042 DISCHARGED 0
BIT043 N N N N N N N N N N N N N N N N
BIT046 154 86 55 65.33333 35.9 77 44 96 90 54 96 15 N N 0.45 20.7
BIT047 120 150 62 91.33333 38.8 72 8.7 302 90 68 40 11.5 N N 0.28 52.1
BIT048 0 84 20.4 270 12 470 18 10.9 y n
BIT049 76 126 63 84 36.2 n n n n n n n n n 0.21 n
BIT050 86 101 57 71.66667 36.3 125 7.1 351 90 64 13 n n n 0.21 n
BIT052 104 139 74 95.66667 36.2 n n n n n n n n n 0.21 n
BIT053 95 160 95 116.6667 37 101 3.6 100 n n n n n n 0.32 n
BIT055 71 80 51 60.66667 37.4 n n n n n n n n n 0.21 n
BIT060 118 106 46 66 37.3 92 14.6 317 90 80 17 10.6 Y Y 0.65 12.7
BIT061 99 140 77 98 35.5 n n n n n n n n n 0.21 n
BIT066 61 140 65 90 35.6 n n n n n n n n n 0.21 n
BIT067 DISCHARGED 0
BIT069 56 120 69 36.5 n n n n n n n n n 0.21 n
BIT070 81 132 73 35.5 n n n n n n n n n 0.21 n
BIT072 DISCHARGED 0
BIT073 n n n 0 n 126 5.9 271 68 74 n 11.4 n n 0.21 n
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Lactate Norad CRP CVVH/HD Sedated GCS Antibiotics Septic	source Steroids CAM	+ve Tranexamic	acid Transfusion MAP	SOFA PLT	SOFA CREAT	SOFA BILI	SOFA RESP	SOFA GCS	SOFA SOFA	DAY	8
BIT001 N 0 88 N N 15 N N N N N N 0 0 0 0 0 0 0
BIT002 N 0 219 N N 15 Y N N N N N 0 0 0 1 0 0 1
BIT003 N 0 N N N 15 N N N N N Y 1 0 0 0 0 0 1
BIT004 N 0 N N N 15 N N N N Y Y 0 0 0 0 0 0 0
BIT007 N 0 N N N 15 N N N N N N 0 0 0 0 0 0 0
BIT008 1.3 0 52 N Y N Y Abdomen Y N N Y 0 0 0 1 0 0 1
BIT009 N 0 N N 15 N N N N N N 0 0 0 0 0 0 0
BIT010 N 0 45 N N 15 Y Chest N N N N 0 0 0 0 0 0 0
BIT011 N 0 74 N N 15 N N N N N Y 0 1 0 0 0 0 1
BIT014 N 0 158 N N 15 N N N N Y Y 0 0 0 0 0 0 0
BIT016 1.3 0 134 N N 15 N N N N N N 0 0 0 0 1 0 1
BIT017 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT018 N 0 206 N N 15 Y empirical N N N N 0 0 0 0 0 0 0
BIT021 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT022 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT023 N 0 N N 15 N N N N Y N 0 0 0 0 0 0 0
BIT024 0.6 0 N N 14 Y N N N N Y 0 0 0 0 0 1 1
BIT025 1.1 0 1 N N 15 Y Chest N N N N 1 0 0 0 3 0 4
BIT027 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT029 N 0 N N N 15 N N N N N N 0 0 0 0 0 0 0
BIT035 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT040 N 0 329 N N 15 Y empirical N N N N 0 0 0 1 0 0 1
BIT042 Y N 0 0 0 0 0 0 0
BIT043 N 0 N N N N N N N N N N 0 0 0 0 0 0 0
BIT046 1.6 0 73 N N 14 Y empirical N N Y Y 1 2 0 2 3 1 9
BIT047 0.8 0 N N N 15 N Y N Y Y 0 0 0 2 1 0 3
BIT048 563 y y y empirical y n y y 0 0 0 0 0 0 0
BIT049 n 0 n n n 15 n n n y n 0 0 0 0 0 0 0
BIT050 n 0 166 n n 15 n n n y n 0 0 0 0 0 0 0
BIT052 n 0 n n n 15 n n n y y 0 0 0 0 0 0 0
BIT053 n 0 n n n 15 n n n y y 0 1 0 0 0 0 1
BIT055 n 0 n n n 15 n n n y y 1 0 0 0 0 0 1
BIT060 1.3 0.07 N Y 12 N Y Y Y Y 3 0 0 0 4 2 9
BIT061 n 0 n n n 15 n n n y y 0 0 0 0 0 0 0
BIT066 n 0 n n n 15 n n n n n 0 0 0 0 0 0 0
BIT067 y n 0 0 0 0 0 0 0
BIT069 n 0 n n n 15 n n n y y 1 0 0 0 0 0 1
BIT070 n 0 n n n 15 y empirical n n y n 1 0 0 0 0 0 1
BIT072 y eye y n n n 0 0 0 0 0 0 0
BIT073 n 0 15 n n 15 y empirical y n y n 0 0 0 0 0 0 0
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Appendix	6	-	Mean	Interleukin-6	concentrations	for	triplicate	patient	serum	samples	with	
standard	deviation	for	each	triplicate	
	
Patient	ID	 IL-6	D1	 D1	SD	 IL-6	D3	 D3	SD	 IL-6	D5	 D5	SD	
BIT001	 11.3283	 0.9530	 2.4228	 0.0292	 3.0025	 0.0723	
BIT002	 10.7934	 0.3000	 5.4975	 0.3256	 5.1244	 0.3172	
BIT003	 4.7401	 0.3551	 5.5119	 0.1875	 3.7344	 0.2526	
BIT004	 2.7799	 0.0147	 6.3927	 0.2931	 4.9771	 0.1508	
BIT007	 25.3024	 2.0796	 10.5158	 0.8736	 4.4768	 0.5955	
BIT008	 No	Sample	 No	Sample	 2020.8664	 170.5098	 51.5865	 1.2747	
BIT009	 25.9519	 1.1096	 14.4543	 0.1097	 26.3803	 0.6223	
BIT010	 60.3894	 3.5942	 32.1705	 1.9517	 14.8551	 0.2760	
BIT011	 32.3502	 0.6154	 No	Sample	 No	Sample	 11.3450	 0.2522	
BIT014	 255.4891	 18.2785	 278.6363	 15.1042	 27.0436	 2.0413	
BIT016	 7.1854	 0.1036	 5.5007	 0.2906	 4.1860	 0.1874	
BIT017	 136.0772	 6.4167	 32.2258	 5.6547	 35.8879	 0.2194	
BIT018	 54.2813	 2.2867	 39.4671	 2.3461	 10.9028	 1.0234	
BIT021	 55.0690	 5.8551	 18.5171	 0.9390	 2.4316	 0.2073	
BIT022	 25.9795	 0.8281	 10.9857	 1.5302	 2.4178	 0.0863	
BIT023	 62.0062	 3.6937	 33.9118	 1.0813	 5.7620	 0.0957	
BIT024	 296.9882	 7.7382	 21.4745	 1.1173	 12.8513	 0.3852	
BIT025	 1188.8666	 27.6828	 57.2524	 2.3106	 118.5821	 2.8819	
BIT027	 82.1823	 1.9754	 10.8751	 0.6663	 106.6008	 4.7322	
BIT029	 88.4424	 3.4160	 16.2232	 0.4194	 7.2821	 0.1807	
BIT035	 23.3124	 1.4037	 6.7432	 0.0415	 6.5359	 0.5026	
BIT040	 77.3317	 4.0353	 25.3715	 2.4820	 31.5763	 1.6702	
BIT042	 85.3883	 1.2650	 29.1441	 1.5558	 8.4706	 0.2941	
BIT043	 21.3224	 0.5117	 20.7973	 0.2719	 13.6390	 4.6577	
BIT046	 7.3927	 0.6112	 43.3226	 1.8412	 12.6163	 0.3056	
BIT047	 46.1694	 1.8038	 68.1972	 1.2747	 19.2772	 0.3526	
BIT048	 41.5123	 0.4173	 421.3611	 18.4044	 285.8775	 14.0998	
BIT049	 46.5563	 1.9535	 9.7419	 0.4153	 2.1967	 0.0479	
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BIT050	 56.1745	 2.6663	 68.8191	 6.3337	 2.7771	 0.2127	
BIT052	 19.0008	 0.7671	 11.3726	 0.3526	 3.8550	 0.2045	
BIT053	 30.8301	 3.9548	 26.8225	 0.9143	 7.4618	 0.2283	
BIT055	 3.6339	 0.1658	 2.1690	 0.2760	 7.0334	 0.2719	
BIT058	 525.9173	 8.7858	 143.7607	 3.8314	 9.9492	 1.8210	
BIT060	 117.5733	 4.7740	 32.8753	 3.8878	 101.8194	 0.6333	
BIT061	 12.4505	 0.2760	 34.9344	 1.0626	 8.3047	 0.2533	
BIT066	 8.5811	 0.3830	 1.2017	 0.4998	 1.8650	 0.4981	
BIT069	 88.1245	 1.0414	 0.2481	 0.5266	 2.5560	 0.1436	
BIT070	 18.2546	 0.4194	 32.6542	 1.6453	 5.1401	 0.1570	
BIT072	 0.8285	 0.0957	 1.9617	 2.5641	 0.2620	 0.1333	
BIT073	 55.5665	 1.7929	 1.0773	 0.2912	 0.9944	 1.3938	
SR002	 57.3768	 3.2343	 56.5062	 2.7127	 34.4645	 0.4069	
SR003	 807.1246	 39.8579	 101.7365	 2.7136	 54.2260	 3.3252	
SR008	 110.8641	 1.0260	 22.8287	 0.4781	 13.8048	 0.3526	
SR009	 146.0823	 27.4667	 122.8661	 0.9562	 4635.4485	 365.5366	
SR010	 28.0939	 0.7678	 132.3460	 4.9082	 34.0638	 0.3590	
SR011	 53.9082	 1.6397	 8.8299	 0.5598	 2.0999	 0.1658	
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Appendix	7	-	Patient	SOFA	scores	over	a	5-day	period	
	
Patient	ID	 SOFA	D1	 SOFA	D3	 SOFA	D5	
BIT001	 3	 0	 0	
BIT002	 5	 2	 1	
BIT003	 2	 2	 0	
BIT004	 0	 1	 0	
BIT007	 1	 1	 0	
BIT008	 1	 4	 5	
BIT009	 1	 1	 1	
BIT010	 4	 2	 0	
BIT011	 1	 1	 0	
BIT014	 3	 0	 0	
BIT016	 5	 5	 4	
BIT017	 0	 2	 2	
BIT018	 0	 1	 3	
BIT021	 2	 0	 0	
BIT022	 0	 0	 0	
BIT023	 2	 1	 0	
BIT024	 1	 7	 2	
BIT025	 11	 5	 4	
BIT027	 5	 3	 0	
BIT029	 2	 1	 0	
BIT035	 0	 0	 0	
BIT040	 0	 0	 1	
BIT042	 0	 0	 0	
BIT043	 3	 0	 0	
BIT046	 5	 9	 8	
BIT047	 6	 5	 2	
BIT048	 5	 5	 4	
BIT049	 5	 1	 1	
BIT050	 6	 0	 0	
165	
BIT052	 2	 1	 0	
BIT053	 3	 4	 1	
BIT055	 2	 5	 0	
BIT058	 N/A	 N/A	 N/A	
BIT060	 9	 8	 5	
BIT061	 3	 3	 2	
BIT066	 0	 0	 1	
BIT069	 5	 2	 0	
BIT070	 0	 0	 0	
BIT072	 2	 0	 0	
BIT073	 5	 1	 1	
SR002	 8	 5	 8	
SR003	 9	 8	 8	
SR008	 6	 1	 1	
SR009	 N/A	 N/A	 N/A	
SR010	 N/A	 N/A	 N/A	
SR011	 N/A	 N/A	 N/A	
Abbreviations:	N/A,	Patient	SOFA	score	unavailable	at	the	time	of	writing.	
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Appendix	8	-	Interleukin-10	concentrations	for	triplicate	patient	serum	samples	
	
Patient	ID	 IL-10	D1	 SD	 IL-10	D3	 SD	 IL-10	D5	 SD	
BIT001	 5.2654	 0.3725	 2.5059	 0.0569	 2.6244	 0.0137	
BIT002	 4.4673	 0.0958	 2.5513	 0.0205	 2.5078	 0.0712	
BIT003	 2.4980	 0.0272	 2.5454	 0.0237	 2.4130	 0.0395	
BIT004	 2.8831	 0.0214	 2.7883	 0.0330	 2.8713	 0.0718	
BIT007	 5.8730	 0.4245	 5.4169	 0.3020	 0.6899	 0.3604	
BIT008	 No	Sample	 No	Sample	 33.2499	 4.0467	 5.3547	 0.1534	
BIT009	 2.2656	 0.1402	 0.7003	 0.0933	 0.7832	 0.1565	
BIT010	 6.1736	 0.3110	 0.7832	 0.1402	 0.3064	 0.1257	
BIT011	 2.1515	 0.2250	 No	Sample	 No	Sample	 1.0631	 0.0718	
BIT014	 19.3904	 0.5502	 6.6090	 0.1244	 1.9753	 0.2177	
BIT016	 20.0091	 0.8500	 2.7745	 0.0239	 2.7370	 0.0224	
BIT017	 14.1037	 0.7567	 2.6906	 0.2657	 2.0790	 0.0783	
BIT018	 4.5358	 0.2939	 0.7625	 0.0823	 1.0527	 0.0359	
BIT021	 15.2025	 1.0566	 10.7243	 0.4141	 1.7162	 0.0647	
BIT022	 1.4881	 0.0180	 1.2704	 0.8803	 0.3375	 0.0647	
BIT023	 5.5827	 0.0440	 6.0596	 0.2375	 1.7680	 0.0180	
BIT024	 7.5005	 0.3052	 2.0168	 0.1402	 1.4155	 0.0933	
BIT025	 18.4886	 0.5138	 3.3229	 0.2608	 3.4266	 0.1295	
BIT027	 4.9608	 0.1731	 0.7936	 0.1425	 14.6324	 0.8856	
BIT029	 10.2371	 0.3577	 2.9808	 0.2023	 2.4729	 0.1866	
BIT035	 3.5095	 0.1177	 2.0375	 0.0539	 1.9442	 0.0933	
BIT040	 6.6815	 0.1768	 4.6809	 0.4581	 3.1674	 0.1402	
BIT042	 8.1432	 0.4357	 1.9028	 0.1822	 1.8717	 0.0783	
BIT043	 4.5047	 0.2375	 2.0272	 0.1177	 1.4363	 0.2375	
BIT046	 3.6339	 0.0950	 3.0638	 0.0622	 2.5558	 0.2071	
BIT047	 8.1224	 0.1257	 6.6815	 0.1000	 7.3139	 0.2645	
BIT048	 20.4374	 0.7066	 4.9504	 0.0647	 12.8079	 1.4752	
BIT049	 7.5419	 0.3156	 2.5351	 0.0622	 2.1101	 0.0475	
BIT050	 5.8315	 0.0539	 4.2040	 0.2292	 2.5351	 0.0311	
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BIT052	 23.6924	 1.0136	 1.4363	 0.1177	 0.5552	 0.0950	
BIT053	 3.9242	 0.3938	 3.1674	 0.0718	 2.1723	 0.1295	
BIT055	 1.4985	 0.0359	 1.3015	 0.1092	 1.6540	 0.0647	
BIT058	 128.6391	 2.6091	 8.1639	 0.2967	 3.7376	 0.0950	
BIT060	 49.3900	 1.5541	 4.2144	 0.2850	 6.7126	 0.4679	
BIT061	 2.8564	 0.0950	 2.6802	 0.1470	 1.7680	 0.0180	
BIT066	 3.1985	 0.1900	 2.0790	 0.1565	 1.9961	 0.0950	
BIT069	 31.1767	 0.8420	 1.9028	 0.0359	 1.8820	 0.1077	
BIT070	 2.4003	 0.1295	 1.8509	 0.0933	 1.9028	 0.1768	
BIT072	 3.0119	 0.0783	 2.0168	 0.0475	 1.9857	 0.1092	
BIT073	 3.8827	 0.0950	 2.1101	 0.0180	 2.4936	 0.3115	
SR002	 4.7120	 0.0311	 3.4473	 0.0647	 2.1515	 0.1713	
SR003	 39.2416	 2.3795	 2.6388	 0.1257	 21.4844	 1.0890	
SR008	 7.6819	 0.0660	 2.4211	 0.0718	 1.9028	 0.0647	
SR009	 4.5565	 0.1077	 4.8571	 0.1257	 57.5793	 3.2396	
SR010	 5.9766	 0.3888	 9.7603	 0.3068	 2.8979	 0.1534	
SR011	 3.4473	 0.0359	 2.1826	 0.2023	 2.5040	 0.0311	
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Appendix	9	-	Significantly	modified	metabolites	in	Day	1	trauma	patient	serum	samples	
	
Table	15)	The	D1	metabolites	identified	in	patients	with	interleukin-10	concentrations	of	
>12	pg/ml.	
Description	 Max	Fold	Change	 m/z	
Munetone	 1.025472303	 455.1220115	
alpha-Methyl-m-tyrosine	 1.795774295	 178.085297	
DG(14:1(9Z)/22:1(13Z)/0:0)	 1.978404598	 643.5264083	
4-hydroxy-3-all-trans-decaprenylbenzoate	 2.178383295	 840.645032	
PE(20:3(5Z,8Z,11Z)/24:0)	 2.181271853	 834.6383569	
ubiquinone-7	 2.266962038	 659.4991604	
ubiquinol-9	 2.382961134	 795.6366729	
SM(d19:1/24:1(15Z))	 2.835119335	 862.6708856	
PS(O-20:0/20:0)	 3.093220862	 816.6469225	
5-O-mycaminosyltylonolide	 3.218512167	 615.3864577	
abrusoside	A	 3.667869723	 681.3436326	
1,2-dioctanoyl-sn-glycero-3-phosphoserine	 3.778979068	 510.251131	
Lactucin	 4.042674261	 277.1056635	
N-3-(6-Hydroxy-2-naphthyl)-2,2-dimethylpentanoic	acid	 4.149461227	 543.2796911	
encainide	 4.401388367	 335.215046	
Sambacolignoside	 4.832954226	 462.1641061	
Graphinone	 4.898774186	 319.1537541	
filipin	III	 6.145829424	 637.3954667	
1-O-trans-cinnamoyl-beta-D-glucopyranose	 6.243818991	 328.1378124	
diacetylchitobiose-6'-phosphate(2-)	 6.628058432	 485.115622	
sulfoglycolithocholic	acid	 16.98931479	 512.2670485	
Dinoxin	B	 41.54089278	 613.2998733	
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Appendix	10	-	Significantly	modified	metabolites	in	Day	3	trauma	patient	serum	samples	
	
Table	16)	The	D3	metabolites	identified	in	patients	with	interleukin-10	concentrations	of	
>12	pg/ml.	
Description	 Max	Fold	Change	 m/z	
1-O-palmitoyl-2-O-[1-(14)C]-linoleoyl-sn-glycero-3-
phosphocholine	
1.161735132	 760.586052	
PC(15:0/19:1(9Z))	 1.161735132	 760.586052	
Indoleacrylic	acid	 1.186425062	 188.0708579	
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine	 1.198420784	 734.5698887	
sphingosine	1-phosphate	 1.209928541	 380.2554797	
1-palmitoyl-2-(9Z-heptadecenoyl)-sn-glycero-3-
phosphocholine	
1.224626223	 763.5942226	
withalongolide	H	 1.269517773	 761.3798447	
mastoparan-A	 1.304697126	 812.5351886	
N-(2-hydroxyhenicosanoyl)-1-O-beta-D-glucosyl-15-
methylhexadecasphing-4-enine	
1.333966577	 794.6056798	
PS(17:0/22:4(7Z,10Z,13Z,16Z))	 1.343204887	 413.7860746	
PS(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))	 1.402896048	 397.754044	
PC(15:0/18:1(11Z))	 1.403677367	 746.5693917	
chrysogeside	D	 2.024084196	 788.5434407	
12S-hydroxy-16-heptadecynoic	acid	 2.028355776	 563.4292865	
PS(19:1(9Z)/22:2(13Z,16Z))	 2.029918818	 836.5803482	
tryptamine	 2.040537793	 159.0927115	
3-Hydroxyethylbacteriochlorophyllide	a	 2.057699249	 615.243979	
validamycin	A	 2.063994793	 478.1974203	
1-octadecanoyl-2-(7Z,10Z,13Z,16Z)-
docosatetraenoyl-sn-glycero-3-
phosphoethanolamine	
2.06736313	 776.5590549	
PC(15:0/18:2(9Z,12Z))	 2.072554764	 724.5267455	
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1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-glycero-3-phosphocholine	
2.076690637	 840.5302249	
PC(20:3(8Z,11Z,14Z)/P-16:0)	 2.11123002	 802.5585318	
GlcCer(d18:2/20:0)	 2.119893	 788.5789628	
PS(18:0/21:0)	 2.161728031	 814.5963463	
N-pentadecanoylsphingosine-1-phosphocholine	 2.171551685	 723.5197242	
1-oleoyl-2-linoleoyl-sn-glycero-3-phosphocholine	 2.213813018	 818.5540813	
tryptophol	 2.255029639	 142.0660967	
N-(octadecanoyl)-pentadecasphing-4-enine-1-
phosphoethanolamine	
2.279921018	 645.4961903	
4-(hydroxymethyl)benzenesulfonic	acid	 2.310644245	 187.0070987	
nelfinavir(1+)	 2.311460013	 567.3160352	
cefditoren	 2.335407119	 541.0226888	
N-Undecylbenzenesulfonic	acid	 2.388269828	 311.1682475	
SM(d17:1/26:1)	 2.602691124	 861.6604733	
2-Dodecylbenzenesulfonic	acid	 2.606535581	 325.1837676	
1-octadecanoyl-2-(7Z,10Z,13Z,16Z)-
docosatetraenoyl-sn-glycero-3-
phosphoethanolamine	
2.639937684	 776.5542718	
1-(1Z-octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-glycero-3-
phosphoethanolamine	zwitterion	
2.666503752	 774.5425822	
1,2-dioleoyl-sn-glycero-3-phosphocholine	 2.786108562	 820.5687263	
Acacetin	7-glucuronosyl-(1->2)-glucuronide	 2.94520252	 671.102883	
kinetin	 2.945917708	 429.1538366	
TG(17:1(9Z)/17:2(9Z,12Z)/17:2(9Z,12Z))[iso3]	 3.000104573	 873.6682825	
cannabinerolate	 3.075178428	 340.2014055	
N-(4-hydroxyphenyl)ethoxycarbothioamide	 3.253366949	 196.0431535	
4-(hydroxymethyl)benzenesulfonic	acid	 3.338710567	 187.0071651	
Izumiphenazine	B	 3.358396783	 503.0746343	
Broussonin	C	 3.601232625	 311.1682809	
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Cholic	acid	glucuronide	 3.615522134	 619.2867178	
1-hexadecanoyl-sn-glycero-3-phospho-D-myo-
inositol	
3.683851138	 571.2874536	
Xylarenone	C,	(rel)-	 3.709455172	 863.5619864	
1-O-oleoyl-sn-glycero-3-phosphocholine	 3.766520274	 556.3223247	
3-O-sulfo-beta-D-galactose	 3.899418025	 259.0121958	
alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-
(1->4)-N-acetyl-beta-D-glucosamine	
5.639433664	 655.2240267	
chenodeoxycholic	acid	 6.93414554	 391.2844859	
PG(22:4(7Z,10Z,13Z,16Z)/0:0)	 7.010237177	 595.2860054	
Tetrahydroaldosterone-3-glucuronide	 7.702602288	 539.2490686	
N-(4-hydroxyphenyl)ethoxycarbothioamide	 8.758731038	 196.0434759	
alborixin	 9.307318298	 865.5662862	
ergosta-5,7,22,24(28)-tetraen-3beta-yl	acetate	 12.42471216	 871.6529564	
geissospermine	 18.33675809	 613.3574145	
glycochenodeoxycholic	acid	7-sulfate	 18.56891078	 510.255934	
PI(16:1(9Z)/0:0)	 19.22760442	 569.271834	
cholic	acid	 26.66142448	 389.2680757	
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Appendix	11	-	Significantly	modified	metabolites	in	Day	5	trauma	patient	serum	samples	
	
Table	17)	The	D5	metabolites	identified	in	patients	with	interleukin-10	concentrations	of	
>12	pg/ml.		
Description	 Max	Fold	Change	 m/z	
1-hexadecanoyl-sn-glycero-3-phosphocholine	 1.162691341	 496.3402	
1-oleoyl-2-linoleoyl-sn-glycero-3-phosphocholine	 1.190290142	 784.58572	
N-tetracosanoylsphingosine	 1.210806551	 632.63381	
SM(d17:1/24:1)	 1.224592717	 799.66925	
Adouetine	X	 1.269009665	 523.3243	
1-linoleoyl-sn-glycero-3-phosphocholine	 1.272602568	 520.34056	
PC(16:0/18:1(11Z))	 1.287975062	 782.57025	
TG(15:0/18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))	 1.336606421	 897.63545	
1-elaidoyl-sn-glycero-3-phosphocholine	 1.383934792	 522.3563	
SM(d18:2/24:1)	 1.464140515	 833.65021	
undecaprenyl	dihydrogen	phosphate	 1.481116677	 885.6354	
1,2-dilinoleoyl-sn-glycero-3-phosphocholine	 1.577396877	 804.54926	
PS(17:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))	 1.688191802	 410.76215	
N-myristoylsphingosine-1-phosphocholine	 2.038679988	 673.52874	
coenzyme	Q10	 2.054926276	 843.65754	
N-(octadecanoyl)-pentadecasphing-4-enine-1-
phosphoethanolamine	
2.056076132	 645.49619	
TG(17:1(9Z)/17:2(9Z,12Z)/17:2(9Z,12Z))[iso3]	 2.080584041	 873.66828	
SM(d18:0/24:1(15Z)(OH))	 2.138313768	 809.65406	
BQ	518	 2.167508224	 631.24081	
1-stearoyl-2-(8-epi-prostaglandin	F2alpha)-sn-glycero-3-
phosphocholine	
2.189330969	 840.5765	
1-arachidonoyl-sn-glycero-3-phosphocholine	 2.212555681	 578.30011	
[(1->4)-alpha-D-galacturonosyl]n	 2.214400532	 175.02458	
PS(19:0/22:0)	 2.225594435	 842.63427	
acetaminophen	O-beta-D-glucosiduronic	acid	 2.226640792	 326.08765	
1,2-dioleoyl-sn-glycero-3-phosphocholine	 2.296154359	 820.56873	
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N-pentadecanoylsphingosine-1-phosphocholine	 2.33879719	 723.51972	
Mo(V)-molybdopterin	cytosine	dinucleotide(2-)	 2.389107471	 843.92679	
acetaminophen	O-beta-D-glucosiduronic	acid	 2.548877944	 326.08766	
TG(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))[iso
3]	
2.723249213	 815.62437	
3-oxopropanoic	acid	 2.76362566	 175.02463	
N-(2-hydroxyheptadecanoyl)-15-methylhexadecasphing-
4-enine-1-phosphocholine	
2.777370868	 699.54655	
Glionitrin	B	 2.83105144	 364.04121	
2,2'-biimidazole	 2.873456213	 113.02494	
glucoraphenin	 2.921141098	 470.00011	
validamycin	A	 3.56627774	 478.19742	
PC(18:4(6Z,9Z,12Z,15Z)/P-16:0)	 4.066336488	 736.52729	
(3a,5b,7a,12a)-24-[(carboxymethyl)amino]-1,12-
dihydroxy-24-oxocholan-3-yl-b-D-Glucopyranosiduronic	
acid	
4.211322656	 622.32165	
3-carboxyphenyl	phenylacetamidomethylphosphonate	 4.462697571	 384.03944	
ergosta-5,7,22,24(28)-tetraen-3beta-yl	acetate	 4.795272992	 871.65296	
geissospermine	 16.71930533	 613.35741	
amoxicillin	 63.91268563	 364.09636	
	
